WO2023078288A1 - Systems and methods for enhanced immunotherapies - Google Patents
Systems and methods for enhanced immunotherapies Download PDFInfo
- Publication number
- WO2023078288A1 WO2023078288A1 PCT/CN2022/129205 CN2022129205W WO2023078288A1 WO 2023078288 A1 WO2023078288 A1 WO 2023078288A1 CN 2022129205 W CN2022129205 W CN 2022129205W WO 2023078288 A1 WO2023078288 A1 WO 2023078288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- engineered
- fold
- receptor
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 35
- 238000009169 immunotherapy Methods 0.000 title description 8
- 210000002865 immune cell Anatomy 0.000 claims abstract description 354
- 210000004027 cell Anatomy 0.000 claims abstract description 270
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 238000000338 in vitro Methods 0.000 claims abstract description 25
- 230000035755 proliferation Effects 0.000 claims abstract description 17
- 210000000822 natural killer cell Anatomy 0.000 claims description 382
- 230000000694 effects Effects 0.000 claims description 180
- 230000014509 gene expression Effects 0.000 claims description 178
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 137
- 239000000427 antigen Substances 0.000 claims description 135
- 108091007433 antigens Proteins 0.000 claims description 135
- 102000036639 antigens Human genes 0.000 claims description 135
- 108090000623 proteins and genes Proteins 0.000 claims description 134
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 131
- 229920001184 polypeptide Polymers 0.000 claims description 129
- 102000005962 receptors Human genes 0.000 claims description 115
- 108020003175 receptors Proteins 0.000 claims description 115
- 230000027455 binding Effects 0.000 claims description 92
- 230000002829 reductive effect Effects 0.000 claims description 79
- -1 KIR2D Proteins 0.000 claims description 77
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 75
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 75
- 230000011664 signaling Effects 0.000 claims description 69
- 102000004127 Cytokines Human genes 0.000 claims description 68
- 108090000695 Cytokines Proteins 0.000 claims description 68
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 63
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 62
- 102000015696 Interleukins Human genes 0.000 claims description 55
- 108010063738 Interleukins Proteins 0.000 claims description 55
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 46
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 44
- 239000003446 ligand Substances 0.000 claims description 37
- 102000040430 polynucleotide Human genes 0.000 claims description 37
- 108091033319 polynucleotide Proteins 0.000 claims description 37
- 239000002157 polynucleotide Substances 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 210000000130 stem cell Anatomy 0.000 claims description 37
- 230000003013 cytotoxicity Effects 0.000 claims description 31
- 231100000135 cytotoxicity Toxicity 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 102000003812 Interleukin-15 Human genes 0.000 claims description 28
- 108090000172 Interleukin-15 Proteins 0.000 claims description 28
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 26
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 22
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 21
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 20
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 20
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 19
- 238000012986 modification Methods 0.000 claims description 19
- 102100025221 CD70 antigen Human genes 0.000 claims description 17
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 17
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 17
- 108010075383 Suppressor of Cytokine Signaling Proteins Proteins 0.000 claims description 17
- 102000008036 Suppressor of Cytokine Signaling Proteins Human genes 0.000 claims description 17
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 17
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 16
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 15
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 15
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 15
- 101150069255 KLRC1 gene Proteins 0.000 claims description 15
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 15
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 15
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 14
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 14
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 14
- 230000034994 death Effects 0.000 claims description 14
- 231100000517 death Toxicity 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 14
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 13
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 13
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 13
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 13
- 102000017578 LAG3 Human genes 0.000 claims description 13
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 102100038077 CD226 antigen Human genes 0.000 claims description 12
- 102100032937 CD40 ligand Human genes 0.000 claims description 12
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 12
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 12
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 12
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 12
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 12
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 12
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 12
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
- 239000010445 mica Substances 0.000 claims description 12
- 229910052618 mica group Inorganic materials 0.000 claims description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 11
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims description 11
- 108010029697 CD40 Ligand Proteins 0.000 claims description 11
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 claims description 11
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims description 11
- 101001075464 Homo sapiens DNA-binding protein RFXANK Proteins 0.000 claims description 11
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 11
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 11
- 101000979565 Homo sapiens Protein NLRC5 Proteins 0.000 claims description 11
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 claims description 11
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 claims description 11
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 11
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 11
- 108700002010 MHC class II transactivator Proteins 0.000 claims description 11
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 11
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 11
- 102100023432 Protein NLRC5 Human genes 0.000 claims description 11
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 claims description 11
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 11
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims description 11
- 102100028082 Tapasin Human genes 0.000 claims description 11
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 11
- 102100040012 UL16-binding protein 1 Human genes 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 10
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 10
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 10
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 claims description 10
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 10
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 10
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 claims description 10
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 10
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 10
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 10
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 10
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 10
- 102100039373 Membrane cofactor protein Human genes 0.000 claims description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 10
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims description 10
- 230000004068 intracellular signaling Effects 0.000 claims description 10
- 108010059434 tapasin Proteins 0.000 claims description 10
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 9
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 9
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 9
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 9
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 9
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 9
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 9
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 9
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 9
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 9
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 9
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 9
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 9
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 9
- 102100034980 ICOS ligand Human genes 0.000 claims description 9
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 9
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 9
- 102100035487 Nectin-3 Human genes 0.000 claims description 9
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 9
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 7
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 7
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 6
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 6
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 6
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 6
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 102100037904 CD9 antigen Human genes 0.000 claims description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 5
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 5
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 5
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims description 5
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 5
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims description 5
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 4
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 4
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 4
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 4
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims description 4
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 4
- 102100033461 Interleukin-17A Human genes 0.000 claims description 4
- 102100033454 Interleukin-17F Human genes 0.000 claims description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 4
- 101710137414 Suppressor of cytokine signaling 4 Proteins 0.000 claims description 4
- 101710137416 Suppressor of cytokine signaling 6 Proteins 0.000 claims description 4
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims description 3
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 3
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims description 3
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims description 3
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims description 3
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 claims description 3
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 claims description 3
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 claims description 3
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 claims description 3
- 101710124413 Portal protein Proteins 0.000 claims description 3
- 101710137389 Probable tail terminator protein Proteins 0.000 claims description 3
- 101150045565 Socs1 gene Proteins 0.000 claims description 3
- 101150043341 Socs3 gene Proteins 0.000 claims description 3
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 claims description 3
- 102100030524 Suppressor of cytokine signaling 4 Human genes 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 claims description 2
- 101150072667 Bcl3 gene Proteins 0.000 claims description 2
- 101710137422 Suppressor of cytokine signaling 2 Proteins 0.000 claims description 2
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 claims description 2
- 102100030523 Suppressor of cytokine signaling 5 Human genes 0.000 claims description 2
- 101710137415 Suppressor of cytokine signaling 5 Proteins 0.000 claims description 2
- 102100030530 Suppressor of cytokine signaling 6 Human genes 0.000 claims description 2
- 101710137344 Suppressor of cytokine signaling 7 Proteins 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 6
- 102100026882 Alpha-synuclein Human genes 0.000 claims 3
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 8
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 60
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 57
- 108091008874 T cell receptors Proteins 0.000 description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 24
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 238000010362 genome editing Methods 0.000 description 22
- 102000053602 DNA Human genes 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 20
- 108050003558 Interleukin-17 Proteins 0.000 description 19
- 102000013691 Interleukin-17 Human genes 0.000 description 19
- 230000002195 synergetic effect Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 108010002350 Interleukin-2 Proteins 0.000 description 12
- 102000000588 Interleukin-2 Human genes 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000002688 persistence Effects 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 239000013598 vector Substances 0.000 description 11
- 108091033409 CRISPR Proteins 0.000 description 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 10
- 102100030704 Interleukin-21 Human genes 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 10
- 210000002304 esc Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 108010074108 interleukin-21 Proteins 0.000 description 10
- 229950010342 uridine triphosphate Drugs 0.000 description 10
- 238000010354 CRISPR gene editing Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 8
- 102000013462 Interleukin-12 Human genes 0.000 description 8
- 102100021592 Interleukin-7 Human genes 0.000 description 8
- 108010002586 Interleukin-7 Proteins 0.000 description 8
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000004055 small Interfering RNA Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 7
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 102100027207 CD27 antigen Human genes 0.000 description 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 6
- 102000000311 Cytosine Deaminase Human genes 0.000 description 6
- 108010080611 Cytosine Deaminase Proteins 0.000 description 6
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 6
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 6
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 6
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 6
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 6
- 108010043610 KIR Receptors Proteins 0.000 description 6
- 102000002698 KIR Receptors Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 6
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000007783 downstream signaling Effects 0.000 description 6
- 108091006024 signal transducing proteins Proteins 0.000 description 6
- 102000034285 signal transducing proteins Human genes 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000008682 Argonaute Proteins Human genes 0.000 description 5
- 108010088141 Argonaute Proteins Proteins 0.000 description 5
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 5
- 108700012439 CA9 Proteins 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 206010010144 Completed suicide Diseases 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 5
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000003735 Mesothelin Human genes 0.000 description 5
- 108090000015 Mesothelin Proteins 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 5
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 5
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 5
- 102100029198 SLAM family member 7 Human genes 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 5
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- 235000011178 triphosphate Nutrition 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 4
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 4
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 4
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 4
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 4
- 101150083678 IL2 gene Proteins 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 108010065637 Interleukin-23 Proteins 0.000 description 4
- 102000013264 Interleukin-23 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108010002335 Interleukin-9 Proteins 0.000 description 4
- 102000000585 Interleukin-9 Human genes 0.000 description 4
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 4
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 4
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 210000003981 ectoderm Anatomy 0.000 description 4
- 210000001900 endoderm Anatomy 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 108090000567 Caspase 7 Proteins 0.000 description 3
- 102100029855 Caspase-3 Human genes 0.000 description 3
- 102100038902 Caspase-7 Human genes 0.000 description 3
- 102100026550 Caspase-9 Human genes 0.000 description 3
- 108090000566 Caspase-9 Proteins 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 3
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 3
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 3
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 3
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 description 3
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 3
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102100030694 Interleukin-11 Human genes 0.000 description 3
- 108090000177 Interleukin-11 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 3
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- 102100030703 Interleukin-22 Human genes 0.000 description 3
- 108010066979 Interleukin-27 Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 102100021596 Interleukin-31 Human genes 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 3
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 102100023123 Mucin-16 Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 3
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 3
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 102100040010 UL-16 binding protein 5 Human genes 0.000 description 3
- 102100039989 UL16-binding protein 2 Human genes 0.000 description 3
- 102100040011 UL16-binding protein 3 Human genes 0.000 description 3
- 102100040013 UL16-binding protein 6 Human genes 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102100022748 Wilms tumor protein Human genes 0.000 description 3
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 229960002204 daratumumab Drugs 0.000 description 3
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229950009760 epratuzumab Drugs 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 108010074109 interleukin-22 Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 229950003734 milatuzumab Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 229960003989 tocilizumab Drugs 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 229950000815 veltuzumab Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 102100032412 Basigin Human genes 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 108090000342 C-Type Lectins Proteins 0.000 description 2
- 102000003930 C-Type Lectins Human genes 0.000 description 2
- 102100026194 C-type lectin domain family 2 member B Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
- 241000218631 Coniferophyta Species 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 241000214054 Equine rhinitis A virus Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 102100040578 G antigen 7 Human genes 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- 101000912618 Homo sapiens C-type lectin domain family 2 member B Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 2
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 2
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 2
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 2
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 2
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 2
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 2
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 description 2
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 2
- 101000945346 Homo sapiens Killer cell immunoglobulin-like receptor 2DS5 Proteins 0.000 description 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 2
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 2
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 2
- 101000945492 Homo sapiens Killer cell immunoglobulin-like receptor 3DS1 Proteins 0.000 description 2
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 2
- 101000697493 Homo sapiens Large proline-rich protein BAG6 Proteins 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 2
- 101000863880 Homo sapiens Sialic acid-binding Ig-like lectin 6 Proteins 0.000 description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 2
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 2
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 2
- 102100039879 Interleukin-19 Human genes 0.000 description 2
- 108050009288 Interleukin-19 Proteins 0.000 description 2
- 102100036679 Interleukin-26 Human genes 0.000 description 2
- 101710181613 Interleukin-31 Proteins 0.000 description 2
- 108010067003 Interleukin-33 Proteins 0.000 description 2
- 101710181549 Interleukin-34 Proteins 0.000 description 2
- 108091007973 Interleukin-36 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 2
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 2
- 102100033629 Killer cell immunoglobulin-like receptor 2DL5A Human genes 0.000 description 2
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 2
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 description 2
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 description 2
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 2
- 102100033626 Killer cell immunoglobulin-like receptor 2DS5 Human genes 0.000 description 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 2
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 2
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 2
- 102100034833 Killer cell immunoglobulin-like receptor 3DS1 Human genes 0.000 description 2
- 101710131918 Killer cell lectin-like receptor subfamily B member 1A Proteins 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 102100028047 Large proline-rich protein BAG6 Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010075393 Myeloid-Lymphoid Leukemia Protein Proteins 0.000 description 2
- 102000008037 Myeloid-Lymphoid Leukemia Protein Human genes 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 2
- 102000002755 Natural Cytotoxicity Triggering Receptor 1 Human genes 0.000 description 2
- 108010004220 Natural Cytotoxicity Triggering Receptor 2 Proteins 0.000 description 2
- 102000002751 Natural Cytotoxicity Triggering Receptor 2 Human genes 0.000 description 2
- 102000002752 Natural Cytotoxicity Triggering Receptor 3 Human genes 0.000 description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 241001672814 Porcine teschovirus 1 Species 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 102100038567 Properdin Human genes 0.000 description 2
- 108010005642 Properdin Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 102100029216 SLAM family member 5 Human genes 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 description 2
- 102100029947 Sialic acid-binding Ig-like lectin 6 Human genes 0.000 description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 2
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 241001648840 Thosea asigna virus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101710127857 Wilms tumor protein Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 108091092259 cell-free RNA Proteins 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 229940126610 derlotuximab biotin Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960004497 dinutuximab Drugs 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 229960004413 flucytosine Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229950002140 futuximab Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 102000056003 human IL15 Human genes 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108090000681 interleukin 20 Proteins 0.000 description 2
- 102000004114 interleukin 20 Human genes 0.000 description 2
- 102000003898 interleukin-24 Human genes 0.000 description 2
- 108090000237 interleukin-24 Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229950001237 lilotomab Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229950005674 modotuximab Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 2
- 229950007157 zolbetuximab Drugs 0.000 description 2
- MFZSNESUTRVBQX-XEURHVNRSA-N (2S)-2-amino-6-[4-[[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]disulfanyl]pentanoylamino]hexanoic acid Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSSC(C)CCC(=O)NCCCC[C@H](N)C(O)=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 MFZSNESUTRVBQX-XEURHVNRSA-N 0.000 description 1
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- LAXVMANLDGWYJP-UHFFFAOYSA-N 2-amino-5-(2-aminoethyl)naphthalene-1-sulfonic acid Chemical compound NC1=CC=C2C(CCN)=CC=CC2=C1S(O)(=O)=O LAXVMANLDGWYJP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- 229940127148 AGS67E Drugs 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000016626 Agrimonia eupatoria Nutrition 0.000 description 1
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 1
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102100025665 Angiopoietin-related protein 1 Human genes 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 1
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102000052666 B-Cell Lymphoma 3 Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000218495 Bactrocera correcta Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 108010064528 Basigin Proteins 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001536303 Botryococcus braunii Species 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102000024905 CD99 Human genes 0.000 description 1
- 108060001253 CD99 Proteins 0.000 description 1
- 101150108242 CDC27 gene Proteins 0.000 description 1
- 229940038671 CDX-1401 vaccine Drugs 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100355609 Caenorhabditis elegans rae-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100039532 Calcium-activated chloride channel regulator 2 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710181340 Chaperone protein DnaK2 Proteins 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 244000249214 Chlorella pyrenoidosa Species 0.000 description 1
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 101710198480 Clumping factor A Proteins 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100024462 Cyclin-dependent kinase 4 inhibitor B Human genes 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 description 1
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
- 101710127030 Dermatan-sulfate epimerase Proteins 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 101100219190 Drosophila melanogaster byn gene Proteins 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100035078 ETS-related transcription factor Elf-2 Human genes 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 229940126626 Ektomab Drugs 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055191 EphA3 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 description 1
- 101100129584 Escherichia coli (strain K12) trg gene Proteins 0.000 description 1
- 229940126611 FBTA05 Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 102100039699 G antigen 4 Human genes 0.000 description 1
- 102100039698 G antigen 5 Human genes 0.000 description 1
- 101710092267 G antigen 5 Proteins 0.000 description 1
- 102100039713 G antigen 6 Human genes 0.000 description 1
- 101710092269 G antigen 6 Proteins 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 101150063370 Gzmb gene Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100040407 Heat shock 70 kDa protein 1B Human genes 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 description 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000888580 Homo sapiens Calcium-activated chloride channel regulator 2 Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000980919 Homo sapiens Cyclin-dependent kinase 4 inhibitor B Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000877377 Homo sapiens ETS-related transcription factor Elf-2 Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 1
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001055308 Homo sapiens Immunoglobulin heavy constant epsilon Proteins 0.000 description 1
- 101001008896 Homo sapiens Inactive histone-lysine N-methyltransferase 2E Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000721712 Homo sapiens NTF2-related export protein 1 Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101000601047 Homo sapiens Nidogen-1 Proteins 0.000 description 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101000688606 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Proteins 0.000 description 1
- 101000610208 Homo sapiens Poly(A) polymerase gamma Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 description 1
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 description 1
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 description 1
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000713322 Homo sapiens SAP30-binding protein Proteins 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 description 1
- 101000709473 Homo sapiens Sialic acid-binding Ig-like lectin 14 Proteins 0.000 description 1
- 101000709471 Homo sapiens Sialic acid-binding Ig-like lectin 16 Proteins 0.000 description 1
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101100370133 Homo sapiens TPH1 gene Proteins 0.000 description 1
- 101000649068 Homo sapiens Tapasin Proteins 0.000 description 1
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 101000607314 Homo sapiens UL16-binding protein 6 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102100026212 Immunoglobulin heavy constant epsilon Human genes 0.000 description 1
- 102100027767 Inactive histone-lysine N-methyltransferase 2E Human genes 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108050002021 Integrator complex subunit 2 Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 102100032832 Integrin alpha-7 Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102100035014 Interleukin-17 receptor B Human genes 0.000 description 1
- 101710186071 Interleukin-17 receptor B Proteins 0.000 description 1
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 1
- 101710186068 Interleukin-17 receptor C Proteins 0.000 description 1
- 102100035015 Interleukin-17 receptor D Human genes 0.000 description 1
- 101710186062 Interleukin-17 receptor D Proteins 0.000 description 1
- 102100035016 Interleukin-17 receptor E Human genes 0.000 description 1
- 101710186076 Interleukin-17 receptor E Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100030692 Interleukin-20 Human genes 0.000 description 1
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 1
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N Iodine I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000042218 MIC family Human genes 0.000 description 1
- 108091077479 MIC family Proteins 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 102000005727 Mammaglobin A Human genes 0.000 description 1
- 108010031030 Mammaglobin A Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241000196323 Marchantiophyta Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101001062862 Mus musculus Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
- 101100176487 Mus musculus Gzmc gene Proteins 0.000 description 1
- 101100181099 Mus musculus Klra1 gene Proteins 0.000 description 1
- 101100181100 Mus musculus Klra2 gene Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241001250129 Nannochloropsis gaditana Species 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 101000621505 Peanut clump virus (isolate 87/TGTA2) Suppressor of RNA silencing Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 102100024242 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 102100040153 Poly(A) polymerase gamma Human genes 0.000 description 1
- 241000985694 Polypodiopsida Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 101100443768 Rattus norvegicus Dock9 gene Proteins 0.000 description 1
- 101001023831 Rattus norvegicus Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100036909 SAP30-binding protein Human genes 0.000 description 1
- 102100031778 SH2 domain-containing protein 1B Human genes 0.000 description 1
- 101710097986 SH2 domain-containing protein 1B Proteins 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000593524 Sargassum patens Species 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 description 1
- 101710143293 Sialic acid-binding Ig-like lectin 10 Proteins 0.000 description 1
- 102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 description 1
- 102100034370 Sialic acid-binding Ig-like lectin 14 Human genes 0.000 description 1
- 102100034375 Sialic acid-binding Ig-like lectin 16 Human genes 0.000 description 1
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 description 1
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102100030529 Suppressor of cytokine signaling 7 Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100033224 Terminal uridylyltransferase 7 Human genes 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 241001196954 Theilovirus Species 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- JCZSFCLRSONYLH-UHFFFAOYSA-N Wyosine Natural products N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3C1OC(CO)C(O)C1O JCZSFCLRSONYLH-UHFFFAOYSA-N 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 description 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 1
- NOXMCJDDSWCSIE-DAGMQNCNSA-N [[(2R,3S,4R,5R)-5-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O NOXMCJDDSWCSIE-DAGMQNCNSA-N 0.000 description 1
- AZJLCKAEZFNJDI-DJLDLDEBSA-N [[(2r,3s,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 AZJLCKAEZFNJDI-DJLDLDEBSA-N 0.000 description 1
- AZRNEVJSOSKAOC-VPHBQDTQSA-N [[(2r,3s,5r)-5-[5-[(e)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]prop-1-enyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCCNC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)=C1 AZRNEVJSOSKAOC-VPHBQDTQSA-N 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N [[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- ZXZIQGYRHQJWSY-NKWVEPMBSA-N [hydroxy-[[(2s,5r)-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 ZXZIQGYRHQJWSY-NKWVEPMBSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229950005008 abituzumab Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229950004283 actoxumab Drugs 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229950008995 aducanumab Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003227 afelimomab Drugs 0.000 description 1
- 229950008459 alacizumab pegol Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229950006061 anatumomab mafenatox Drugs 0.000 description 1
- 229950006588 anetumab ravtansine Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 108010069801 angiopoietin 4 Proteins 0.000 description 1
- 229950010117 anifrolumab Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 101150059062 apln gene Proteins 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229950000847 ascrinvacumab Drugs 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950005122 atinumab Drugs 0.000 description 1
- 229950000103 atorolimumab Drugs 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- 229960004965 begelomab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- 229950010559 besilesomab Drugs 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 description 1
- 229950008086 bezlotoxumab Drugs 0.000 description 1
- 229950001303 biciromab Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229950006326 bimagrumab Drugs 0.000 description 1
- 229950002853 bimekizumab Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- 229950011350 bococizumab Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 229950001478 brontictuzumab Drugs 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940126608 cBR96-doxorubicin immunoconjugate Drugs 0.000 description 1
- 229950009667 camidanlumab tesirine Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 229950011547 cantuzumab ravtansine Drugs 0.000 description 1
- 229950002176 caplacizumab Drugs 0.000 description 1
- 108010023376 caplacizumab Proteins 0.000 description 1
- 229940034605 capromab pendetide Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 229950000771 carlumab Drugs 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229950010905 citatuzumab bogatox Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 229950001565 clazakizumab Drugs 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 229950002595 clivatuzumab tetraxetan Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229950007906 codrituzumab Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229950005458 coltuximab ravtansine Drugs 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 229950009735 concizumab Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 229950001954 crenezumab Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229950005026 dapirolizumab pegol Drugs 0.000 description 1
- 108010048522 dapirolizumab pegol Proteins 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229950008135 dectrekumab Drugs 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229950007998 demcizumab Drugs 0.000 description 1
- 230000006114 demyristoylation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229950004079 denintuzumab mafodotin Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229950002756 depatuxizumab Drugs 0.000 description 1
- 229950008925 depatuxizumab mafodotin Drugs 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229950011037 diridavumab Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229950005168 dorlimomab aritox Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950009964 drozitumab Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229950011109 edobacomab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 229950010217 eldelumab Drugs 0.000 description 1
- 229950002519 elgemtumab Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229950002507 elsilimomab Drugs 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 229950004255 emibetuzumab Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229950003048 enavatuzumab Drugs 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950000565 enlimomab pegol Drugs 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 229950007313 enokizumab Drugs 0.000 description 1
- 229950001752 enoticumab Drugs 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229950006414 epitumomab cituxetan Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229950004912 etrolizumab Drugs 0.000 description 1
- 229950004341 evinacumab Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 229940093443 fanolesomab Drugs 0.000 description 1
- 229950001488 faralimomab Drugs 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229950000335 fasinumab Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 229950004409 firivumab Drugs 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 229950010043 fletikumab Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229950004356 foralumab Drugs 0.000 description 1
- 229950011078 foravirumab Drugs 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 229950009370 fulranumab Drugs 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229950004792 gavilimomab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 229950003717 gevokizumab Drugs 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229950009672 glembatumumab vedotin Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229940126613 gomiliximab Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229950006359 icrucumab Drugs 0.000 description 1
- 229960002308 idarucizumab Drugs 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 229950003680 imalumab Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 229950007354 imciromab Drugs 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229950009230 inclacumab Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229950011428 indatuximab ravtansine Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 229950000932 indusatumab vedotin Drugs 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 229940050282 inebilizumab-cdon Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229950007937 inolimomab Drugs 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010043603 integrin alpha4beta7 Proteins 0.000 description 1
- 108010024084 integrin alpha7 Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 230000006831 intrinsic signaling Effects 0.000 description 1
- 229940005977 iodine i-131 Drugs 0.000 description 1
- 229950003629 ipafricept Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229950009645 istiratumab Drugs 0.000 description 1
- 229950003818 itolizumab Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229950010828 keliximab Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229950004881 labetuzumab govitecan Drugs 0.000 description 1
- CBNAAKBWBABMBY-LQCKLLCCSA-N labetuzumab-sn38 Chemical compound N([C@@H](CCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O CBNAAKBWBABMBY-LQCKLLCCSA-N 0.000 description 1
- 229950000482 lampalizumab Drugs 0.000 description 1
- 108010032674 lampalizumab Proteins 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 229950001275 lemalesomab Drugs 0.000 description 1
- 229950007439 lenzilumab Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 229950004529 lifastuzumab vedotin Drugs 0.000 description 1
- 229950009923 ligelizumab Drugs 0.000 description 1
- 229940126616 lilotomab satetraxetan Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229950006208 lodelcizumab Drugs 0.000 description 1
- 229950000359 lokivetmab Drugs 0.000 description 1
- 229950009758 loncastuximab tesirine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950003526 lorvotuzumab mertansine Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950008140 lulizumab pegol Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 229950010079 lumretuzumab Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229950008083 maslimomab Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 229950007254 mavrilimumab Drugs 0.000 description 1
- 101150094281 mcl1 gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229950002142 minretumomab Drugs 0.000 description 1
- 229950000035 mirvetuximab soravtansine Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229950008897 morolimumab Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229950003027 nacolomab tafenatox Drugs 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 229950009793 naptumomab estafenatox Drugs 0.000 description 1
- 229950008353 narnatumab Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960002915 nebacumab Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950010012 nemolizumab Drugs 0.000 description 1
- 229950009675 nerelimomab Drugs 0.000 description 1
- 229950002697 nesvacumab Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960003419 obiltoxaximab Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229950010465 odulimomab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229950010006 olokizumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 229950002104 ontuxizumab Drugs 0.000 description 1
- 229950010704 opicinumab Drugs 0.000 description 1
- 229950009057 oportuzumab monatox Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229950009007 orticumab Drugs 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 229950000121 otlertuzumab Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229950003709 oxelumab Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229950009723 ozanezumab Drugs 0.000 description 1
- 229950004327 ozoralizumab Drugs 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940126618 pankomab Drugs 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 229950000037 pasotuxizumab Drugs 0.000 description 1
- 229950003522 pateclizumab Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229950011098 pendetide Drugs 0.000 description 1
- 229940067082 pentetate Drugs 0.000 description 1
- 229950005079 perakizumab Drugs 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229950010074 pinatuzumab vedotin Drugs 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229950008092 placulumab Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 229950003486 ponezumab Drugs 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229950003700 priliximab Drugs 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229950011407 pritoxaximab Drugs 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- QQXQGKSPIMGUIZ-AEZJAUAXSA-N queuosine Chemical compound C1=2C(=O)NC(N)=NC=2N([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=C1CN[C@H]1C=C[C@H](O)[C@@H]1O QQXQGKSPIMGUIZ-AEZJAUAXSA-N 0.000 description 1
- 229950003033 quilizumab Drugs 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 229950009885 ralpancizumab Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229950000987 refanezumab Drugs 0.000 description 1
- 229950005854 regavirumab Drugs 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229950005978 rinucumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 229950010699 roledumab Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 229950000143 sacituzumab govitecan Drugs 0.000 description 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229950000106 samalizumab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229950008834 seribantumab Drugs 0.000 description 1
- 229950003850 setoxaximab Drugs 0.000 description 1
- 229950004951 sevirumab Drugs 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229950003763 sofituzumab vedotin Drugs 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 229950011267 solitomab Drugs 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229950002549 stamulumab Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229950010708 sulesomab Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229950001915 suvizumab Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229950010265 tabalumab Drugs 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 229950004218 talizumab Drugs 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 229950001603 taplitumomab paptox Drugs 0.000 description 1
- 229950007435 tarextumab Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229950000864 technetium (99mtc) nofetumomab merpentan Drugs 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229950008300 telimomab aritox Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- 229950009054 tesidolumab Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- IBVCSSOEYUMRLC-GABYNLOESA-N texas red-5-dutp Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(C#CCNS(=O)(=O)C=2C=C(C(C=3C4=CC=5CCCN6CCCC(C=56)=C4OC4=C5C6=[N+](CCC5)CCCC6=CC4=3)=CC=2)S([O-])(=O)=O)=C1 IBVCSSOEYUMRLC-GABYNLOESA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- 229950004269 tisotumab vedotin Drugs 0.000 description 1
- 101150061299 tme gene Proteins 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 229950008836 tosatoxumab Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229950005808 tovetumab Drugs 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229950010086 tregalizumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950006444 trevogrumab Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 229950005082 tuvirumab Drugs 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 229950010095 ulocuplumab Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 229950001694 vadastuximab talirine Drugs 0.000 description 1
- 229950001876 vandortuzumab vedotin Drugs 0.000 description 1
- 229950008718 vantictumab Drugs 0.000 description 1
- 229950000449 vanucizumab Drugs 0.000 description 1
- 229950000386 vapaliximab Drugs 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 229950002148 vatelizumab Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229950005208 vepalimomab Drugs 0.000 description 1
- 229950010789 vesencumab Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- JCZSFCLRSONYLH-QYVSTXNMSA-N wyosin Chemical compound N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JCZSFCLRSONYLH-QYVSTXNMSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 108010015889 zeta receptor Proteins 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009083 ziralimumab Drugs 0.000 description 1
- 229950001346 zolimomab aritox Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- Cancer e.g., neoplasm, tumor
- cancer is a leading cause of death worldwide, accounting for about 10 million deaths annually. Cancer continues to bring increasing health, economic, and emotional burden on individuals, families, communities, and countries. Increase understanding of cancer biology (e.g., specifically cancer immune biology) and genetic engineering has encouraged development of adoptive cell therapies (e.g., cellular immunotherapy) , with a goal to treat or control a number of different cancers.
- adoptive cell therapies e.g., cellular immunotherapy
- the present disclosure provides methods and systems for treating cancer.
- Some aspects of the present disclosure provide engineered immune cells (e.g., engineered natural killer (NK) cells) and methods of use thereof for treatment of cancer, such as, e.g., as hematologic malignancies or solid tumors.
- engineered immune cells e.g., engineered natural killer (NK) cells
- NK natural killer
- the present disclosure provides an engineered NK cell, comprising: (1) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell; and (2) one or more members selected from the group consisting of:
- an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
- hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
- a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21,
- the present disclosure provides an engineered NK cell, comprising enhanced expression or activity level of an activating NK receptor as compared to a control NK cell, wherein the activating NK receptor is configured to bind an antigen of NKG2D, NKP30, NKP44, NKP46, NKP80, and/or DNAM1, and wherein the activating NK receptor does not comprise a heterologous intracellular signaling domain.
- the present disclosure provides an engineered NK cell, comprising a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is selected from the group consisting of CD70, CLEC12A, TIM-3, CD9, CD26, TRAIL-R4 (DCR2) , and NKG2D ligand, wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the chimeric polypeptide receptor.
- an engineered NK cell comprising: (1) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is CD38 and/or BCMA; and (2) one or more members selected from the group consisting of:
- an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
- hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
- a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21,
- the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the one or more members.
- the present disclosure provides an engineered NK cell, comprising: (1) reduced expression or activity level of a suppressor of cytokine (SOCS) protein; and (2) one or more members selected from the group consisting of:
- SOCS suppressor of cytokine
- IL interleukin
- an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
- hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
- the engineered NK cell exhibits enhanced cytotoxicity against a target cell as compared to a control cell. In some embodiments of any one of the compositions disclosed herein, the engineered NK cell induces reduced immune response in a host cell as compared to a control cell.
- the host cell is an immune cell.
- the present disclosure provides a method comprising: administering to a subject in need thereof a subject composition of any one of the compositions disclosed herein.
- the separate therapeutic agent comprises a chemotherapeutic agent.
- FIG. 1 illustrates nucleic acid vectors encoding one or more genes, such as an activating NK receptor.
- FIG. 2A illustrates nucleic acid vectors encoding an activating NK receptor and/or a DAP protein.
- FIGs. 2B and 2C illustrate expression level of the activating NK receptor in cells treated with one of the nucleic acid vectors from FIG. 2A.
- FIG. 3A illustrates nucleic acid vectors encoding a chimeric polypeptide receptor (e.g., a chimeric antigen receptor) exhibiting specific binding to an antigen, such as CLL-1.
- FIG. 3B illustrates examples of transgenes encoding a CD16 variant that can be inserted into the genome of a host cell.
- FIG. 3C illustrates different endogenous genes that can be suppressed in an engineered immune cell for immunotherapies.
- FIG. 4A illustrates a structural of anti-CLL-1 chimeric polypeptide receptor (e.g., anti-CLL-1 chimeric antigen receptor (CAR) ) .
- FIG. 4B shows cytotoxicity level of anti-CLL-1 CAR NK cells and non-modified control NK cells, against CLL-1 expressing HL60 tumor cells.
- FIG. 4C shows expression level of CD107A in anti-CLL-1 CAR NK cells and non-modified control NK cells, upon being in contact with the CLL-1 expressing HL60 tumor cells.
- CAR anti-CLL-1 chimeric antigen receptor
- FIG. 5A shows CD56 expression of engineered NK cells from iPSCs engineered to enhance expression and/or activity level of an activating NK receptor.
- FIG. 5B shows FACS fluoresces intensity of engineered NK cells overexpressing an activating NK receptor.
- FIG. 6A shows cytotoxicity analysis of engineered NK cells with enhanced NK receptor and NK cells derived from iPSCs, against solid tumor cells, Calu-3.
- FIG. 6B shows serial cytotoxicity analysis with engineered NK cells and NK cells derived from iPSCs against THP1 and SKOV3.
- FIG. 6C shows cytotoxicity analysis with engineered NK cells and non-modified control NK cells against THP1 and MOLM13.
- FIG. 6D shows expression profile of NKG2D and NKP30 in engineered NK cells compared to NK cells derived from iPSCs during in vitro killing assay.
- FIG. 7 shows tumor burden of mice injected with engineered NK cells expressing NK receptors compared to mice injected NK cells without engineering.
- FIG. 8A shows change in mice body weight post injection of engineered NK cells expressing NK receptors using SKOV3 tumor model.
- FIG. 8B shows survival proportions of mice harboring SKOV3 tumor with or without injection of engineered NK cells.
- FIG. 8C shows pharmacokinetics of hCD56+ cells in peripheral blood of mice injected with engineered NK cells.
- FIG. 8D shows tumor burden of mice with SKOV3 injected with different dose of engineered NK cells.
- FIG. 9A shows cytotoxicity analysis of NK cells with TGFb-R2 knock out and control NK cells incubated with GFP labeled THP1 cells, with different TGF-b dosage at 24 hours and 72 hours.
- FIG. 9B shows serial cytotoxicity analysis of NK cells with TGFb-R2 knock out and control NK cells incubated with GFP labeled THP1 cells with different TGF-b dosage.
- FIG. 10A shows knockout efficiency of TGFb-R2 in NK cells.
- FIG. 10B shows FACS analysis of NKG2D and NKP30 expression in NK cells with TGFb-R2 knocked out, with or without TGF-b treatment.
- FIG. 11A shows cytotoxicity analysis of cord blood natural killer (CBNK) incubated with different ratio of wild type K562 or HLA-E K562.
- FIG. 11B shows result of CD107a assay of CBNK incubated with different ratio of K562, HLA-E K562, or CBNK alone.
- FIG. 11C shows FACS analysis of NKG2A expression in CBNK with knockout of NKG2A and with HS2 knockout as control.
- FIG. 11D shows cytotoxicity analysis of CBNK with NKG2A knockout and CBNK with H2S knockout incubated different ratio of wild type K562 or HLA-E K562.
- FIG. 12A shows quantification of CD45+/CD46+ NK cells differentiated from iPSCs engineered with SOCS2 knockout.
- FIG. 12B shows FACS fluorescence intensity of engineered NK cells with SOCS2 knockout.
- FIG. 12C shows number of hCD56+/hC45+ NK cells cultured in presence of peripheral blood cells with IL-2 or IL-15 supplementation, to compare persistency level of NK cells with SOCS2 knockout, that of unmodified NK cells, and that of NK cells with CISH knockout.
- FIG. 13 illustrates nucleic acid vectors encoding an DNAM1 and TIGIT and shows FACS analysis of TIGIT expression in 293T cells transfected with the nucleic acid vectors.
- FIG. 14 illustrates nucleic acid vector encoding NKP80 and shows FACS analysis of NKP80 expression in iPSCs transfected with the nucleic acid vector.
- achimeric transmembrane receptor includes a plurality of chimeric transmembrane receptors.
- the term “about” or “approximately” generally mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1%of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” meaning within an acceptable error range for the particular value should be assumed.
- a cell generally refers to a biological cell.
- a cell can be the basic structural, functional and/or biological unit of a living organism.
- a cell can originate from any organism having one or more cells. Some non-limiting examples include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g.
- algal cell e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like
- seaweeds e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like
- seaweeds e.g.
- a fungal cell e.g., a yeast cell, a cell from a mushroom
- an animal cell e.g. fruit fly, cnidarian, echinoderm, nematode, etc.
- a cell from a vertebrate animal e.g., fish, amphibian, reptile, bird, mammal
- a cell from a mammal e.g., a pig, a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, a human, etc.
- a cell is not originating from a natural organism (e.g. a cell can be a synthetically made, sometimes termed an artificial cell) .
- reprogramming generally refers to a method of increasing the potency of a cell or dedifferentiating the cell to a less differentiated state.
- a cell that has an increased cell potency has more developmental plasticity (i.e., can differentiate into more cell types) compared to the same cell in the non-reprogrammed state.
- a reprogrammed cell is one that is in a less differentiated state than the same cell in a non-reprogrammed state.
- differentiated generally refers to a process by which an unspecialized ( “uncommitted” ) or less specialized cell acquires the features of a specialized cell such as, e.g., an immune cell.
- a differentiated or differentiation-induced cell is one that has taken on a more specialized ( “committed” ) position within the lineage of a cell.
- the term “committed” generally refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type.
- pluripotent generally refers to the ability of a cell to form all lineages of the body or soma (i.e., the embryo proper) .
- embryonic stem cells are a type of pluripotent stem cells that are able to form cells from each of the three germs layers, the ectoderm, the mesoderm, and the endoderm.
- Pluripotency can be a continuum of developmental potencies ranging from the incompletely or partially pluripotent cell (e.g., an epiblast stem cell) , which is unable to give rise to a complete organism to the more primitive, more pluripotent cell, which is able to give rise to a complete organism (e.g., an embryonic stem cell) .
- iPSCs induced pluripotent stem cells
- differentiated cells e.g., differentiated adult, neonatal, or fetal cells
- iPSCs reprogrammed stem cells
- the iPSCs produced do not refer to cells as they are found in nature.
- iPSCs can be engineered to differentiation directly into committed cells (e.g., natural killer (NK) cells.
- NK natural killer
- iPSCs can be engineered to differentiate first into tissue-specific stem cells (e.g., hematopoietic stem cells (HSCs) ) , which can be further induced to differentiate into committed cells (e.g., NK cells) .
- tissue-specific stem cells e.g., hematopoietic stem cells (HSCs)
- HSCs hematopoietic stem cells
- ESCs generally refers to naturally occurring pluripotent stem cells of the inner cell mass of the embryonic blastocyst. Embryonic stem cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm.
- ESCs can be engineered to differentiation directly into committed cells (e.g., NK cells) .
- ESCs can be engineered to differentiate first into tissue-specific stem cells (e.g., HSCs) , which can be further induced to differentiate into committed cells (e.g., NK cells) .
- isolated stem cells generally refers to any type of stem cells disclosed herein (e.g., ESCs, HSCs, mesenchymal stem cells (MSCs) , etc. ) that are isolated from a multicellular organism.
- HSCs can be isolated from a mammal’s body, such as a human body.
- an embryonic stem cells can be isolated from an embryo.
- isolated generally refers to a cell or a population of cells, which has been separated from its original environment.
- a new environment of the isolated cells is substantially free of at least one component as found in the environment in which the “un-isolated” reference cells exist.
- An isolated cell can be a cell that is removed from some or all components as it is found in its natural environment, for example, isolated from a tissue or biopsy sample.
- the term also includes a cell that is removed from at least one, some or all components as the cell is found in non-naturally occurring environments, for example, isolated form a cell culture or cell suspension. Therefore, an isolated cell is partly or completely separated from at least one component, including other substances, cells or cell populations, as it is found in nature or as it is grown, stored or subsisted in non-naturally occurring environments.
- hematopoietic stem and progenitor cells generally refers to cells which are committed to a hematopoietic lineage but are capable of further hematopoietic differentiation (e.g., into NK cells) and include, multipotent hematopoietic stem cells (hematoblasts) , myeloid progenitors, megakaryocyte progenitors, erythrocyte progenitors, and lymphoid progenitors.
- hematoblasts multipotent hematopoietic stem cells
- HSCs Hematopoietic stem and progenitor cells
- myeloid monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells
- lymphoid lineages T cells, B cells, NK cells
- HSCs can be CD34+ hematopoietic cells capable of giving rise to both mature myeloid and lymphoid cell types including T cells, NK cells and B cells.
- immune cell generally refers to a differentiated hematopoietic cell.
- Non-limiting examples of an immune cell can include an NK cell, a T cell, a monocyte, an innate lymphocyte, a tumor-infiltrating lymphocyte, a macrophage, a granulocyte, etc.
- NK cell or “Natural Killer cell” generally refers to a subset of peripheral blood lymphocytes defined by the expression of CD56 or CD16 and the absence of the T cell receptor (CD3) .
- NK cells that are phenotypically CD3-and CD56+, expressing at least one of NKG2C and CD57 (e.g., NKG2C, CD57, or both in same or different degrees) , and optionally, CD16, but lack expression of one or more of the following: PLZF, SYK, FceR ⁇ , and EAT-2.
- isolated subpopulations of CD56+ NK cells can exhibit expression of CD16, NKG2C, CD57, NKG2D, NCR ligands, NKp30, NKp40, NKp46, activating and inhibitory KIRs, NKG2A and/or DNAM-1.
- nucleotide generally refers to a base-sugar-phosphate combination.
- a nucleotide can comprise a synthetic nucleotide.
- a nucleotide can comprise a synthetic nucleotide analog.
- Nucleotides can be monomeric units of a nucleic acid sequence (e.g. deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) ) .
- nucleotide can include ribonucleoside triphosphates adenosine triphosphate (ATP) , uridine triphosphate (UTP) , cytosine triphosphate (CTP) , guanosine triphosphate (GTP) and deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof.
- Such derivatives can include, for example, [ ⁇ S] dATP, 7-deaza-dGTP and 7-deaza-dATP, and nucleotide derivatives that confer nuclease resistance on the nucleic acid molecule containing them.
- nucleotide as used herein can refer to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives.
- ddNTPs dideoxyribonucleoside triphosphates
- Illustrative examples of dideoxyribonucleoside triphosphates can include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP.
- a nucleotide may be unlabeled or detectably labeled by well-known techniques. Labeling can also be carried out with quantum dots.
- Detectable labels can include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.
- Fluorescent labels of nucleotides may include but are not limited fluorescein, 5-carboxyfluorescein (FAM) , 2′7′-dimethoxy-4′5-dichloro-6-carboxyfluorescein (JOE) , rhodamine, 6-carboxyrhodamine (R6G) , N, N, N′, N′-tetramethyl-6-carboxyrhodamine (TAMRA) , 6-carboxy-X-rhodamine (ROX) , 4-(4′dimethylaminophenylazo) benzoic acid (DABCYL) , Cascade Blue, Oregon Green, Texas Red, Cyanine and 5- (2′-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS) .
- FAM 5-carboxyfluorescein
- JE 2′7′-dimethoxy-4′5-dichloro-6-carboxyfluorescein
- fluorescently labeled nucleotides can include [R6G] dUTP, [TAMRA] dUTP, [R110] dCTP, [R6G] dCTP, [TAMRA] dCTP, [JOE] ddATP, [R6G] ddATP, [FAM] ddCTP, [R110] ddCTP, [TAMRA] ddGTP, [ROX] ddTTP, [dR6G] ddATP, [dR110] ddCTP, [dTAMRA] ddGTP, and [dROX] ddTTP available from Perkin Elmer, Foster City, Calif.
- Nucleotides can also be labeled or marked by chemical modification.
- a chemically-modified single nucleotide can be biotin-dNTP.
- biotinylated dNTPs can include, biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP) , biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP) , and biotin-dUTP (e.g. biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP) .
- polynucleotide oligonucleotide, ” or “nucleic acid, ” as used interchangeably herein, generally refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof, either in single-, double-, or multi-stranded form.
- a polynucleotide can be exogenous or endogenous to a cell.
- a polynucleotide can exist in a cell-free environment.
- a polynucleotide can be a gene or fragment thereof.
- a polynucleotide can be DNA.
- a polynucleotide can be RNA.
- a polynucleotide can have any three dimensional structure, and can perform any function, known or unknown.
- a polynucleotide can comprise one or more analogs (e.g. altered backbone, sugar, or nucleobase) . If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, florophores (e.g.
- rhodamine or flurescein linked to the sugar thiol containing nucleotides, biotin linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudourdine, dihydrouridine, queuosine, and wyosine.
- Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA) , transfer RNA (tRNA) , ribosomal RNA (rRNA) , short interfering RNA (siRNA) , short-hairpin RNA (shRNA) , micro-RNA (miRNA) , ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA) , nucleic acid probes, and primers.
- the sequence of nucleotides can be interrupted by non-nucleotide components.
- the term “gene” generally refers to a nucleic acid (e.g., DNA such as genomic DNA and cDNA) and its corresponding nucleotide sequence that is involved in encoding an RNA transcript.
- genomic DNA includes intervening, non-coding regions as well as regulatory regions and can include 5′and 3′ends.
- the term encompasses the transcribed sequences, including 5′and 3′untranslated regions (5′-UTR and 3′-UTR) , exons and introns.
- the transcribed region will contain “open reading frames” that encode polypeptides.
- a “gene” comprises only the coding sequences (e.g., an “open reading frame” or “coding region” ) necessary for encoding a polypeptide.
- genes do not encode a polypeptide, for example, ribosomal RNA genes (rRNA) and transfer RNA (tRNA) genes.
- rRNA ribosomal RNA genes
- tRNA transfer RNA
- the term “gene” includes not only the transcribed sequences, but in addition, also includes non-transcribed regions including upstream and downstream regulatory regions, enhancers and promoters.
- a gene can refer to an “endogenous gene” or a native gene in its natural location in the genome of an organism.
- a gene can refer to an “exogenous gene” or a non-native gene.
- a non-native gene can refer to a gene not normally found in the host organism but which is introduced into the host organism by gene transfer.
- a non-native gene can also refer to a gene not in its natural location in the genome of an organism.
- a non-native gene can also refer to a naturally occurring nucleic acid or polypeptide sequence that comprises mutations, insertions and/or deletions (e.g., non-native sequence) .
- expression generally refers to one or more processes by which a polynucleotide is transcribed from a DNA template (such as into an mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins.
- Transcripts and encoded polypeptides can be collectively referred to as “gene product. ” If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell.
- Up-regulated, with reference to expression, generally refers to an increased expression level of a polynucleotide (e.g., RNA such as mRNA) and/or polypeptide sequence relative to its expression level in a wild-type state while “down-regulated” generally refers to a decreased expression level of a polynucleotide (e.g., RNA such as mRNA) and/or polypeptide sequence relative to its expression in a wild-type state.
- Expression of a transfected gene can occur transiently or stably in a cell. During “transient expression” the transfected gene is not transferred to the daughter cell during cell division. Since its expression is restricted to the transfected cell, expression of the gene is lost over time.
- stable expression of a transfected gene can occur when the gene is co-transfected with another gene that confers a selection advantage to the transfected cell.
- a selection advantage may be a resistance towards a certain toxin that is presented to the cell.
- amino acid chains of any length, including full length proteins, and proteins with or without secondary and/or tertiary structure (e.g., domains) .
- the terms also encompass an amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulation such as conjugation with a labeling component.
- amino acid and amino acids, ” as used herein, generally refer to natural and non-natural amino acids, including, but not limited to, modified amino acids and amino acid analogues.
- Modified amino acids can include natural amino acids and non-natural amino acids, which have been chemically modified to include a group or a chemical moiety not naturally present on the amino acid.
- Amino acid analogues can refer to amino acid derivatives.
- amino acid includes both D-amino acids and L-amino acids.
- derivative, ” “variant, ” or “fragment, ” as used herein with reference to a polypeptide generally refers to a polypeptide related to a wild type polypeptide, for example either by amino acid sequence, structure (e.g., secondary and/or tertiary) , activity (e.g., enzymatic activity) and/or function.
- Derivatives, variants and fragments of a polypeptide can comprise one or more amino acid variations (e.g., mutations, insertions, and deletions) , truncations, modifications, or combinations thereof compared to a wild type polypeptide.
- engineered, ” “chimeric, ” or “recombinant, ” as used herein with respect to a polypeptide molecule generally refers to a polypeptide molecule having a heterologous amino acid sequence or an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the polypeptide molecule, as well as cells or organisms which express the polypeptide molecule.
- Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion.
- an engineered or recombinant polynucleotide e.g.,
- gene editing moiety generally refers to a moiety which can edit a nucleic acid sequence, whether exogenous or endogenous to a cell comprising the nucleic acid sequence.
- a gene editing moiety regulates expression of a gene by editing a nucleic acid sequence.
- a gene editing moiety can regulate expression of a gene by editing genomic DNA sequence.
- a gene editing moiety can regulate expression of a gene by editing an mRNA template. Editing a nucleic acid sequence can, in some cases, alter the underlying template for gene expression.
- a gene editing moiety can be capable of regulating expression or activity of a gene by specifically binding to a target sequence operatively coupled to the gene (or a target sequence within the gene) , and regulating the production of mRNA from DNA, such as chromosomal DNA or cDNA.
- a gene editing moiety can recruit or comprise at least one transcription factor that binds to a specific DNA sequence, thereby controlling the rate of transcription of genetic information from DNA to mRNA.
- a gene editing moiety can itself bind to DNA and regulate transcription by physical obstruction, for example preventing proteins such as RNA polymerase and other associated proteins from assembling on a DNA template.
- a gene editing moiety can regulate expression of a gene at the translation level, for example, by regulating the production of protein from mRNA template.
- a gene editing moiety can regulate gene expression by affecting the stability of an mRNA transcript.
- antibody generally refers to a proteinaceous binding molecule with immunoglobulin-like functions.
- the term antibody includes antibodies (e.g., monoclonal and polyclonal antibodies) , as well as derivatives, variants, and fragments thereof.
- Antibodies include, but are not limited to, immunoglobulins (Ig's) of different classes (i.e. IgA, IgG, IgM, IgD and IgE) and subclasses (such as IgG1, IgG2, etc. ) .
- a derivative, variant or fragment thereof can refer to a functional derivative or fragment which retains the binding specificity (e.g., complete and/or partial) of the corresponding antibody.
- Antigen-binding fragments include Fab, Fab′, F (ab′) 2, variable fragment (Fv) , single chain variable fragment (scFv) , minibodies, diabodies, and single-domain antibodies ( “sdAb” or “nanobodies” or “camelids” ) .
- the term antibody includes antibodies and antigen-binding fragments of antibodies that have been optimized, engineered or chemically conjugated. Examples of antibodies that have been optimized include affinity-matured antibodies. Examples of antibodies that have been engineered include Fc optimized antibodies (e.g., antibodies optimized in the fragment crystallizable region) and multispecific antibodies (e.g., bispecific antibodies) .
- chimeric polypeptide receptor generally refers to a non-natural polypeptide receptor comprising one or more antigen binding moieties, each antigen binding moiety capable of binding to a specific antigen.
- a chimeric polypeptide receptor can be monospecific (i.e., capable of binding to one type of specific antigen) .
- a chimeric polypeptide receptor can be multi-specific (i.e., capable of binding to two or more different types of specific antigens) .
- a chimeric polypeptide receptor can be monovalent (i.e., comprising a single antigen binding moiety) .
- a chimeric polypeptide receptor can be multivalent (i.e., comprising a plurality of antigen binding moieties) .
- a chimeric polypeptide receptor can comprise a T-cell receptor (TCR) fusion protein (TFP) or a chimeric antigen receptor (CAR) .
- TCR T-cell receptor
- TFP T-cell receptor
- an antigen binding domain generally refers to a construct exhibiting preferential binding to a specific target antigen.
- An antigen binding domain can be a polypeptide construct, such as an antibody, modification thereof, fragment thereof, or a combination thereof.
- the antigen binding domain can be any antibody as disclosed herein, or a functional variant thereof.
- Non-limiting examples of an antigen binding domain can include a murine antibody, a human antibody, a humanized antibody, a camel Ig, a shark heavy-chain-only antibody (VNAR) , Ig NAR, a chimeric antibody, a recombinant antibody, or antibody fragment thereof.
- Non-limiting examples of antibody fragment include Fab, Fab′, F (ab) ′2, F (ab) ′3, Fv, single chain antigen binding fragment (scFv) , (scFv) 2, disulfide stabilized Fv (dsFv) , minibody, diabody, triabody, tetrabody, single-domain antigen binding fragments (sdAb, Nanobody) , recombinant heavy-chain-only antibody (VHH) , and other antibody fragments that maintain the binding specificity of the whole antibody.
- safety switch generally refers to an engineered polypeptide construct designed to prevent potential toxicity or otherwise adverse effects of a cell therapy. When expressed in a cell, the safety switch can induce death of the host cell, thereby inactivating activity of the cell in a host (e.g., in a subject’s body) .
- the safety switch can be a suicide moiety.
- the cell can be programmed to express the suicide moiety at certain stage of its life-cycle (e.g., time-programmed) . In some cases, expression of the suicide moiety in a cell can be conditional or inducible.
- conditional regulation (e.g., expression) of a suicide moiety can include control through a small molecule-mediated post-translational activation and tissue-specific and/or temporal transcriptional regulation.
- the safety switch can be an inducible suicide moiety.
- a safety switch can mediate induction of apoptosis, inhibition of protein synthesis, DNA replication, growth arrest, transcriptional and post-transcriptional genetic regulation, and/or antibody-mediated depletion.
- a safety switch can be activated by an exogenous molecule (e.g., a drug or a prodrug) that, when activated, triggers apoptosis and/or cell death of a cell (e.g., engineered NK cell as disclosed herein) .
- an exogenous molecule e.g., a drug or a prodrug
- apoptosis and/or cell death of a cell e.g., engineered NK cell as disclosed herein
- hypo-immunity regulator generally refers to a polypeptide construct in a cell, wherein either enhanced expression (e.g., via knock-in of a heterologous gene) or reduced expression (e.g., via knock-out or knock-down of an endogenous gene) of the hypo-immunity regulator in the cell can help the cell to reduce or avoid immune response (e.g., immune attack, such as adaptive immune rejection) from a host’s body upon administration to the host’s body.
- immune response e.g., immune attack, such as adaptive immune rejection
- cells e.g., engineered NK cells as disclosed herein
- the hypo-immunity regulator can be modified to exhibit either enhanced expression or reduced expression of the hypo-immunity regulator, such that the cells can evade the host immune attack upon second or further infusion of the cells into the host (i.e., recipient) .
- the cells would not be rejected by the host’s immune system (e.g., antibody-mediated complement cytotoxicity, or antibody-dependent cellular cytotoxicity (ADCC) ) and/or (ii) would be rejected at a slower rate by the host’s immune system as compared with a control cell without the enhanced expression or reduced expression of the hypo-immunity regulator.
- the host’s immune system e.g., antibody-mediated complement cytotoxicity, or antibody-dependent cellular cytotoxicity (ADCC)
- ADCC antibody-dependent cellular cytotoxicity
- a cell exhibiting the enhanced expression or reduced expression of the hypo-immunity regulator can be referred to as exhibiting “hypo-immunity” or being “immune-privileged. ”
- enhanced hypo-immunity e.g., enhanced resistance against ADCC
- a population of engineered immune cells e.g., a population of engineered NK cells
- an antibody e.g., SSEA-4 antibody
- in vivo e.g., upon administration to a subject’s bloodstream
- engineering of an immune cell can enhance the immune cell’s resistance against immune rejection (e.g., ADCC) by at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, at least or up to about 80%, at least or up to about 85%, at least or up to about 90%, at least or up to about 95%, at least or up to about 100%, at least or up to about 150%, at least or up to about 200%, at least or up to about 300%, at least or up to about 400%, or at least or up to about 500%.
- ADCC immune rejection
- the enhanced resistance against immune rejection (e.g., ADCC) can be ascertained in vitro in a medium comprising at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, or at least or up to about 80%, human complement.
- a medium comprising at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, or at least or up to about 80%, human complement.
- immune checkpoint inhibitor generally refers to a group of molecules presented on a cell surface of an immune cell (e.g., T cells, myeloid cells, NK cells, B cells, etc. ) that can modulate immune response of the cell by down-regulating or inhibiting the immune response of the immune cell against a target cell, such as a cancer cell (i.e., anti-cancer or anti-tumor immune response) .
- a target cell such as a cancer cell (i.e., anti-cancer or anti-tumor immune response) .
- the target cell can express a receptor or a ligand of the immune checkpoint inhibitor presented on the surface of the immune cell, to engage with the immune checkpoint inhibitor and down-regulate or inhibit the immune response of the immune cells against the target cell.
- down-regulating or inhibiting expression of the immune checkpoint inhibitor in the immune cell can, in some cases, enhance or prolong the immune response of the immune cell against a target cell.
- an exogenous interleukin can comprise an interleukin that is not secreted by the cell or the population of cells (e.g., the engineered immune cell (s) , such as the engineered NK cells as disclosed herein) , and can be artificially added to the environment.
- an exogenous interleukin may comprise a recombinant interleukin protein that is added to a medium.
- an exogenous interleukin may comprise a recombinant interleukin protein that is administered to a subject in need thereof.
- the term “persistence” as used herein may generally refer to a presence of at least a portion of a population of cells (e.g., a population of engineered immune cells, such as a population of engineered NK cells as disclosed herein) remaining in an environment after introducing the population of cells to the environment (e.g., in an in vitro medium, in the serum after intravenous (IV) administration, etc. ) .
- a persistence may be ascertained by a duration of time that at least a portion of the population of cells remain in the environment at a detectable level.
- persistence of a population of cells may correlate to the half-life of the population of cells in the environment (e.g., medium, blood stream, etc. ) .
- a population of cells of interest e.g., a population of engineered immune cells, such as a population of engineered NK cells
- a population of cells having a greater persistence level (e.g., at least 5%greater) in an environment after a period of time (e.g., after at least about 5 days) than a control population of cells in a comparable environment after a comparable period of time may indicate that a greater proportion (e.g., at least 5%greater) of the size of the population of cells have survived as compared to the control population of cells.
- immune response generally refers to T cell mediated and/or B cell mediated immune responses from a host’s immune system to an object (e.g., a foreign object) .
- An example of an immune response include T cell responses, e.g., cytokine production and cellular cytotoxicity.
- an immune response can be indirectly effected by T cell activation, e.g., antibody production (humoral responses) and activation of cytokine responsive cells, such as macrophages.
- the term “enhanced expression, ” “increased expression, ” or “upregulated expression” generally refers to production of a moiety of interest (e.g., a polynucleotide or a polypeptide) to a level that is above a normal level of expression of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of expression can be substantially zero (or null) or higher than zero.
- the moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain.
- the moiety of interest can comprise a heterologous gene or polypeptide construct that is introduced to or into the host strain.
- a heterologous gene encoding a polypeptide of interest can be knocked-in (KI) to a genome of the host strain for enhanced expression of the polypeptide of interest in the host strain.
- the term “enhanced activity, ” “increased activity, ” or “upregulated activity” generally refers to activity of a moiety of interest (e.g., a polynucleotide or a polypeptide) that is modified to a level that is above a normal level of activity of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of activity can be substantially zero (or null) or higher than zero.
- the moiety of interest can comprise a polypeptide construct of the host strain.
- the moiety of interest can comprise a heterologous polypeptide construct that is introduced to or into the host strain.
- a heterologous gene encoding a polypeptide of interest can be knocked-in (KI) to a genome of the host strain for enhanced activity of the polypeptide of interest in the host strain.
- reduced expression, ” “decreased expression, ” or “downregulated expression” generally refers to a production of a moiety of interest (e.g., a polynucleotide or a polypeptide) to a level that is below a normal level of expression of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of expression is higher than zero.
- the moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain.
- the moiety of interest can be knocked-out or knocked-down in the host strain.
- reduced expression of the moiety of interest can include a complete inhibition of such expression in the host strain.
- reduced activity, ” “decreased activity, ” or “downregulated activity” generally refers to activity of a moiety of interest (e.g., a polynucleotide or a polypeptide) that is modified to a level that is below a normal level of activity of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of activity is higher than zero.
- the moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain.
- the moiety of interest can be knocked-out or knocked-down in the host strain.
- reduced activity of the moiety of interest can include a complete inhibition of such activity in the host strain.
- subject generally refers to a vertebrate, preferably a mammal such as a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
- treatment generally refers to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit.
- a treatment can comprise administering a system or cell population disclosed herein.
- therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment.
- a composition can be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.
- an effective amount or “therapeutically effective amount” generally refers to the quantity of a composition, for example a composition comprising immune cells such as lymphocytes (e.g., T lymphocytes and/or NK cells) comprising a system of the present disclosure, that is sufficient to result in a desired activity upon administration to a subject in need thereof.
- lymphocytes e.g., T lymphocytes and/or NK cells
- therapeutically effective generally refers to that quantity of a composition that is sufficient to delay the manifestation, arrest the progression, relieve or alleviate at least one symptom of a disorder treated by the methods of the present disclosure.
- T cells are part of the adaptive immune system and can be primed to recognize a specific threat by recognizing immune proteins (i.e., antigens) on a foreign cell surface.
- immune proteins i.e., antigens
- NK cells are part of the innate immune response and can respond to a broad range of objects that consider to be “non-self. ”
- NK cells can attack their target cells without sensitization (i.e., antigen-specific priming) to eliminate foreign substances.
- Unmodified NK cells derived from a subject can be cultured and expanded ex vivo, then administered to the subject as a treatment to attack their target cells, e.g., cancer cells.
- target cells e.g., cancer cells.
- NK cell-based therapies can be limited due to short half-life and/or poor proliferation of NK cells ex vivo or in vivo.
- unmodified NK cells can be ineffective in targeting harder-to-treat cancers, such as myeloma or solid tumors.
- ex vivo production of NK cells based on blood-derived stem cells e.g., HSCs
- immune cells e.g., NK cells, T cells, etc.
- NK cells e.g., T cells, etc.
- Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell) .
- Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell.
- Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target.
- the engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo.
- the engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) .
- the engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.
- engineered immune cells e.g., engineered NK cells
- engineered immune cells disclosed herein can be derived from an isolated stem cell (e.g., isolated ESCs) .
- engineered immune cells disclosed herein can be derived from induced stem cells (e.g., iPSCs) .
- the stem cell disclosed herein can be an autologous cell or derived from the autologous cell.
- the autologous cell can be obtained from a subject having a condition or is suspected of having the condition. Alternatively, the autologous cell can be obtained from the subject before the subject is found to have the condition.
- the autologous cell can be an allogeneic cell, e.g., a universal stem cell with reduced immunogenicity and with reduced amount or no need for immunosuppressive drugs.
- the autologous cell can be obtained from a healthy donor.
- the engineered immune cell (e.g., engineered NK cell) can be an autologous cell.
- the engineered immune cell can be obtained from a subject having a condition or is suspected of having the condition. Alternatively, the engineered immune cell can be obtained from the subject before the subject is found to have the condition.
- the engineered immune cell can be an allogeneic cell, e.g., for a universal allogenic immunotherapy with reduced immunogenicity and with reduced amount or no need for immunosuppressive drugs.
- the engineered immune cell can be obtained from a healthy donor.
- T cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered T cell) .
- T cells can be engineered to exhibit enhanced proliferation as compared to a control cell.
- T cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target.
- the engineered T cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo.
- the engineered T cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) .
- the engineered T cells can be autologous to the subject. Alternatively, the engineered T cells can be allogeneic to the subject.
- NK cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered NK cell) .
- NK cells can be engineered to exhibit enhanced proliferation as compared to a control cell.
- NK cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target.
- the engineered NK cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo.
- the engineered NK cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) .
- the engineered NK cells can be autologous to the subject. Alternatively, the engineered NK cells can be allogeneic to the subject.
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise or exhibit one or more members of the following:
- a chimeric polypeptide receptor e.g., a chimeric antigen receptor (CAR) , an engineered T cell receptor (TCR) , etc.
- CAR chimeric antigen receptor
- TCR engineered T cell receptor
- antigen binding moiety capable of binding to an antigen, (e.g., optionally wherein the antigen is not a NKG2D ligand)
- an antigen e.g., optionally wherein the antigen is not a NKG2D ligand
- a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell wherein the heterologous CD16 variant does not bind a ligand of the activating NK receptor (e.g., NKG2D ligand) ; and/or
- (#7) reduced expression and/or activity level of an immune checkpoint inhibitor e.g., PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, 2B4, etc.
- an immune checkpoint inhibitor e.g., PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, 2B4, etc.
- hypo-immunity regulator e.g., B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, CD59, etc. ) ; and/or
- a hypo-immunity regulator e.g., B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta,
- a safety switch capable of effecting death of the engineered NK cell (e.g., upon a stimulus, such as exposure to an activating moiety, such as light or antibody) ;
- cytokine e.g., interleukin (IL)
- IL interleukin
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#1) .
- the engineered immune cell can exhibit (#1) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#1) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#2) .
- the engineered immune cell can exhibit (#2) and one or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and two or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and three or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and four or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and five or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and six or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and seven or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and eight or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#2) and all members of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#3) .
- the engineered immune cell can exhibit (#3) and one or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and two or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and three or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and four or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and five or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and six or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and seven or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and eight or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#3) and all members of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#4) .
- the engineered immune cell can exhibit (#4) and one or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and two or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and three or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and four or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and five or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and six or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and seven or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and eight or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#4) and all members of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#5) .
- the engineered immune cell can exhibit (#5) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#5) and all members of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#6) .
- the engineered immune cell can exhibit (#6) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#6) and all members of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#7) .
- the engineered immune cell can exhibit (#7) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#7) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#8) .
- the engineered immune cell can exhibit (#8) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell can exhibit (#8) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#9) .
- the engineered immune cell can exhibit (#9) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell can exhibit (#9) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
- the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#10) .
- the engineered immune cell can exhibit (#1) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- the engineered immune cell can exhibit (#10) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
- An engineered immune cell (e.g., an engineered NK cell) comprising one or more members selected from the group constanting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced the activity (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc. ) , as compared to a control immune cell lacking at least one of the one or more members.
- an engineered immune cell e.g., an engineered NK cell
- an engineered immune cell comprising one or more members selected from the group constanting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced the activity (
- an engineered NK cell can comprise at least the enhanced expression and/or activity level of the activating NK receptor, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking enhanced expression/activity level of the activating NK receptor.
- an engineered NK cell can comprise a chimeric antigen receptor (e.g., a CAR) comprising an antigen binding moiety capable of binding CD70, CLEC12A, CD9, CD26, TRAIL-R4 (DCR2) , NKG2D ligand, and/or TIM-3, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking the CAR.
- a chimeric antigen receptor e.g., a CAR
- DCR2 TRAIL-R4
- An engineered immune cell (e.g., an engineered NK cell) comprising two or more members selected from the group constanting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced activity (e.g., persistence of viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc. ) , as compared to a control immune cell lacking at least one of the two or more members.
- enhanced activity e.g., persistence of viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc.
- an engineered NK cell can comprise (A) the enhanced expression and/or activity level of the activating NK receptor and (B) at least one or more members selected from the group consisting of (#5) , (#6) , (#7) , and (#8) , as disclosed herein, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking (A) and/or (B) .
- an engineered NK cell can comprise (A) a chimeric antigen receptor (e.g., a CAR) comprising an antigen binding moiety capable of binding CD70, CLEC12A, and/or TIM-and (B) at least one or more members selected from the group consisting of (#1) , (#7) , (#8) , and (#9) , as disclosed herein, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking (A) and/or (B) .
- a chimeric antigen receptor e.g., a CAR
- B at least one or more members selected from the group consisting of (#1) , (#7) , (#8) , and (#9) , as disclosed herein
- the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking (A) and/or (B) .
- any combination of two or more members selected from the group constanting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can induce a synergistic effect on (e.g., can synergistically enhance) an activity of the engineered immune cell (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc.
- an activity of the engineered immune cell e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc.
- an individual effect on e.g., an individual enhancement of
- the activity of a control immune cell comprising only one of the two or more members
- a sum of the individual effect on e.g., the sum of the individual enhancements of
- an engineered NK cell can exhibit at least (#1) the enhanced expression and/or activity level of an activating NK receptor and (#2) the chimeric polypeptide receptor (e.g., a CAR) comprising one or more antigen binding moieties capable of binding to an antigen that is, optionally, not a NKG2D ligand, such as BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10.
- a NKG2D ligand such as BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10.
- (#1) and (#2) can yield a synergistic effect in the engineered NK cell, such that an activity of the engineered NK cell (e.g., cytotoxicity against a cancer cell) is greater than that of (i) an individual enhancement of the activity in a control NK cell engineered to comprise only one of (#1) and (#2) and/or (ii) a sum of the individual enhancements thereof.
- an activity of the engineered NK cell e.g., cytotoxicity against a cancer cell
- Non-limiting examples of the enhanced activity of the engineered immune cell can include viability of the engineered immune cell, proliferation (or growth rate) of the engineered immune cell, survival of the engineered immune cell, cytotoxicity against a target cell such as a cancer cell, and maintenance of stemness of the engineered immune cell (e.g., stem-like T cells) .
- Such enhancement in activity can occur (or can be ascertained) in vitro, ex vivo, or in vivo.
- the enhanced activity can be at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more, as compared to that in a control immune cell.
- the enhanced activity can be at most about 100%, at most about 99%, 95%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 60%, at most about 50%, at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, at most about 2%, at most about 1%, or less, as compared to that in a control immune cell.
- the enhanced activity can be at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more, as compared to a control immune cell.
- the enhanced activity can be at most about 500-fold, at most about 200-fold, at most about 100-fold, at most about 50-fold, at most about 40-fold, at most about 30-fold, at most about 25-fold, at most about 20-fold, at most about 15-fold, at most about 10-fold, at most about 9-fold, at most about 8-fold, at most about 7-fold, at most about 6-fold, at most about 5-fold, at most about 4-fold, at most about 3-fold, at most about 2-fold, at most about 1-fold, at most about 0.5-fold, at most about 0.2-fold, at most about 0.1-fold, or less, as compared to a control immune cell.
- the synergistic effect as disclosed herein can be greater than (i) and/or (ii) by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more.
- the synergistic effect can be greater than (i) and/or (ii) by at most about 100%, at most about 99%, 95%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 60%, at most about 50%, at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, at most about 2%, at most about 1%, or less.
- the synergistic effect can be greater than (i) and/or (ii) by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more.
- the synergistic effect can be greater than (i) and/or (ii) by at most about 500-fold, at most about 200-fold, at most about 100-fold, at most about 50-fold, at most about 40-fold, at most about 30-fold, at most about 25-fold, at most about 20-fold, at most about 15-fold, at most about 10-fold, at most about 9-fold, at most about 8-fold, at most about 7-fold, at most about 6-fold, at most about 5-fold, at most about 4-fold, at most about 3-fold, at most about 2-fold, at most about 1-fold, at most about 0.5-fold, at most about 0.2-fold, at most about 0.1-fold, or less.
- any combination of two or more members selected from the group constanting of (#1) , (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can induce a synergistic effect on (e.g., can synergistically enhance) each other (e.g., A having a synergistic effect on B, B having as synergistic effect on A, or both) .
- An engineered immune cell (e.g., an engineered NK cell) can comprise at least a first member and a second member (e.g., that is different than the first member) selected from the group constanting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein.
- the synergistic effect between the first member and the second member can be such that the engineered immune cell exhibit first member in a greater degree than (i) an individual degree of the first member in a control cell comprising only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
- the synergistic effect between the first member and the second member can be such that the engineered immune cell exhibit first member in a greater degree than (i) an individual degree of the first member in a control cell comprising only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
- the degree of the first member and/or the second member can be a degree of enhancement in a target moiety’s expression, activity, and/or signaling thereof (e.g., (#1) , (#4) , (#5) , and/or (#10) , as disclosed herein) .
- the degree of the first member and/or the second member, as disclosed herein, can be a degree of reduction in a target moiety’s expression, activity, and/or signaling thereof (e.g., (#3) , (#6) , (#7) , and/or (#8) , as disclosed herein) .
- the degree of the first member and/or the second member, as disclosed herein can be a degree of expression and/or activity of a target moiety (e.g., (#2) , (#5) , (#9) , and/or (#10) , as disclosed herein) .
- an engineered NK cell as disclosed herein can comprise the enhanced expression and/or activity level of the activating NK receptor (first member) and the enhanced expression and/or activity level of DAP (second member) .
- the synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of enhancement in the expression and/or activity level of the activating NK receptor, as compared to (i) an individual degree of enhancement in the expression and/or activity level of the activating NK receptor in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
- the synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of enhancement in the expression and/or activity level of the DAP, as compared to (i) an individual degree of enhancement of the expression and/or activity level in the DAP in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
- an engineered NK cell as disclosed herein can comprise the enhanced expression and/or activity level of the activating NK receptor (first member) and the reduced expression and/or activity level of the SOCS protein (second member) .
- the synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of enhancement of the expression and/or activity level of the activating NK receptor, as compared to (i) an individual degree of enhancement in the expression and/or activity level of the activating NK receptor in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
- the synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of reduction in the expression and/or activity level of the SOCS protein, as compared to (i) an individual degree of reduction in the expression and/or activity level of the SOCS protein in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
- the degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more.
- the degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at most about 100%, at most about 99%, 95%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 60%, at most about 50%, at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, at most about 2%, at most about 1%, or less.
- the degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15- fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more.
- the degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at most about 500-fold, at most about 200-fold, at most about 100-fold, at most about 50-fold, at most about 40-fold, at most about 30-fold, at most about 25-fold, at most about 20-fold, at most about 15-fold, at most about 10-fold, at most about 9-fold, at most about 8-fold, at most about 7-fold, at most about 6-fold, at most about 5-fold, at most about 4-fold, at most about 3-fold, at most about 2-fold, at most about 1-fold, at most about 0.5-fold, at most about 0.2-fold, at most about 0.1-fold, or less.
- the engineered immune cell (e.g., the engineered NK cell) can comprise/exhibit the enhanced expression and/or activity level of the activating NK receptor as compared to a control NK cell, as disclosed herein.
- the activating NK receptor can comprise NKG2D, NKP30 (e.g., NKP30A and/or NKP30B isoforms) , NKP44, NKP46, a modification thereof, a functional variant thereof, and/or a combination thereof.
- the activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKG2D or a modification thereof.
- the activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKP30 or a modification thereof.
- the activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKP44 or a modification thereof.
- the activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKP46 or a modification thereof.
- the activating NK receptor as disclosed herein may not comprise NKG2C.
- the activating NK receptor may comprise NKG2C.
- the activating NK receptor as disclosed herein may comprise CD100 (SEMA4D) , CD16 (FcgRIIIA) , CD160 (BY55) , CD244 (2B4, SLAMF4) , CD27, CD94–NKG2C, CD94–NKG2E, CD94-NKG2H, CD96, CRTAM, DAP12, DNAM1 (CD226) , KIR2DL4, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1, Ly49, NCR, NKG2D (KLRK1, CD314) , NKp30 (NCR3) , NKp44 (NCR2) , NKp46 (NCR1) , NKp80 (KLRF1, CLEC5C) , NTB-A (SLAMF6) , PSGL1, SLAMF7 (CRACC, CS1, CD319) , CD161 (NKR-P1
- the activating NK receptor can be an endogenous activating NK receptor.
- an endogenous gene encoding the activating NK receptor can be activated (e.g., via a CRISPR-Cas system as disclosed herein) to enhance the expression and/or activity of the NK receptor.
- the activating NK receptor can be a heterologous receptor.
- the heterologous activating NK receptor can be delivered to the engineered immune cell, and/or a heterologous gene (or a heterologous polynucleotide sequence) encoding an activating NK receptor can be delivered to the engineered immune cell.
- Such heterologous gene may or may not be integrated into the genome of the engineered immune cell.
- the activating NK receptor may be a fusion protein, e.g., at least a portion (or all) of the activating NK receptor can be fused with at least a portion (or all) of a heterologous protein.
- the activating NK receptor can comprise a chimeric antigen receptor (CAR) comprising (i) at least a portion of an antigen binding domain of the activating NK receptor (e.g., at least a portion of an extracellular domain of the activating NK receptor) and (ii) an intracellular signaling domain of a CAR (e.g., a first-, second-, or third-regeneration CAR) .
- the activating NK receptor may not be a fusion protein.
- the activating NK receptor may not comprise (i) a heterologous transmembrane and/or (ii) a heterologous signaling domain (e.g., a heterologous intracellular signaling domain) .
- the activating NK receptor can be configured to bind (or capable of binding to) an antigen or ligand of NKG2D, NKP30, NKP44, and/or NKP46, NKP80, and/or DNAM1.
- a ligand of NKG2D can include a MIC family protein (e.g., MICA, MICB, etc. ) and RAET1/ULBP family protein (e.g., RAET1E/ULBP4, RAET1G/ULBP5, RAET1H/ULBP2, RAET1/ULBP1, RAET1L/ULBP6, RAET1N/ULBP3, Rae-1, H60, MULT-1, etc. ) .
- Non-limiting examples of a ligand of NKP30 can include BAT3, BAG6, B7-H6, and galectin (e.g., galenctin-3) .
- Non-limiting examples of a ligand of NKP44 can include mixed-lineage leukemia protein (MLL) (e.g., MLL5, such as 21spe-MLL5) , heparan sulfate (HS) proteoglycans (HSPG) , Nidogen glycoprotein (NID) (e.g., NID1) , Proliferating Cell Nuclear Antigen (PCNA) , Platelet-Derived Growth Factor (PDGF) (e.g., PDGF-DD) , and exosomes.
- MLL5 mixed-lineage leukemia protein
- HSPG heparan sulfate
- NID Nidogen glycoprotein
- PCNA Proliferating Cell Nuclear Antigen
- PDGF Platelet-Derived Growth Factor
- Non-limiting examples of a ligand of NKP46 can include a cytokine such as interleukin (IL) (e.g., IL-2, IL-15, etc. ) , glycoproteins such as HSPG and/or complement factor P (CFP) .
- IL interleukin
- CPF complement factor P
- Non-limiting examples of a ligand of NKP80 can include AICL and CLEC2B.
- Non-limiting examples of a ligand of DNAM1 can include CD112 and CD155.
- the enhanced expression and/or activity level of the activating NK receptor in the engineered immune cell can be greater than that in a control immune cell by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more.
- the enhanced expression and/or activity level of the activating NK receptor in the engineered immune cell can be greater than that in the control immune cell by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more.
- the control immune cell can be an immune cell (e.g., an NK cell) that is not induced to exhibit an endogenous gene encoding the activating NK receptor.
- the control immune cell can be an immune cell (e.g., an NK cell) that does not comprise a heterologous activating NK receptor or a gene encoding thereof.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise/exhibit the chimeric polypeptide receptor (e.g., CAR, engineered TCR, etc. ) comprising the antigen binding moiety capable of binding to the antigen.
- the antigen may not be a ligand of the activating NK receptor as disclosed herein.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKG2D.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKP30.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKP44. In another example, the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKP46.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can be selected from the group consisting of CD70, C-type lectin domain family protein (e.g., CLEC12A) , TIM-3, CD38, CD9, CD26, TRAIL-R4 (DCR2) , NKG2D ligand, and BCMA.
- C-type lectin domain family protein e.g., CLEC12A
- TIM-3 e.g., CD38, CD9, CD26, TRAIL-R4 (DCR2) , NKG2D ligand, and BCMA.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise CD70.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise a C-type lectin domain family protein, e.g., C-type lectin domain family 12 member A (CLEC12A or CLL-1) .
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise TIM-3.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise CD38.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise BCMA.
- the engineered immune cell can exhibit the reduced expression and/or activity level of the SOCS protein.
- the SOCS protein can include CIS, SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, and SOCS-7.
- the SOCS protein can comprise SOCS2.
- the SOCS protein can be an endogenous protein.
- an endogenous gene encoding the SOCS protein can be hindered or modified (e.g., via a CRISPR-Cas system as disclosed herein, or via a small molecule or protein inhibitor of the SOCS2 protein itself) to reduce the expression and/or activity of SOCS protein.
- the reduced expression and/or activity level of the SOCS protein (e.g., SOCS2) in the engineered immune cell (e.g., the engineered NK cell) can be less than that in a control immune cell (e.g., that is not contacted by a CRISPR/Cas protein to hinder or modify a gene encoding the SOCS protein) by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 00%, or about 100%.
- SOCS2 SOCS2
- a control immune cell e.g., that is not contacted by a CRISPR/Cas protein to hinder or modify a gene encoding the SOCS protein
- the reduced expression and/or activity level of the SOCS protein (e.g., SOCS2) in the engineered immune cell (e.g., the engineered NK cell) can be less than that in the control immune cell by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more.
- SOCS2 SOCS2
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise (or exhibit) the enhanced expression and/or activity level of DAP.
- DAP can include DAP-10 and DAP-12.
- the DAP can be an endogenous DAP, and the engineered immune cell can be induced (e.g., via action of a nuclease system) to exhibit the enhanced expression or activity level of the endogenous DAP.
- the engineered immune cell can be contacted with (e.g., transfected or transduced with) as a CRISPR-Cas system comprising a Cas protein and a guide nucleic acid molecule that are configured to form a complex capable of binding a gene that (i) encodes the endogenous DAP or (ii) controls expression and/or activity of the endogenous DAP.
- the DAP can be a heterologous DAP.
- the heterologous DAP or a gene encoding thereof can be delivered (e.g., via transfection, viral delivery vehicles, non-viral delivery vehicles, etc. ) to the engineered immune cell.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise (or exhibit) the heterologous cytokine (e.g., IL) and/or the heterologous receptor thereof for enhanced signaling of the cytokine in the engineered immune cell, as compared to that in a control NK cell.
- the heterologous cytokine e.g., IL
- the heterologous cytokine (e.g., the heterologous IL) and/or the heterologous receptor thereof, as disclosed herein, can be of the same species as that of the engineered immune cell (e.g., the engineered NK cell) .
- both the heterologous cytokine (and/or the heterologous receptor thereof) and the engineered immune cell can be of human origin.
- the heterologous cytokine (and/or the heterologous receptor thereof) can be of a different species than that of the engineered immune cell.
- a heterologous cytokine e.g., the heterologous IL and/or the heterologous receptor thereof, as disclosed herein, can be introduced to the engineered immune cell (e.g., engineered NK cell) by contacting a heterologous polynucleotide encoding the heterologous cytokine and/or the heterologous receptor thereof to the engineered immune cell.
- the heterologous polynucleotide can be integrated into the engineered immune cell’s chromosome (e.g., nuclear chromosome) .
- the heterologous polynucleotide may not and need not be integrated into the chromosome of the engineered immune cell.
- a mRNA encoding a heterologous cytokine can be introduced (or inserted into) the engineered immune cell.
- the cytokine as disclosed herein can be IL.
- An IL as disclosed herein can comprise at least 1, 2, 3, 4, 5, or more different types of ILs.
- An IL as disclosed herein can comprise at most 5, 4, 3, or 2 different type of ILs.
- the IL can be a single type of IL.
- Non-limiting examples of the IL can include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36.
- the IL can comprise one or more members selected from the group consisting of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and functional modifications thereof.
- the engineered immune cell e.g., an engineered NK cell
- the engineered immune cell can comprise at least a portion of heterologous variant of any one of the IL as disclosed herein, such as human IL-15 (or a gene encoding thereof) .
- the engineered immune cell e.g., an engineered NK cell
- the engineered immune cell can comprise at least a portion of heterologous variant of a receptor of any one of the IL as disclosed herein, such as human IL-15 receptor (IL-15R) (or a gene encoding thereof) .
- IL-15R human IL-15 receptor
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be a secretory cytokine.
- the heterologous cytokine may not and need not be secreted by the engineered immune cell.
- the heterologous cytokine can be bound to a cell surface of the engineered immune cell.
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be a secretory cytokine.
- An expression cassette encoding the heterologous cytokine can be introduced to the engineered immune cell.
- the expression cassette can further encode an additional heterologous polypeptide, e.g., a heterologous receptor.
- a first polynucleotide sequence encoding the heterologous cytokine and a second polynucleotide sequence encoding the additional heterologous polypeptide (e.g., the heterologous receptor) can be coupled to each other via a polynucleotide linker encoding a cleavage linker.
- the heterologous receptor can be a respective receptor of the heterologous cytokine (e.g., heterologous IL-15 ⁇ or IL-15 ⁇ for heterologous IL-15) .
- the expression cassette may not and need not encode any additional heterologous polypeptide other than the heterologous cytokine.
- a cleavable linker as disclosed herein can comprise a self-cleaving peptide, such as a self-cleaving 2A peptide.
- Self-cleaving peptides can be found in members of the Picornaviridae virus family, including aphthoviruses such as foot-and-mouth disease virus (FMDV) , equine rhinitis A virus (ERAV) , Thosea asigna virus (TaV) and porcine tescho virus-1 (PTV-I) , and cardioviruses such as Theilovirus (e.g., Theiler's murine encephalomyelitis) and encephalomyocarditis viruses.
- Non-limiting examples of the self-cleaving 2A peptide can include “F2A” , “E2A” , “P2A” , “T2A” , and functional variants thereof.
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be bound to a cell surface the engineered immune cell (e.g., the engineered NK cell) .
- the engineered immune cell can be genetically modified such that a heterologous polynucleotide sequence encoding the heterologous cytokine is coupled to a gene encoding an endogenous transmembrane protein of the engineered immune cell.
- the endogenous transmembrane protein can be a respective receptor of the heterologous cytokine (e.g., heterologous IL-15 ⁇ or IL-15 ⁇ for heterologous IL-15) .
- an expression cassette encoding a heterologous fusion polypeptide comprising (i) the heterologous cytokine that is coupled to (ii) a heterologous receptor can be introduced to the engineered immune cell.
- the heterologous cytokine may not and need not be cleavable from the heterologous receptor.
- Non-limiting examples of the heterologous receptor can include a respective receptor of the heterologous cytokine (e.g., heterologous IL-15 ⁇ or IL-15 ⁇ for heterologous IL-15) , or a different receptor such as a common gamma chain ( ⁇ C ) receptor or a modification thereof.
- An expression cassette as disclosed herein can be integrated into the genome of the engineered cell (e.g., the engineered NK cell) via action of a gene editing moiety as disclosed herein.
- the expression cassette may not and need not be integrated into the genome of the engineered cell.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced signaling of an endogenous signaling pathway that involves the heterologous cytokine (e.g., the heterologous IL, such as the heterologous IL-15) and/or the heterologous receptor (e.g., the heterologous IL receptor, such as the heterologous IL-15R) as disclosed herein.
- the enhanced signaling of the endogenous signaling pathway as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., JAK3, STAT3, STAT5, etc.
- a downstream gene e.g., Mcl1, Cdk4/6, Mki67, Tnf, Gzmb, Gzmc, Ifng, etc. for IL-15/IL-15R
- PCR polymerase chain reaction
- enhanced signaling of the endogenous signaling pathway that is induced by the heterologous cytokine and/or the heterologous receptor can be characterized by an increase in phosphorylation of a downstream signaling protein by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about
- enhanced signaling of the endogenous signaling pathway that is induced by the heterologous cytokine and/or the heterologous receptor can be characterized by an increased expression of a downstream gene by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or
- CD16 signaling e.g., constitutively activated signaling of CD16
- engineered immune cell e.g., engineered NK cell
- Enhanced CD16 signaling (e.g., constitutively activated signaling of CD16) of the engineered immune cell (e.g., engineered NK cell) as disclosed herein can be achieved by having non-cleavable CD16 variant in the subject cell.
- CD16 e.g., CD16a
- immune cells e.g., NK cells
- ADCC antibody-dependent cell-mediated cytotoxicity
- the binding between CD16 and the monomeric IgG can induce cleavage of the CD16 protein at a cleavage site near the transmembrane domain, to regulates the cell surface density of CD16 upon immune cell activation.
- the endogenous CD16 of the engineered immune cell can be modified to enhance its signaling.
- an enhanced signaling variant of CD16 can be artificially introduced to the engineered immune cell.
- the engineered immune cell’s endogenous gene encoding CD16 can be genetically modified in its ectodomain (e.g., F176V) via action of a gene editing moiety as disclosed herein, such that the modified CD16 exhibits higher binding affinity to its target (e.g., monomeric IgG) as compared to a natural CD16.
- a heterologous gene encoding such modified CD16 can be introduced to the cell.
- the engineered immune cell’s endogenous gene encoding CD16 can be genetically modified via action of a gene editing moiety as disclosed herein, such that the modified CD16 is non-cleavable and can induce enhanced CD16 signaling.
- the cleavage site e.g., position 195-198 in the membrane-proximal region (position 189-212) of CD16 can be modified or eliminated (e.g., CD16 S197P variant as a non-cleavable CD16 variant) .
- a heterologous gene encoding such modified CD16 can be introduced to the cell.
- a heterologous gene encoding a heterologous CD16 variant that (i) exhibits higher binding affinity to its target (e.g., monomeric IgG) and (ii) is non-cleavable can be introduced to the cell (i.e., hnCD16) .
- the heterologous CD16 variant can be a modified CD16 comprising, for example, F176V and S197P, as disclosed herein.
- the heterologous CD variant can be a fusion receptor protein comprising (i) at least a portion of CD16 with an inactivated cleavage site and (ii) an ectodomain of a different cell surface protein, such as a glycoprotein (e.g., CD64) , that exhibits enhanced binding to the target (e.g., monomeric IgG) as compared to an unmodified CD16.
- a fusion receptor protein comprising (i) at least a portion of CD16 with an inactivated cleavage site and (ii) an ectodomain of a different cell surface protein, such as a glycoprotein (e.g., CD64) , that exhibits enhanced binding to the target (e.g., monomeric IgG) as compared to an unmodified CD16.
- a heterologous gene as disclosed herein can be integrated into the genome of the engineered cell (e.g., the engineered NK cell) via action of a gene editing moiety as disclosed herein.
- the heterologous gene may not and need not be integrated into the genome of the engineered cell.
- the enhanced CD16 signaling of the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., SHP-1) via Western blotting or (ii) expression of a downstream gene (e.g., CD25, IFN-gamma, TNF, etc. ) via Western blotting or PCR techniques.
- a downstream signaling protein e.g., SHP-1
- a downstream gene e.g., CD25, IFN-gamma, TNF, etc.
- the CD16 signaling of the engineered immune cell (e.g., the engineered NK cell comprising hnCD16) of the present disclosure can be greater than CD16 signaling of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- enhanced CD16 signaling of the engineered immune cell e.g., the engineered NK cell comprising hnCD16
- the engineered immune cell can be characterized by an increase in phosphorylation of a downstream signaling protein by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up or
- enhanced CD16 signaling of the engineered immune cell e.g., the engineered NK cell comprising hnCD16
- the engineered immune cell can be characterized by an increased expression of a downstream gene by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- the CD16 signaling of the engineered immune cell e.g., the engineered NK cell comprising hnCD16
- the CD16 signaling of the engineered immune cell can be more prolonged (e.g., a longer duration of time of activated CD16 signaling) than CD16 signaling of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or
- the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise reduced activity of endogenous cytokine signaling (e.g., endogenous IL signaling, such as endogenous IL-17 signaling) .
- the engineered immune cell can be derived from an isolated stem cell (e.g., an isolated ESC) .
- the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
- the engineered NK cell can be treated with inhibitors (e.g., small molecule inhibitors) of the endogenous cytokine signaling.
- the engineered NK cell can comprise reduced expression of endogenous IL (e.g., endogenous IL-17) or endogenous receptor thereof (e.g., via indel or transgene mutation, via transient or permanent suppression, etc. ) .
- the engineered NK cell can comprise reduced expression of endogenous IL-17.
- the engineered NK cell can comprise reduced expression of endogenous IL-17R.
- the engineered NK cell can comprise reduced expression of endogenous IL-17 and endogenous IL-17R.
- the endogenous cytokine as disclosed herein can be an endogenous IL.
- An endogenous IL as disclosed herein can comprise at least 1, 2, 3, 4, 5, or more different types of endogenous ILs.
- An endogenous IL as disclosed herein can comprise at most 5, 4, 3, or 2 different type of endogenous ILs.
- the endogenous IL can be a single type of endogenous IL.
- Non-limiting examples of the endogenous IL can include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36.
- the endogenous IL can be IL-17.
- Non-limiting examples of endogenous Il-17 can include IL-17A, IL-17F, and natural mutations thereof.
- the engineered immune cell e.g., an engineered NK cell
- the engineered immune cell as disclosed herein can exhibit reduced expression or activity of IL-17A or IL-17F.
- an endogenous gene encoding the endogenous cytokine e.g., an endogenous IL, such as IL-17
- an endogenous cytokine e.g., an endogenous IL, such as IL-17
- a gene editing moiety as disclosed herein.
- the endogenous receptor can be a respective receptor of any cytokine as disclosed herein (e.g., a respective receptor of any IL as disclosed herein) .
- the endogenous receptor can be a respective receptor of IL (e.g., IL-17R for IL-7 signaling) .
- IL-17R can include IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE, and variants thereof.
- the endogenous IL-17R comprises IL-17RA.
- the reduced expression or activity of the endogenous cytokine e.g., an endogenous IL, such as IL-17
- endogenous receptor thereof as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., PI3K, Act1, MAP3K, MEK1/2, MKK3/6, MKK4/7, MKK3/6, ERK, p38, JNK, etc. for IL-17) or (ii) expression of a downstream gene via Western blotting or PCT techniques.
- a downstream signaling protein e.g., PI3K, Act1, MAP3K, MEK1/2, MKK3/6, MKK4/7, MKK3/6, ERK, p38, JNK, etc.
- a downstream gene of IL cytokine can include a chemokine (e.g., CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, CCL2, CCL20, etc. ) , a cytokine (e.g., IL-6, TNFa, G-CSF, GM-CSF, etc. ) , an acute phase response molecule (e.g., SAA, CRP, lipocalin 2/24p3, etc. ) , and/or an enzyme (e.g., a metalloproteinase, such as MMP1, MMP3, MMP9, MMP13) .
- a chemokine e.g., CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, CCL2, CCL20, etc.
- a cytokine e.g., IL-6, TNFa, G-CSF, GM-CSF, etc.
- reduced expression or activity of the endogenous cytokine e.g., the endogenous IL, such as IL-17
- engineered immune cell e.g., engineered NK cell
- reduced expression or activity of the endogenous cytokine can be characterized by a decrease in phosphorylation of a downstream signaling protein of the endogenous cytokine by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-
- reduced expression or activity of the endogenous cytokine e.g., the endogenous IL, such as IL-17
- engineered immune cell e.g., engineered NK cell
- reduced expression or activity of the endogenous cytokine can be characterized by a decrease in the expression of a downstream gene of the endogenous cytokine by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced expression profile of a specific cell marker for a committed immune cell (e.g., a NK cell marker) as compared to a control cell that does not exhibit the reduced activity of the endogenous cytokine signaling (e.g., endogenous IL signaling, such as endogenous IL-17 signaling) as disclosed herein.
- a specific cell marker for committed NK cells can include CD57 or killer immunoglobulin-like receptors (KIR) .
- KIR can comprise KIR2D and/or KIR3D.
- KIR2D can comprise KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, and/or KIR2DS5.
- KIR3D can comprise KIR3DL1, KIR3DL2, KIR3DL3, and/or KIR3DS1.
- the enhanced expression profile of the specific cell marker for the committed immune cell (e.g., CD57 or KIR for NK cells) as disclosed herein can be ascertained by a number of methods, including, but are not limited to, Western blotting or PCR techniques.
- the expression of the specific cell marker for a committed immune cell (e.g., CD57 or KIR or NK cells) in the engineered immune cell of the present disclosure can be greater than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about
- the engineered immune cell (e.g., the engineered NK cell) comprising one or more members (e.g., two or more members) selected from the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced survival in the presence of tumor cells as compared to a control cell lacking at least one of the one or more members.
- members e.g., two or more members
- the engineered immune cell can, in the presence of tumor cells, survive longer than the control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit reduced expression or activity of one or more immune checkpoint inhibitors (e.g., PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, 2B4, etc. ) .
- the one or more immune checkpoint inhibitors can be endogenous to the engineered immune cell.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous CTLA-4.
- the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous TIM-3.
- the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous KIR2D.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous NKG2A.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit reduced expression and/or activity of endogenous TIGIT.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit reduced expression and/or activity of endogenous TGF beta receptor.
- the engineered immune cell e.g., the engineered NK cell
- the reduced expression or activity of the immune checkpoint inhibitor (e.g., CD94, CD96, TGF beta receptor, etc. ) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit reduced expression or activity of one or more hypo-immunity regulators (e.g., one or more endogenous immune regulator polypeptides) , as disclosed herein.
- one or more hypo-immunity regulators e.g., one or more endogenous immune regulator polypeptides
- the one or more hypo-immunity regulators can be selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit reduced expression or activity of one or more endogenous polypeptides (e.g., endogenous immune regulating polypeptide) .
- the one or more endogenous polypeptides can comprise one or more members of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN2, PTPN6, and/or CD70.
- the one or more endogenous polypeptides can comprise one or more members of NLRC5, RFXANK, RFXAP, CD80, CD7, TAP2, TAP1, TAPBP.
- the reduced expression or activity of such one or more endogenous polypeptides in the engineered NK cell can enhance one or more characteristics of the engineered NK cell (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, etc. ) .
- the reduced expression or activity of such one or more endogenous polypeptides in the engineered NK cell can enhance persistence of the engineered cell in a sub-optimal environment.
- the reduced expression or activity of such one or more endogenous polypeptides in the engineered NK cell can enhance resistance against immune rejection (e.g., ADCC cytotoxicity of the engineered NK cell) .
- the expression or activity of the hypo-immunity regulator (e.g., the endogenous hypo-immunity regulator) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than the same in a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to
- the engineered immune cell can exhibit reduced expression or activity of endogenous CD38 as compared to a control cell.
- Such engineered immune cell may be used to treat a subject who has or is suspected of having white blood cell cancer, such as multiple myeloma (MM) .
- MM multiple myeloma
- any one of the engineered immune cell e.g., the engineered NK cell
- expression or activity of endogenous CD38 of the engineered immune cell may not and need not be modified.
- Such engineered immune cell may be used to treat a subject who has or is suspected of having a disease (e.g., cancer, tumor) that is not multiple myeloma.
- the engineered immune cell (e.g., the engineered NK cell) can comprise the chimeric polypeptide receptor (or at least one chimeric polypeptide receptor) comprising an antigen binding moiety capable of binding to an antigen, as provided in the present disclosure.
- the engineered immune cell can comprise a plurality of different chimeric polypeptide receptors to specifically bind a plurality of different antigens.
- the engineered immune cell can comprise at least one chimeric polypeptide receptor that comprises a plurality of antigen binding moieties to specifically bind a plurality of different antigens.
- the engineered immune cell can comprise a safety switch capable of effecting death of the engineered immune cell.
- the engineered immune cell can comprise a gene encoding the safety switch (e.g., integrated into the genome of the immune cell) , via action of the gene editing moiety, as disclosed herein.
- a prodrug can be introduced to the engineered immune cell (e.g., administered to a subject comprising the engineered immune cell) in the event of an adverse event or when the adaptive immunotherapy is no longer necessary, and the prodrug can be activated by the safety switch molecule to kill the subject immune cell.
- the safety switch can comprise one or more members selected from the group consisting of caspase (e.g., caspase 3, 7, or 9) , thymidine kinase, cytosine deaminase, modified EGFR, B-cell CD20, and functional variants thereof.
- the safety switch can be activated via an activator (e.g., a small molecule or a protein, such as an antibody) for post-translational, temporal, and/or site-specific regulation of death (or depletion) of the subject engineered immune cell.
- an activator e.g., a small molecule or a protein, such as an antibody
- Non-limiting examples of a safety switch and its activator can include Caspase 9 (or caspase 3 or 7) and AP1903; thymidine kinase (TK) and ganciclovir (GCV) ; and cytosine deaminase (CD) and 5-fluorocytosine (5-FC) .
- Caspase 9 or caspase 3 or 7
- AP1903 thymidine kinase
- GCV ganciclovir
- CD cytosine deaminase
- 5-FC 5-fluorocytosine
- modified epidermal growth factor receptor (EGFR) containing epitope recognized by an antibody e.g., anti-EGFR Ab, such as cetuximab
- an antibody e.g., anti-EGFR Ab, such as cetuximab
- the engineered immune cells e.g., the engineered NK cells
- the engineered immune cells can comprise a safety switch protein selected from the group consisting of caspase 9 (caspase 3 or 7) , thymidine kinase, cytosine deaminase, modified EGFR, and B-cell CD20.3
- the engineered immune cell can exhibit enhanced persistence or survival (e.g., in an environment substantially free of exogenous cytokine, such as IL-2 or IL-5; or in an environment with sub-optimal dose of such exogenous cytokine; in vitro environment; in vivo environment, etc. ) as compared to a control cell.
- the engineered immune cell as disclosed herein can exhibit enhanced persistence or survival (e.g., in vitro, ex vivo, or in vivo) that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to
- the engineered immune cell can exhibit enhanced proliferation or growth rate (e.g., in an environment substantially free of exogenous cytokine, such as IL-2 or IL-5; or in an environment with sub-optimal dose of such exogenous cytokine; in vitro environment; in vivo environment, etc. ) as compared to a control cell.
- enhanced proliferation or growth rate e.g., in an environment substantially free of exogenous cytokine, such as IL-2 or IL-5; or in an environment with sub-optimal dose of such exogenous cytokine; in vitro environment; in vivo environment, etc.
- the engineered immune cell as disclosed herein can exhibit enhanced proliferation or growth rate (e.g., in vitro, ex vivo, or in vivo) that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up
- the engineered immune cell can exhibit enhanced cytotoxicity against a target cell as compared to a control cell.
- the engineered immune cell as disclosed herein can exhibit cytotoxicity (e.g., in vitro, ex vivo, or in vivo) against a target cell or a target population of cells that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or
- the engineered immune cell can induce reduced immune response from separate immune cells (e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host) as compared to a control cell.
- separate immune cells e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host
- the engineered immune cell as disclosed herein can reduce the immune response from the separate immune cells by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold,
- the engineered immune cell can exhibit enhanced half-life upon exposure to separate immune cells (e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host) as compared to a control cell.
- separate immune cells e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host
- the half-life of the engineered immune cells can be greater than that of the control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about
- the engineered immune cell can effect enhanced function or pathological condition of a bodily tissue of a subject as compared to a control cell.
- treatment with the engineered immune cell can effect enhanced function or pathological condition of a bodily tissue of a subject by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold,
- the engineered immune cell can effect delayed degeneration of function or pathological condition of a bodily tissue of a subject as compared to a control cell.
- treatment with the engineered immune cell can effect delayed degeneration of function or pathological condition of a bodily tissue of a subject by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up
- the bodily tissue can comprise one or more members selected from the group consisting of blood, plasma, serum, urine, perilymph fluid, feces, saliva, semen, amniotic fluid, cerebrospinal fluid, bile, sweat, tears, sputum, synovial fluid, vomit, bone, heart, thymus, artery, blood vessel, lung, muscle, stomach, intestine, liver, pancreas, spleen, kidney, gall bladder, thyroid gland, adrenal gland, mammary gland, ovary, prostate gland, testicle, skin, adipose, eye, brain, infected tissue, diseased tissue, malignant tissue, calcified tissue, and healthy tissue.
- the bodily tissue can comprise one or more members selected from the group consisting of blood, plasma, serum, urine, perilymph fluid, feces, saliva, semen, amniotic fluid, cerebrospinal fluid, bile, sweat, tears, sputum, synovial fluid, vomit, bone, heart,
- the engineered immune cell can induce immune response towards a target cell.
- the target can be, for example, a diseased cell, a cancer cell, a tumor cell, etc.
- a heterologous gene can be operatively coupled to (e.g., for knock-in) a constitutive, inducible, temporal, tissue-specific, and/or cell type-specific promoter.
- a promoter of interest can include CMV, EF1a, PGK, CAG, and UBC.
- Non-limiting examples of an insertion site can include AAVS1, CCR5, ROSA26, collagen, HTRP, H11, B2M, GAPDH, TCR, RUNX1, TAP1, TAP2, tapasin, NLRC5, CIITA, RFXANK, CIITA, RFX5, RFXAP, TCR a or b constant region, NKG2A, NKG2D, CD38, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT.
- any one of the engineered immune cell e.g., the engineered NK cell
- TME tumor microenvironment gene
- having reduced expression or activity of a TME can enhance the engineered immune cell’s immune activity against a target cell.
- a TME gene may be an immune checkpoint inhibitor.
- Non-limiting examples of the TME can include: NKG2A, NKG2D, PD1, CTLA4, LAG3, TIM3, TIGIT, KIR2D, CD94, CD96, TGF beta receptor, 2B4, and SHIP2.
- any one of the engineered immune cell e.g., the engineered NK cell
- can exhibit one or more heterologous genes e.g., knocked-in
- enhanced function CD137, CD80, CD86, DAP10 (e.g., with or without point mutation) .
- any one of the engineered immune cell e.g., the engineered NK cell
- endogenous genes for, e.g., hypo-immunity: B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, and a NKG2DL (e.g., ULBP1) .
- any one of the engineered immune cell e.g., the engineered NK cell
- can exhibit one or more heterologous genes e.g., knocked-in for, e.g., hypo-immunity: HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
- heterologous genes e.g., knocked-in for, e.g., hypo-immunity: HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
- any one of the engineered immune cell e.g., the engineered NK cell
- can exhibit one or more heterologous genes e.g., knocked-in: CD3, CD4, CD80, 41BBL, and CD131.
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can comprise a chimeric polypeptide receptor as disclosed herein (e.g., at least 1, 2, 3, 4, 5, or more different types of chimeric polypeptide receptors) .
- the engineered immune cell can be engineered to express a chimeric polypeptide receptor transiently or permanently.
- a recombinant chimeric polypeptide receptor can be delivered to the engineered immune cell via, e.g., a liposome, and be incorporated into the engineered immune cell via membrane fusion.
- a heterologous polynucleotide construct encoding the chimeric polypeptide receptor can be delivered to the engineered immune cell.
- the heterologous polynucleotide construct i.e., a gene
- encoding the heterologous polynucleotide construct can be incorporated into the chromosome of the engineered immune cell (i.e., chromosomal gene) or, alternatively, may not or need not be integrated into the chromosome of the engineered immune cell as disclosed herein.
- a chimeric polypeptide receptor can comprises a T cell receptor fusion protein (TFP) .
- T cell receptor fusion protein or “TFP” generally refers to a recombinant polypeptide construct comprising (i) one or more antigen binding moieties (e.g., monospecific or multispecific) , (ii) at least a portion of TCR extracellular domain, (iii) at least a portion of TCR transmembrane domain, and (iv) at least a portion of TCR intracellular domain.
- an endogenous T cell receptor (TCR) of the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be inactivated.
- a function of the endogenous TCR of the engineered immune cell can be inhibited by an inhibitor.
- a gene encoding a subunit of the endogenous TCR can be inactivated (e.g., edited via action of the gene editing moiety as disclosed herein) such that the endogenous TCR is inactivated.
- the gene encoding the subunit of endogenous TCR can be one or more of: TCR ⁇ , TCR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , and CD3 ⁇ .
- a chimeric polypeptide receptor can comprises a chimeric antigen receptor (CAR) .
- CAR chimeric antigen receptor
- the term “chimeric antigen receptor” or “CAR” generally refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as “an intracellular or intrinsic signaling domain” ) comprising a functional signaling domain derived from a stimulatory molecule.
- the stimulatory molecule may be the zeta chain associated with the T cell receptor complex.
- the intracellular signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule.
- the costimulatory molecule may comprise 4-1BB (i.e., CD137) , CD27, and/or CD28.
- the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein.
- the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen recognition domain, wherein the leader sequence is optionally cleaved from the antigen recognition domain (e.g., a scFv) during cellular processing and localization of the CAR to the cellular membrane.
- a CAR may be a first-, second-, third-, or fourth-generation CAR system, a functional variant thereof, or any combination thereof.
- First-generation CARs include an antigen binding domain with specificity for a particular antigen (e.g., an antibody or antigen-binding fragment thereof such as an scFv, a Fab fragment, a VHH domain, or a VH domain of a heavy-chain only antibody) , a transmembrane domain derived from an adaptive immune receptor (e.g., the transmembrane domain from the CD28 receptor) , and a signaling domain derived from an adaptive immune receptor (e.g., one or more (e.g., three) ITAM domains derived from the intracellular region of the CD3 ⁇ receptor or Fc ⁇ RI ⁇ ) .
- an adaptive immune receptor e.g., one or more (e.g., three) ITAM domains derived from the intracellular region of the CD3 ⁇ receptor or Fc ⁇ RI ⁇
- Second-generation CARs modify the first-generation CAR by addition of a co-stimulatory domain to the intracellular signaling domain portion of the CAR (e.g., derived from co-stimulatory receptors that act alongside T-cell receptors such as CD28, CD137/4-1BB, and CD134/OX40) , which abrogates the need for administration of a co-factor (e.g., IL-2) alongside a first-generation CAR.
- Third-generation CARs add multiple co-stimulatory domains to the intracellular signaling domain portion of the CAR (e.g., CD3 ⁇ -CD28-OX40, or CD3 ⁇ -CD28-41BB) .
- Fourth-generation CARs modify second-or third-generation CARs by the addition of an activating cytokine (e.g., IL-12, IL-23, or IL-27) to the intracellular signaling portion of the CAR (e.g., between one or more of the costimulatory domains and the CD3 ⁇ ITAM domain) or under the control of a CAR-induced promoter (e.g., the NFAT/IL-2 minimal promoter) .
- a CAR may be a new generation CAR system that is different than the first-, second-, third-, or fourth-generation CAR system as disclosed herein.
- a hinge domain (e.g., the linker between the extracellular antigen binding domain and the transmembrane domain) of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3c CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, NKp30, NKp44, NKp46, NKG2C, NKG2D, or T cell receptor polypeptide.
- a transmembrane domain of a CAR in the engineered immune cell can comprise a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3c CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, NKp30, NKp44, NKp46, NKG2C, NKG2D, or T cell receptor polypeptide.
- the hinge domain and the transmembrane domain of a CAR as disclosed herein can be derived from the same protein (e.g., CD8) .
- the hinge domain and the transmembrane domain of the CAR as disclosed herein can be derived from different proteins.
- a signaling domain of a CAR can comprise at least or up to about 1 signaling domain, at least or up to about 2 signaling domains, at least or up to about 3 signaling domains, at least or up to about 4 signaling domains, at least or up to about 5 signaling domains, at least or up to about 6 signaling domains, at least or up to about 7 signaling domains, at least or up to about 8 signaling domains, at least or up to about 9 signaling domains, or at least or up to about 10 signaling domains.
- a signaling domain (e.g., a signaling peptide of the intracellular signaling domain) of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of a polypeptide of CD3 ⁇ , 2B4, DAP10, DAP12, DNAM1, CD137 (41BB) , IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, NKG2D, or any combination thereof.
- the signaling domain CAR in the engineered immune cell can comprise a full length or at least a portion of a polypeptide of CD27, CD28, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D, or any combination thereof.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell comprises the chimeric polypeptide receptor (e.g., CAR) that comprises at least CD8 transmembrane domain and one or more of: (i) 2B4 signaling domain and (ii) DAP10 signaling domain.
- the engineered cell e.g., the engineered NK cell
- the chimeric polypeptide receptor e.g., TFP or CAR
- the 2B4 signaling domain can be flanked by the CD8 transmembrane domain and the DAP10 signaling domain.
- the DAP10 signaling domain can be flanked by the CD8 transmembrane domain and the 2B4 signaling domain.
- the chimeric polypeptide receptor as disclosed herein can further comprise yet an additional signaling domain derived from CD3 ⁇ .
- An antigen (i.e., a target antigen) of an antigen binding moiety of a chimeric polypeptide receptor can be a cell surface marker, a secreted marker, or an intracellular marker.
- Non-limiting examples of an antigen (i.e., a target antigen) of an antigen binding moiety of a chimeric polypeptide receptor (e.g., TFP or CAR) as disclosed herein can include ADGRE2, carbonic anhydrase IX (CA1X) , CCRI, CCR4, carcinoembryonic antigen (CEA) , CD3 ⁇ , CD5, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD133, CD138, CD269 (BCMA) , CD S, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen) , epithelial glycoprotein2 (EGP 2) , epithelial glycoprotein-40 (EGP-40) , epithelial cell adhesion molecule (EpCAM)
- antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include 1-40- ⁇ -amyloid, 4-1BB, 5AC, 5T4, activin receptor-like kinase 1, ACVR2B, adenocarcinoma antigen, AGS-22M6, alpha-fetoprotein, angiopoietin 2, angiopoietin 3, anthrax toxin, AOC3 (VAP-1) , B7-H3, Bacillus anthracis anthrax, BAFF, beta-amyloid, B-lymphoma cell, C242 antigen, C5, CA-125, Canis lupus familiaris IL31, carbonic anhydrase 9 (CA-IX) , cardiac myosin, CCL11 (eotaxin-1) , CCR4, CCR5, CD11, CD18, CD125, CD140a, CD147 (basigin) , CD15, CD152, CD154 (CD40L)
- coli shiga toxin type-1 E. coli shiga toxin type-2, EGFL7, EGFR, endotoxin, EpCAM, episialin, ERBB3, Escherichia coli, F protein of respiratory syncytial virus, FAP, fibrin II beta chain, fibronectin extra domain-B, folate hydrolase, folate receptor 1, folate receptor alpha, Frizzled receptor, ganglioside GD2, GD2, GD3 ganglioside, glypican 3, GMCSF receptor ⁇ -chain, GPNMB, growth differentiation factor 8, GUCY2C, hemagglutinin, hepatitis B surface antigen, hepatitis B virus, HER1, HER2/neu, HER3, HGF, HHGFR, histone complex, HIV-1, HLA-DR, HNGF, Hsp90, human scatter factor receptor kinase, human TNF, human beta-amyloid, ICAM-1 (CD54) , IFN- ⁇
- antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include 707-AP, a biotinylated molecule, a-Actinin-4, abl-bcr alb-b3 (b2a2) , abl-bcr alb-b4 (b3a2) , adipophilin, AFP, AIM-2, Annexin II, ART-4, BAGE, b-Catenin, bcr-abl, bcr-abl p190 (e1a2) , bcr-abl p210 (b2a2) , bcr-abl p210 (b3a2) , BING-4, CAG-3, CAIX, CAMEL, Caspase-8, CD171, CD19, CD20, CD22, CD24, CD30, CD33, CD38, CD44v7/8, CDC27, CDK-4, CEA, CLCA2, Cyp-B, DAM-10, DAM-6, DEK-
- antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include an antibody, a fragment thereof, or a variant thereof.
- antibody can be a natural antibody (e.g., naturally secreted by a subject’s immune cell, such as B cells) , a synthetic antibody, or a modified antibody.
- the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include an Fc domain of an antibody from the group comprising 20- (74) - (74) (milatuzumab; veltuzumab) , 20-2b-2b, 3F8, 74- (20) - (20) (milatuzumab; veltuzumab) , 8H9, A33, AB-16B5, abagovomab, abciximab, abituzumab, zlintuzumab) , actoxumab, adalimumab, ADC-1013, ADCT-301, ADCT-402, adecatumumab, aducanumab, afelimomab, AFM13, afutuzumab, AGEN1884, AGS15E, AGS-16C3F, AGS67E, alacizumab pegol, ALD518, alemtu
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain
- the antigen binding domain can be capable of binding specifically and preferentially to an antigen comprising one or more members selected from the group comprising BCMA, CD20, CD22, CD30, CD33, CD38, CD70, Kappa, Lewis Y, NKG2D ligand, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and gp100.
- the NKG2D ligand comprises one or more members selected from the group comprising of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain capable of specifically binding an antigen of a target cell, and the engineered immune cell can exhibit reduced expression or activity of an endogenous gene encoding the same antigen of the chimeric polypeptide receptor.
- a population of the engineered immune cells can avoid targeting and killing each other, e.g., upon administration to a subject in need thereof.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD38.
- the engineered immune cell ’s endogenous gene encoding CD38 can be modified to effect reduced expression or activity of the endogenous CD38.
- the subject engineered immune cells comprising the chimeric polypeptide receptor against CD38 can be capable of targeting and effecting death (or degradation) of plasma cells.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD38.
- the engineered immune cell is an engineered NK cell that is derived from an isolated ESC or an induced stem cell (e.g., iPSC) .
- the engineered immune cell’s endogenous gene encoding CD38 can be modified to effect reduced expression or activity of the endogenous CD38.
- any one of the engineered immune cell e.g., the engineered NK cell disclosed herein can be derived from an isolated stem cell (e.g., an ESC) or an induced stem cell (iPSC) .
- the isolated stem cell or the induced stem cell can be modified (e.g., genetically modified) to generate the engineered immune cell.
- pluripotency of stem cells can be determined, in part, by assessing pluripotency characteristics of the cells.
- Pluripotency characteristics can include, but are not limited to: (i) pluripotent stem cell morphology; (ii) the potential for unlimited self-renewal; (iii) expression of pluripotent stem cell markers including, but not limited to SSEA1 (mouse only) , SSEA3/4, SSEA5, TRA1-60/81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133/prominin, CD140a, CD56, CD73, CD90, CD105, OCT4, NANOG, SOX2, CD30 and/or CD50; (iv) ability to differentiate to all three somatic lineages (ectoderm, mesoderm and endoderm) ; (v) teratoma formation consisting of the three somatic lineages; and (
- stem cells e.g., ESCs or iPSCs
- the stem cells can be genetically modified to express any one of the heterologous polypeptides (e.g., cytokines, receptors, etc. ) as disclosed herein prior to, subsequent to, or during the induced hematopoietic stem cell differentiation.
- the stem cells can be genetically modified to reduce expression or activity of any one of the endogenous genes or polypeptides (e.g., cytokines, receptors, etc. ) as disclosed herein prior to, subsequent to, or during the induced hematopoietic stem cell differentiation.
- such genetically modified CD34+hematopoietic stem cell is or is a source of any one of the engineered immune cell of the present disclosure.
- stem cells as disclosed herein can be cultured in APEL media with ROCKi (Y-27632) (e.g., at about 10 micromolar ( ⁇ M) ) , SCF (e.g., at about 40 nanograms per milliner (ng/mL) of media) , VEGF (e.g., at about 20 ng/mL of media) , and BMP-4 (e.g., at about 20 ng/mL of media) to differentiate into CD34+ hematopoietic stem cells.
- ROCKi Y-27632
- SCF e.g., at about 40 nanograms per milliner (ng/mL) of media
- VEGF e.g., at about 20 ng/mL of media
- BMP-4 e.g., at about 20 ng/mL of media
- the CD34+ hematopoietic stem cells (e.g., genetically modified with one or more features of any one of the engineered immune cell of the present disclosure) can be induced to differentiate in to a committed immune cell, such as T cells or NK cells.
- a committed immune cell such as T cells or NK cells.
- the induced differentiation process generates any one of the engineered NK cell of the present disclosure.
- genetically modified CD34+ hematopoietic stem cells are cultured in the presence of IL-3 (e.g., about 5 ng/mL) , IL-7 (e.g., about 20 ng/mL) , IL-15 (e.g., about 10 ng/mL) , SCF (e.g., about 20 ng/mL) , and Flt3L (e.g., about 10 ng/mL) to differentiate into CD45+ NK cells.
- IL-3 e.g., about 5 ng/mL
- IL-7 e.g., about 20 ng/mL
- IL-15 e.g., about 10 ng/mL
- SCF e.g., about 20 ng/mL
- Flt3L e.g., about 10 ng/mL
- the CD45+ NK cells can be expanded in culture, e.g., in a media comprising IL-2, mbIL-21 aAPC using Gas Permeable Rapid Expansion (G-Rex) platform.
- G-Rex Gas Permeable Rapid Expansion
- iPSC-derived NK cells as disclosed herein can be cultured with one or more heterologous cytokines comprising Il-2, IL-15, or IL-21. In some cases, iPSC-derived NK cells as disclosed herein can be cultured with (e.g., for cell expansion) one or more heterologous cytokines selected from the group consisting of Il-2, IL-15, and IL-21.
- iPSC-derived NK cells as disclosed herein can be cultured with two or more heterologous cytokines selected from the group consisting of Il-2, IL-15, and IL-21 (e.g., IL-2 and IL-15, IL-2 and IL-21, or IL-15 and IL-21) , either simultaneously or sequentially in any order.
- iPSC-derived NK cells as disclosed herein can be cultured with all of Il-2, IL-15, and IL-21, either simultaneous or sequentially in any order.
- the gene editing moiety as disclosed herein can comprise a CRISPR-associated polypeptide (Cas) , zinc finger nuclease (ZFN) , zinc finger associate gene regulation polypeptides, transcription activator-like effector nuclease (TALEN) , transcription activator-like effector associated gene regulation polypeptides, meganuclease, natural master transcription factors, epigenetic modifying enzymes, recombinase, flippase, transposase, RNA-binding proteins (RBP) , an Argonaute protein, any derivative thereof, any variant thereof, or any fragment thereof.
- Cas CRISPR-associated polypeptide
- ZFN zinc finger nuclease
- TALEN transcription activator-like effector nuclease
- RBP RNA-binding proteins
- Argonaute protein any derivative thereof, any variant thereof, or any fragment thereof.
- the actuator moiety comprises a Cas protein, and the system further comprises a guide RNA (gRNA) which complexes with the Cas protein.
- the actuator moiety comprises an RBP complexed with a gRNA which is able to form a complex with a Cas protein.
- the gRNA comprises a targeting segment which exhibits at least 80%sequence identity to a target polynucleotide.
- the Cas protein substantially lacks DNA cleavage activity.
- a suitable gene editing moiety comprises CRISPR-associated (Cas) proteins or Cas nucleases including type I CRISPR-associated (Cas) polypeptides, type II CRISPR-associated (Cas) polypeptides, type III CRISPR-associated (Cas) polypeptides, type IV CRISPR-associated (Cas) polypeptides, type V CRISPR-associated (Cas) polypeptides, and type VI CRISPR-associated (Cas) polypeptides; zinc finger nucleases (ZFN) ; transcription activator-like effector nucleases (TALEN) ; meganucleases; RNA-binding proteins (RBP) ; CRISPR-associated RNA binding proteins; recombinases; flippases; transposases; Argonaute (Ago) proteins (e.g., prokaryotic Argonaute (pAgo) , archaeal Argonaute (aAgo) , and
- Non-limiting examples of Cas proteins include c2c1, C2c2, c2c3, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD) , Cas6, Cas6e, Cas6f, Cas7, Cas8a, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12) , Cas10, Cas10d, Cas1O, Cas1Od, CasF, CasG, CasH, Cpf1, Csy1, Csy2, Csy3, Cse1 (CasA) , Cse2 (CasB) , Cse3 (CasE) , Cse4 (CasC) , Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, C
- the gene editing moiety as disclosed herein can be fused with an additional functional moiety (e.g., to form a fusion moiety) , and non-limiting examples of a function of the additional functional moiety can include methyltransferase activity, demethylase activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristo
- gene editing e.g., knock in
- delivery of heterologous genetic material can be achieved other viral and non-viral based gene transfer methods can be used to introduce nucleic acids in host cells (e.g., stem cells, hematopoietic stem cells, etc. as disclosed herein) .
- host cells e.g., stem cells, hematopoietic stem cells, etc. as disclosed herein
- Such methods can be used to administer nucleic acids encoding polypeptide molecules of the present disclosure to cells in culture (or in a host organism) .
- Viral vector delivery systems can include DNA and RNA viruses, which can have either episomal or integrated genomes after delivery to the cell.
- Non-viral vector delivery systems can include DNA plasmids, RNA (e.g. a transcript of a vector described herein) , naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
- RNA or DNA viral based systems can be used to target specific cells and traffick the viral payload to the nucleus of the cell.
- Viral vectors can be used to treat cells in vitro, and the modified cells can optionally be administered (ex vivo) . Alternatively, viral vectors can be administered directly (in vivo) to the subject.
- Viral based systems can include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome can occur with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, which can result in long term expression of the inserted transgene.
- Methods of non-viral delivery of nucleic acids can include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides can be used.
- antisense oligonucleotides can be utilized to suppress or silence a target gene expression.
- Non-limiting examples of antisense oligonucleotides can include short hairpin RNA (shRNA) , microRNA (miRNA) , and small interfering RNA (siRNA) .
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be combined with a co-therapeutic agent to treat a subject in need thereof.
- the engineered immune cell can be administered to the subject prior to, concurrent with, or subsequent to administration of the co-therapeutic agent to the subject.
- the present disclosure provides a composition
- a composition comprising (a) any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein and (b) a co-therapeutic agent (i.e., a separate therapeutic agent) (e.g., an antibody, such as anti-CD20 antibody or anti-PD1 antibody) .
- a co-therapeutic agent i.e., a separate therapeutic agent
- an antibody such as anti-CD20 antibody or anti-PD1 antibody
- the engineered immune cell can comprise one or more of: (i) a heterologous cytokine (e.g., a heterologous IL, such as IL-15) as disclosed herein, (ii) a CD16 variant for enhanced CD16 signaling as disclosed herein, and (iii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclose herein.
- the co-therapeutic agent comprises an anti-CD20 antibody.
- the engineered immune cell can comprise the heterologous cytokine (e.g., IL-15) as disclosed herein and one or both of: (ii) the CD16 variant for enhanced CD16 signaling and (iii) the chimeric polypeptide receptor comprising the antigen binding moiety.
- heterologous cytokine e.g., IL-15
- the engineered immune cell can comprise the CD16 variant for enhanced CD16 signaling and one or both of: (i) the heterologous cytokine (e.g., IL-15) and (iii) the chimeric polypeptide receptor comprising the antigen binding moiety.
- the heterologous cytokine e.g., IL-15
- the chimeric polypeptide receptor comprising the antigen binding moiety.
- the engineered immune cell can comprise the chimeric polypeptide receptor comprising the antigen binding moiety and one or both of: (i) the heterologous cytokine (e.g., IL-15) and (ii) the CD16 variant for enhanced CD16 signaling.
- the heterologous cytokine e.g., IL-15
- the CD16 variant for enhanced CD16 signaling e.g., CD16 signaling.
- Non-limiting examples of a co-therapeutic agent can include cytotoxic agents, chemotherapeutic agents, growth inhibitory agents, agents used in radiation therapy, anti-angiogenesis agents, apoptotic agents, anti-tubulin agents, and other agents to treat cancer, for example, anti-CD20 antibodies, anti-PD1 antibodies (e.g., Pembrolizumab) platelet derived growth factor inhibitors (e.g., GLEEVEC TM (imatinib mesylate) ) , a COX-2 inhibitor (e.g., celecoxib) , interferons, cytokines, antagonists (e.g., neutralizing antibodies) that bind to one or more of the following targets PDGFR- ⁇ , BlyS, APRIL, BCMA receptor (s) , TRAIL/Apo2, other bioactive and organic chemical agents, and the like.
- anti-CD20 antibodies e.g., Pembrolizumab
- platelet derived growth factor inhibitors e.g
- cytotoxic agent generally refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
- a cytotoxic agent can include radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, and radioactive isotopes of Lu) , chemotherapeutic agents, e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide) , doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin.
- radioactive isotopes e.g., At211, I131, I125,
- Non-limiting examples of a chemotherapeutic agent can include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone) ; delta-9-tetrahydrocannabinol (dronabinol, ) ; beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan CPT-11 (irinotecan, ) , acetyl
- ABRAXANE Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill. ) , and docetaxel ( Rorer, Antony, France) ; chloranbucil; gemcitabine 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine oxaliplatin; leucovovin; vinorelbine novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO) ; retinoids such as retinoic acid; capecitabine pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of
- chemotherapeutic agent can also include “anti-hormonal agents” or “endocrine therapeutics” that act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer, and are often in the form of systemic, or whole-body treatment. They may be hormones themselves.
- Examples include anti-estrogens and selective estrogen receptor modulators (SERMs) , including, for example, tamoxifen (including tamoxifen) , raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene; anti-progesterones; estrogen receptor down-regulators (ERDs) ; agents that function to suppress or shut down the ovaries, for example, leutinizing hormone-releasing hormone (LHRH) agonists such as and ELIGARD) leuprolide acetate, goserelin acetate, buserelin acetate and tripterelin; other anti-androgens such as flutamide, nilutamide and bicalutamide; and aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example,
- chemotherapeutic agents includes bisphosphonates such as clodronate (for example, or ) , etidronate, NE-58095, zoledronic acid/zoledronate, alendronate, pamidronate, tiludronate, or risedronate; as well as troxacitabine (a1, 3-dioxolane nucleoside cytosine analog) ; antisense oligonucleotides, particularly those that inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Raf, H-Ras, and epidermal growth factor receptor (EGFR) ; vaccines such as vaccine and gene therapy vaccines, for example, vaccine, vaccine, and vaccine; topoisomerase 1 inhibitor; rmRH; lapatinib ditosylate (an ErbB-2 and EGFR dual tyrosine kinase small-molecule inhibitor also known as GW572016)
- Examples of a chemotherapeutic agent can also include antibodies such as alemtuzumab (Campath) , bevacizumab ( Genentech) ; cetuximab ( Imclone) ; panitumumab ( Amgen) , rituximab ( Genentech/Biogen Idec) , pertuzumab ( 2C4, Genentech) , trastuzumab ( Genentech) , tositumomab (Bexxar, Corixia) , and the antibody drug conjugate, gemtuzumab ozogamicin ( Wyeth) .
- antibodies such as alemtuzumab (Campath) , bevacizumab ( Genentech) ; cetuximab ( Imclone) ; panitumumab ( Amgen) , rituximab ( Genentech/Biogen Idec) , pertuzumab ( 2C4, Genentech) ,
- Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, feMzumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolov
- Examples of a chemotherapeutic agent can also include “tyrosine kinase inhibitors” such as an EGFR-targeting agent (e.g., small molecule, antibody, etc. ) ; small molecule HER2 tyrosine kinase inhibitor such as TAK165 available from Takeda; CP-724, 714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI) ; dual-HER inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016; available from Glaxo-SmithKline) , an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis) ; pan-HER inhibitors such as canertinib (CI-1033; Pharmacia) ; Raf-1 inhibitors such as antis
- Examples of a chemotherapeutic agent can also include dexamethasone, interferons, colchicine, metoprine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG live, bevacuzimab, bexarotene, cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, histrelin acetate, ibritumomab, interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxsalen, nandrolone, nelarabine, nofetumomab, opr
- Examples of a chemotherapeutic agent can also include hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate and fluprednidene
- growth inhibitory agent generally refers to a compound or composition which inhibits growth and/or proliferation of a cell (e.g., a cell whose growth is dependent on PD-L1 expression) either in vitro or in vivo.
- the growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase.
- growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase) , such as agents that induce G1 arrest and M-phase arrest.
- Classical M-phase blockers include the vincas (vincristine and vinblastine) , taxanes, and topoisomerase II inhibitors such as the anthracycline antibiotic doxorubicin ( (8S-cis) -10- [ (3-amino-2, 3, 6-trideoxy- ⁇ -L-lyxo-hexapyranosyl) oxy] -7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl) -1-methoxy-5, 12-naphthacenedione) , epirubicin, daunorubicin, etoposide, and bleomycin.
- doxorubicin (8S-cis) -10- [ (3-amino-2, 3, 6-trideoxy- ⁇ -L-lyxo-hexapyranosyl) oxy] -7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl) -1-methoxy-5
- paclitaxel and docetaxel are anticancer drugs both derived from the yew tree.
- Docetaxel Rhone-Poulenc Rorer
- paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be generated from an isolated stem cell (e.g., isolated ESCs, iPSCs, etc. ) .
- isolated stem cell e.g., isolated ESCs, iPSCs, etc.
- the one or more members of the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can be introduced during any stage (or cellular state) between (and including) (a) the isolated stem cell and (b) the differentiated immune cell state thereof (e.g., a terminally differentiated immune cell state, such as a terminally differentiated NK cell state) .
- differentiated immune cell state e.g., a terminally differentiated immune cell state, such as a terminally differentiated NK cell state
- the engineered NK cell can be derived from iPSCs, and the one or more members of the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) can be introduced to the cell at (A) the iPSC state, (B) the hematopoietic stem cell state, and/or (C) the NK cell state.
- the one or more members can be introduced to the cell once during one of (A) , (B) , and (C) .
- the one or more members can be introduced to the cell multiple times during two or all of (A) , (B) , and (C) .
- the engineered NK cell can be derived from iPSCs, and two or more members of the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) can be introduced to the cell at (A) the iPSC state, (B) the hematopoietic stem cell state, and/or (C) the NK cell state.
- the two or more members can be introduced to the cell at the same state selected from the group comprising (A) , (B) , and/or (C) .
- the two or more members can be introduced to the cell at different states selected from the group comprising (A) , (B) , and/or (C) .
- the iPSCs can be (A) engineered to exhibit the heterologous CD16 variant for enhanced CD16 signaling at the iPSC state, (B) subsequently differentiated into hematopoietic stem cells, and (C) engineered to exhibit the enhanced expression and/or activity level of an activating NK receptor during and/or subsequent to being differentiated into NK cells.
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be used (e.g., administered) to treat a subject in need thereof.
- the subject can have or can be suspected of having a condition, such as a disease (e.g., cancer, tumor, tissue degeneration, fibrosis, etc. ) .
- a cell e.g., a stem cell or a committed adult cell
- the engineered immune cell can be administered to the subject for adaptive immunotherapy.
- the subject can be treated (e.g., administered with) a population of engineered immune cells (e.g., engineered NK cells) of the present disclosure for at least or up to about 1 dose, at least or up to about 2 doses, at least or up to about 3 doses, at least or up to about 4 doses, at least or up to about 5 doses, at least or up to about 6 doses, at least or up to about 7 doses, at least or up to about 8 doses, at least or up to about 9 doses, or at least or up to about 10 doses.
- engineered immune cells e.g., engineered NK cells
- the present disclosure provides a method comprising (a) obtaining a cell from a subject; and (b) generating, from the cell, any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein.
- the cell obtained from the subject is ESC.
- the cell e.g., a fibroblast, such as an adult skin fibroblast
- the cell is modified and transformed into an iPSC.
- the present disclosure provides a method comprising administering to a subject in need thereof a population of NK cells comprising any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein.
- the method can further comprise administering to the subject a co-therapeutic agent (e.g., a chemotherapeutic agent, anti-CD20 antibody, etc. ) .
- a co-therapeutic agent e.g., a chemotherapeutic agent, anti-CD20 antibody, etc.
- the present disclosure provides a method comprising administering to a subject in need thereof any one of the composition disclosed herein.
- the composition can comprise (i) any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein and (ii) a co-therapeutic agent (e.g., a chemotherapeutic agent, anti-CD20 antibody, etc. ) .
- Any one of the methods disclosed herein can be utilized to treat a target cell, a target tissue, a target condition, or a target disease of a subject.
- a target disease can be a viral, bacterial, and/or parasitic infection; inflammatory and/or autoimmune disease; or neoplasm such as a cancer and/or tumor.
- a target cell can be a diseased cell.
- a diseased cell can have altered metabolic, gene expression, and/or morphologic features.
- a diseased cell can be a cancer cell, a diabetic cell, and an apoptotic cell.
- a diseased cell can be a cell from a diseased subject. Exemplary diseases can include blood disorders, cancers, metabolic disorders, eye disorders, organ disorders, musculoskeletal disorders, cardiac disease, and the like.
- a variety of target cells can be killed using any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein.
- a target cell can include a wide variety of cell types.
- a target cell can be in vitro.
- a target cell can be in vivo.
- a target cell can be ex vivo.
- a target cell can be an isolated cell.
- a target cell can be a cell inside of an organism.
- a target cell can be an organism.
- a target cell can be a cell in a cell culture.
- a target cell can be one of a collection of cells.
- a target cell can be a mammalian cell or derived from a mammalian cell.
- a target cell can be a rodent cell or derived from a rodent cell.
- a target cell can be a human cell or derived from a human cell.
- a target cell can be a prokaryotic cell or derived from a prokaryotic cell.
- a target cell can be a bacterial cell or can be derived from a bacterial cell.
- a target cell can be an archaeal cell or derived from an archaeal cell.
- a target cell can be a eukaryotic cell or derived from a eukaryotic cell.
- a target cell can be a pluripotent stem cell.
- a target cell can be a plant cell or derived from a plant cell.
- a target cell can be an animal cell or derived from an animal cell.
- a target cell can be an invertebrate cell or derived from an invertebrate cell.
- a target cell can be a vertebrate cell or derived from a vertebrate cell.
- a target cell can be a microbe cell or derived from a microbe cell.
- a target cell can be a fungi cell or derived from a fungi cell.
- a target cell can be from a specific organ or tissue.
- a target cell can be a stem cell or progenitor cell.
- Target cells can include stem cells (e.g., adult stem cells, embryonic stem cells, induced pluripotent stem (iPS) cells) and progenitor cells (e.g., cardiac progenitor cells, neural progenitor cells, etc. ) .
- Target cells can include mammalian stem cells and progenitor cells, including rodent stem cells, rodent progenitor cells, human stem cells, human progenitor cells, etc.
- Clonal cells can comprise the progeny of a cell.
- a target cell can comprise a target nucleic acid.
- a target cell can be in a living organism.
- a target cell can be a genetically modified cell.
- a target cell can be a host cell.
- a target cell can be a totipotent stem cell, however, in some embodiments of this disclosure, the term “cell” may be used but may not refer to a totipotent stem cell.
- a target cell can be a plant cell, but in some embodiments of this disclosure, the term “cell” may be used but may not refer to a plant cell.
- a target cell can be a pluripotent cell.
- a target cell can be a pluripotent hematopoietic cell that can differentiate into other cells in the hematopoietic cell lineage but may not be able to differentiate into any other non-hematopoietic cell.
- a target cell may be able to develop into a whole organism.
- a target cell may or may not be able to develop into a whole organism.
- a target cell may be a whole organism.
- a target cell can be a primary cell.
- cultures of primary cells can be passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, 15 times or more.
- Cells can be unicellular organisms. Cells can be grown in culture.
- a target cell can be a diseased cell.
- a diseased cell can have altered metabolic, gene expression, and/or morphologic features.
- a diseased cell can be a cancer cell, a diabetic cell, and a apoptotic cell.
- a diseased cell can be a cell from a diseased subject. Exemplary diseases can include blood disorders, cancers, metabolic disorders, eye disorders, organ disorders, musculoskeletal disorders, cardiac disease, and the like.
- the target cells may be harvested from an individual by any method.
- leukocytes may be harvested by apheresis, leukocytapheresis, density gradient separation, etc.
- Cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc. can be harvested by biopsy.
- An appropriate solution may be used for dispersion or suspension of the harvested cells.
- Such solution can generally be a balanced salt solution, (e.g. normal saline, phosphate-buffered saline (PBS) , Hank's balanced salt solution, etc.
- PBS phosphate-buffered saline
- Buffers can include HEPES, phosphate buffers, lactate buffers, etc.
- Cells may be used immediately, or they may be stored (e.g., by freezing) . Frozen cells can be thawed and can be capable of being reused. Cells can be frozen in a DMSO, serum, medium buffer (e.g., 10%DMSO, 50%serum, 40%buffered medium) , and/or some other such common solution used to preserve cells at freezing temperatures.
- Non-limiting examples of cells which can be target cells include, but are not limited to, lymphoid cells, such as B cell, T cell (Cytotoxic T cell, Natural Killer T cell, Regulatory T cell, T helper cell) , Natural killer cell, cytokine induced killer (CIK) cells (see e.g.
- myeloid cells such as granulocytes (Basophil granulocyte, Eosinophil granulocyte, Neutrophil granulocyte/Hypersegmented neutrophil) , Monocyte/Macrophage, Red blood cell (Reticulocyte) , Mast cell, Thrombocyte/Megakaryocyte, Dendritic cell; cells from the endocrine system, including thyroid (Thyroid epithelial cell, Parafollicular cell) , parathyroid (Parathyroid chief cell, Oxyphil cell) , adrenal (Chromaffin cell) , pineal (Pinealocyte) cells; cells of the nervous system, including glial cells (Astrocyte, Microglia) , Magnocellular neurosecretory cell, Stellate cell, Boettcher cell, and pituitary (Gonadotrope, Corticotrope, Thyrotrope, Somatotrope, Lactotroph) ; cells of the Respiratory system, including Pneumocyte (Type I pneumocyte, granulocyte,
- Apocrine sweat gland cell odoriferous secretion, sex-hormone sensitive
- Gland of Moll cell in eyelid specialized sweat gland
- Sebaceous gland cell lipid-rich sebum secretion
- Bowman's gland cell in nose washes olfactory epithelium
- Brunner's gland cell in duodenum enzymes and alkaline mucus
- Seminal vesicle cell secretes seminal fluid components, including fructose for swimming sperm
- Prostate gland cell secretes seminal fluid components
- Bulbourethral gland cell massbourethral gland cell
- Bartholin's gland cell vaginal lubricant secretion
- Gland of Littre cell Gland of Littre cell
- Uterus endometrium cell (carbohydrate secretion)
- Isolated goblet cell of respiratory and digestive tracts micus secretion
- Duct cell (of seminal vesicle, prostate gland, etc. ) , Epithelial cells lining closed internal body cavities, Ciliated cells with propulsive function, Extracellular matrix secretion cells, Contractile cells; Skeletal muscle cells, stem cell, Heart muscle cells, Blood and immune system cells, Erythrocyte (red blood cell) , Megakaryocyte (platelet precursor) , Monocyte, Connective tissue macrophage (various types) , Epidermal Langerhans cell, Osteoclast (in bone) , Dendritic cell (in lymphoid tissues) , Microglial cell (in central nervous system) , Neutrophil granulocyte, Eosinophil granulocyte, Basophil granulocyte, Mast cell, Helper T cell, Suppressor T cell, Cytotoxic T cell, Natural Killer T cell, B cell, Natural killer cell, Reticulocyte, Stem cells and committed progenitors for the blood and immune system (various types) ,
- the target cell is a cancer cell.
- cancer cells include cells of cancers including Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblastic leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma
- the targeted cancer cell represents a subpopulation within a cancer cell population, such as a cancer stem cell.
- the cancer is of a hematopoietic lineage, such as a lymphoma.
- the antigen can be a tumor associated antigen.
- the target cell e.g., B cells
- the target cell as disclosed herein is associated or is suspected of being associated with an autoimmune disease.
- the subject being treated with any one of the engineered immune cell (e.g., engineered NK cell) of the present disclosure can have or can be suspected of having an autoimmune disease.
- Non-limiting examples of an autoimmune disease can include acute disseminated encephalomyelitis (ADEM) , acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, allergic asthma, allergic rhinitis, alopecia areata, amyloidosis, ankylosing spondylitis, antibody-mediated transplantation rejection, anti-GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS) , autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED) , autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP) , autoimmune thyroid disease, autoimmune urticaria, axonal &neuronal neuropathies, Balo
- the autoimmune disease comprises one or more members selected from the group comprising rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus (lupus or SLE) , myasthenia gravis, multiple sclerosis, scleroderma, Addison's Disease, bullous pemphigoid, pemphigus vulgaris, Guillain-Barré syndrome, Sjogren syndrome, dermatomyositis, thrombotic thrombocytopenic purpura, hypergammaglobulinemia, monoclonal gammopathy of undetermined significance (MGUS) , Waldenstrom's macroglobulinemia (WM) , chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) , Hashimoto's Encephalopathy (HE) , Hashimoto's Thyroiditis, Graves'Disease, Wegener's Granulomatosis, and antibody-mediated transplantation rejection (e.g., for
- the target disease is acute myeloid leukemia (AML) .
- AML acute myeloid leukemia
- a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to an antigen (e.g., CD33) as disclosed herein
- a heterologous cytokine e.g., IL-15
- CD16 variant for enhanced CD16 signaling as disclosed herein can be administered to a subject in need thereof to treat AML.
- the target disease is non-Hodgkin’s lymphoma (NHL) .
- the target disease is chronic lymphocytic leukemia (CLL) .
- CLL chronic lymphocytic leukemia
- the target disease is B-cell leukemia (BCL) .
- BCL B-cell leukemia
- any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein that comprises one or more of: (i) a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to CD19 as disclosed herein, (ii) a heterologous cytokine (e.g., IL-15) as disclosed herein, and (iii) a CD16 variant for enhanced CD16 signaling as disclosed herein can be administered to a subject in need thereof to treat BCL.
- the target disease is non-small-cell lung carcinoma (NSCLC) .
- NSCLC non-small-cell lung carcinoma
- the target cells form a tumor (i.e., a solid tumor) .
- a tumor treated with the methods herein can result in stabilized tumor growth (e.g., one or more tumors do not increase more than 1%, 5%, 10%, 15%, or 20%in size, and/or do not metastasize) .
- a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks.
- a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months.
- a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years.
- the size of a tumor or the number of tumor cells is reduced by at least about 5%, 10%, 15%, 20%, 25, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%or more.
- the tumor is completely eliminated, or reduced below a level of detection.
- a subject remains tumor free (e.g. in remission) for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks following treatment.
- a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months following treatment.
- a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years after treatment.
- Example 1 Enhanced expression and/or activity level of an activating NK receptor
- cells of interest can be engineered with enhanced or introduced expression level of activating NK receptor.
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) .
- Such immune cells can be derived from the stem cells as disclosed herein.
- such immune cells can be immune cell lines (e.g., NK cell lines) .
- iPSCs can be engineered to generate engineered NK cells exhibiting enhanced expression and/or activity level of an activating NK receptor, e.g., NKG2D, NKP30, NKP44, NKP46, DNAM1, NKP80 or a variant thereof (e.g., see TABLE 1) .
- an activating NK receptor e.g., NKG2D, NKP30, NKP44, NKP46, DNAM1, NKP80 or a variant thereof (e.g., see TABLE 1) .
- a heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200, each heterologous polypeptide encoding at least one activating NK receptor can be in contact with an iPSC or a differentiated cell derivative thereof, to generate the engineered NK cells.
- the heterologous polypeptide 110 is a control vector that does not encode any activating NK receptor.
- Such engineered NK cells can exhibit enhanced cytotoxicity against cancer cells, e.g., for pan-cancer treatment.
- the heterologous polypeptide selected from the group comprising 110, 120, 130, 140, 150, 160, 170, 180, 190, and 200 can further encode a heterologous cytokine and/or a heterologous receptor thereof (e.g., IL15RF) .
- the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can further encode a heterologous CD16 variant for enhanced CD16 signaling.
- any one of the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can come in contact (e.g., via transfection or viral transduction) with the iPSCs prior to inducing differentiation of the iPSCs (e.g., into hematopoietic stem cells) .
- iPSCs can be engineered to express NK receptors.
- any one of the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can come in contact (e.g., via transfection or viral transduction) with hematopoietic stem cells derived from the iPSCs.
- any one of the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can come in contact (e.g., via transfection or viral transduction) with NK cells derived from the iPSCs.
- Example 2 An engineered immune cell with (A) enhanced expression and/or activity level of DAP and (B) enhanced expression and/or activity level of an activating NK receptor.
- cells of interest can be engineered with enhanced or introduced expression level of a plurality of polypeptides.
- the plurality of polypeptides can be different polypeptides.
- the plurality of polypeptides can be complimentary to one another, e.g., in terms of expression level, activity level, etc.
- the plurality of polypeptides may directly interact (e.g., directly bind) with each other. Alternatively, the plurality of polypeptides may not directly interact with each other.
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
- an engineered immune cell e.g., an engineered NK cell
- the presence of (A) enhanced expression and/or activity level of DAP can facilitate or further amplify (B) enhanced expression and/or activity level of the activating NK receptor (e.g., NKG2D) .
- DAP e.g., DAP10
- B enhanced expression and/or activity level of the activating NK receptor
- heterologous polynucleotides 210, 220, and 230 were modified with one of the heterologous polynucleotides 210, 220, and 230.
- the heterologous polynucleotide 230 encodes a heterologous NKG2D without a heterologous DAP10.
- the heterologous polynucleotide 220 encodes a heterologous DAP10 without a heterologous NKG2D.
- the heterologous polynucleotide 210 encodes both the heterologous NKG2D and the heterologous DAP10, to examine the synergy effect of NKG2D and DAP10. Referring to FIGs.
- heterologous NKG2D and the heterologous DAP10 showed enhanced expression of membrane-bound NKG2D, relative to (i) control 293T cells without any heterologous polynucleotide modification, (ii) 293T cells modified with the heterologous NKG2D alone, and (ii) 293T cells modified with the heterologous DAP10 alone.
- induced expression of heterologous activating NK receptor (e.g., NKG2D) in cells e.g., 293T cells, iPSC cells, NK cells
- DAP e.g., DAP-10
- Example 3 Engineered NK cells for acute myeloid leukemia (AML) therapy.
- cells of interest can be engineered with a plurality of modifications.
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) .
- Such immune cells can be derived from the stem cells as disclosed herein.
- such immune cells can be immune cell lines (e.g., NK cell lines) .
- an engineered NK cell can be prepared to exhibit at least three modifications: (A) a chimeric polypeptide receptor (e.g., a chimeric antigen receptor (CAR) , an engineered T cell receptor (TCR) , etc.
- a chimeric polypeptide receptor e.g., a chimeric antigen receptor (CAR)
- CAR chimeric antigen receptor
- TCR engineered T cell receptor
- the features (A) , (B) , and (C) can be introduced in any order during the development of the engineered NK cell (e.g., from iPSCs) .
- the engineered NK cells can be prepared to express a heterologous CAR encoded by any one of the heterologous polynucleotides 310 (ani-CLL-1 CAR) , 320 (anti-CD33 CAR) , 330 (anti-CD70 CAR) , 340 (anti-CD123 CAR) , and/or 350 (anti-TIM3 CAR) (FIG. 3A) .
- the engineered NK cells can also be modified to exhibit enhanced CD16 signaling by inserting the CD16 variant 360 (CD16-IL15RF fusion protein) or 365 (CD16-CD64-IL15RF fusion protein) into the cell’s endogenous CD16 gene (FIG. 3B) .
- the engineered NK cells can also be modified to exhibit knock out of one or more immune regulating proteins, such as 370 (CD33) , 380 (CD70) , and/or 390 (TIM3) (FIG. 3C) .
- immune regulating proteins such as 370 (CD33) , 380 (CD70) , and/or 390 (TIM3) (FIG. 3C) .
- activity e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, etc.
- different optimal combinations can be identified for different applications, such as AML therapy.
- cells of interest can be engineered to comprise a heterologous chimeric polypeptide (e.g., a chimeric antigen receptor) comprising an antigen binding moiety against a specific antibody of a target cell (e.g., a cancer or tumor cell) , to exhibit enhanced cytotoxicity against such target cell.
- a heterologous chimeric polypeptide e.g., a chimeric antigen receptor
- the cells of interest can be immune cells (e.g., NK cells) .
- immune cells can be derived from the stem cells as disclosed herein.
- NK cells derived from stem cells one or more genetic modifications as disclosed herein can be introduced at (A) the stem cell state (e.g., iPSC state) , (B) the hematopoietic stem cell state, and/or (C) the NK cell state.
- the stem cell state e.g., iPSC state
- the hematopoietic stem cell state e.g., IL-12
- C NK cell state
- immune cells can be immune cell lines (e.g., NK cell lines) .
- NK cells expressing a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CLL01 was generated.
- Schematic of anti-CLL-1 CAR structure design is shown in FIG. 4A, wherein TM is short for Transmembrane domain, and SCFV is short for single chain variable fragment.
- CLL1-CAR NK92 cells demonstrated targeted cytotoxicity against HL60 tumor cells that high express CLL-1, as compared to wild type (WT) NK92 cells that lack the anti-CLL-1 CAR (E/T (Effector/Target) equals 1: 1; 1: 5, or 1: 10) .
- E/T Effective/T
- NK92 cells upon contacting the JL60 tumor cells, NK92 cells comprising anti-CLL-1 CAR exhibited a higher expression level of CD107a, as compared to the NK92 cells lacking the anti-CCL-CAR.
- NK cells are involved in innate immunity against targets, such as tumors and viral infections.
- Lysosome-associated membrane protein-1 (LAMP-1 or CD107a, as used interchangeably herein) can be a marker for degranulation of NK cells, and enhanced expression level of CD107a in NK cells can be an indication of cytotoxic activity determination of the NK cell (e.g., the anti-CLL-1 CAR NK cell as disclosed herein) .
- Example 5 Engineered NK cells from iPSCs
- iPSCs can be engineered to generate engineered NK cells exhibiting enhanced expression and/or activity level of an activating NK receptor, e.g., NKG2D, NKP30, NKP44, NKP46, or a variant thereof.
- an activating NK receptor e.g., NKG2D, NKP30, NKP44, NKP46, or a variant thereof.
- engineered iPSCs were differentiated into engineered NK cells (super NK cells) , where there was no difference in hCD56+ cells versus wildtype (ANB) (e.g., iPSC derived NK cells without genetic modifications) .
- FACS fluoresces intensity showed that the engineered NK cells overexpressed an activating NK receptor (FIG. 5B) .
- Example 6 iPSC derived engineered NK exhibit cytotoxicity in vitro
- iPSCs engineered with an activating NK receptor e.g., NKG2D, NKP30 were differentiated to engineered NK cells (super NK) .
- Super NK cells were incubated with solid tumor cells (e.g., Calu-3) at various NK to solid tumor cells ratio (e.g., 10: 1, 1: 1) .
- Super NK cells showed superior cytotoxicity to solid tumor cells, compared to NK cells differentiated from iPSC cells (FIG. 6A) .
- Serial cytotoxicity analysis with super NK cells incubated with solid tumor cells (e.g., THP1 or SKOV3) at 1: 1 ratio showed the ability of super NK cells to maintain long-term cytotoxicity to the solid tumor cells (FIG.
- iPSCs was engineered with more than one activating NK receptors (e.g., NKG2D and NKP30) and differentiated to NK cells (super NK v4.0) .
- super NK v4.0 showed superior killing capability incubated with solid tumor cells (e.g., THP1 or MOLM13) compared to NK cells derived from iPSCs, while maintaining high expression of the NK receptors (FIG. 6D) .
- Example 7 iPSC derived engineered NK exhibit cytotoxicity in vivo
- mice were inoculated with tumor cells labeled with luciferase (e.g., THP1 or SKOV3) only or together with engineered NK cells expressing NK receptors (e.g., NKG2D and NKP30) .
- Tumor burden calculated through the luminescence intensity, revealed that engineered NK cells expressing NK receptors (super NK v4.0) exhibited more cytotoxicity compared to NK cells derived from iPSCs (FIG. 7 and 8D) .
- the mice with super NK v4.0 had weight change post injection (FIG. 8A) but had higher percent survival compared to mice inoculated with tumor cells only (FIG. 8B) .
- the mice with high levels of super NK v4.0 also maintained hCD56+ cells, as measured by pharmacokinetics in peripheral blood (FIG. 8C) .
- Example 8 Gene knockout to enhance NK function
- the cells of interest can be immune cells (e.g., NK cells) .
- immune cells can be derived from the stem cells as disclosed herein.
- stem cell state e.g., iPSC state
- hematopoietic stem cell state e.g., iPSC state
- C hematopoietic stem cell state
- immune cells can be immune cell lines (e.g., NK cell lines) .
- TGFb-R2 was knocked out in NK cells (e.g., with sgRNAs targeting TGFb-R2) and were incubated with GFP labeled tumor cells (e.g., THP1 cells) , with different TGF-b dosage (e.g., 10 ng/ml and 50 ng/ml) at various times (e.g., at 24 hours and 72 hours) .
- TGF-b dosage e.g. 10 ng/ml and 50 ng/ml
- FIG. 9A and 9B knocking out TGFb-R2 rescued NK function under TGF-b treatment, enhancing NK cytotoxicity function.
- Knocking out TGFb-R2 (FIG. 10A) in NK cells also rescued NKG2D and NKP30 expression from TGF-b treatment, as analyzed by FACS (FIG. 10B) .
- CBNK was incubated with wild type K562 and HLA-E K562 cells at different effector cell to target cell ratios (e.g., E/T ratio at 4: 1, 1: 1, and 0.5: 1) .
- Cytotoxicity assay showed that HLAE inhibits NK cytotoxicity function (FIG. 11A) .
- HLA-E K562 cells decreased the percentage of CD107a+ cells, presenting the percentage of activated NK cells.
- NKG2A e.g. with sgRNAs with Cas9 protein
- the NKG2A knocked out cells were incubated with wild type K562 and HLA-E K562.
- FIG. 11D NKG2A knock out rescued NK function during targeting of the HLA-E cells, assessed via cytotoxicity assay.
- SOCS2 was knocked out in iPSCs.
- engineered iPSCs were differentiated into engineered NK cells (TD, representing various SOCS2 knock outs) , where there was no difference in hCD56+ cells versus wildtype (ANB) (e.g., iPSC derived NK cells without genetic modifications) , as quantified via FACS fluoresces intensity (FIG. 12B) .
- TD engineered NK cells
- ANB wildtype e.g., iPSC derived NK cells without genetic modifications
- FACS fluoresces intensity FACS fluoresces intensity
- Embodiment 1 An engineered NK cell, comprising:
- an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
- hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
- a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21,
- the engineered NK cell comprises (i) the heterologous CD16 variant;
- the engineered NK cell comprises (ii) the reduced expression and/or activity level of the endogenous CD38; and/or
- the engineered NK cell comprises (iii) the reduced expression of the one or more genes selected from the group consisting of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, CD70; and/or
- the engineered NK cell comprises (iv) the reduced expression and/or activity of the immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
- the engineered NK cell comprises (v) the reduced expression and/or activity of the hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and/or
- the hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A
- the engineered NK cell comprises (vi) the safety switch;
- the engineered NK cell comprises two or more members selected from the group consisting of (i) , (ii) , (iii) , (iv) , and (v) ; and/or
- the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking (1) the enhanced expression or activity level of the activating NK receptor and/or (2) the one or more members selected from the group consisting of (i) - (iv) ; and/or
- the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking (1) the enhanced expression or activity level of the activating NK receptor and/or (2) the one or more members selected from the group consisting of (i) - (iv) ; and/or
- (j) further comprising a heterologous interleukin (IL) cytokine and/or receptor for enhanced interleukin signaling as compared to the control NK cell; and/or
- IL interleukin
- (k) further comprising a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
- Embodiment 2 An engineered NK cell, comprising:
- the engineered NK cell exhibits at least about 0.1-fold or at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to the control NK cell;
- the enhanced expression or activity level of the activating NK receptor on the engineered NK cell is at least about 0.1-fold or at least about 0.5-fold greater than that in the control NK cell
- the activating NK receptor does not comprise a heterologous intracellular signaling domain
- the activating NK receptor does not comprise a heterologous transmembrane domain
- the activating NK receptor does not comprise a heterologous antigen binding domain.
- Embodiment 3 An engineered NK cell, comprising:
- an activating NK receptor as compared to a control NK cell, wherein the activating NK receptor is configured to bind an antigen of NKG2D, NKP30, and/or NKP44, NKP46, NKP80, and/or DNAM1 and wherein the activating NK receptor does not comprise a heterologous intracellular signaling domain.
- Embodiment 4 The engineered NK cell of any one of the preceding Embodiments, wherein:
- the activating NK receptor is endogenous to the engineered NK cell
- the engineered NK cell comprises a heterologous polynucleotide sequence encoding the activating NK receptor
- the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the enhanced expression or activity level of the activating NK receptor;
- the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking the enhanced expression or activity level of the activating NK receptor.
- Embodiment 5 An engineered NK cell, comprising:
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is selected from the group consisting of CD70, CLEC12A, and TIM-3, CD9, CD26, TRAIL-R4 (DCR2) , and NKG2D ligand,
- the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the chimeric polypeptide receptor,
- the antigen is selected from the group consisting of CD70, CLEC12A, and TIM-3; and/or
- the antigen is CD70 or TIM-3;
- the engineered NK cell exhibits at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in the cytotoxicity against the target cell as compared to the control NK cell;
- the engineered NK cell exhibits at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in the proliferation as compared to the control NK cell.
- Embodiment 6 An engineered NK cell, comprising
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is CD38 and/or BCMA;
- an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
- hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
- a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21,
- the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the one or more members,
- the engineered NK cell comprises (i) the enhanced expression or activity level of the activating NK receptor;
- the engineered NK cell comprises (ii) the reduced expression and/or activity of the immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
- the engineered NK cell comprises (iii) the reduced expression and/or activity of rgw hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and/or
- rgw hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113
- the engineered NK cell comprises (iv) the safety switch;
- the engineered NK cell comprises two or more members selected from the group consisting of (i) , (ii) , (iii) , and (iv) .
- Embodiment 7 An engineered NK cell, comprising:
- IL interleukin
- an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
- hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
- Embodiment 8 The engineered NK cell of any one of the preceding Embodiments, wherein:
- the NK cell comprises (i) the enhanced expression or activity level of endogenous activating NK receptor;
- the engineered NK cell comprises (ii) the heterologous interleukin (IL) cytokine and/or receptor; and/or
- the engineered NK cell comprises (iii) the heterologous CD16 variant;
- the engineered NK cell comprises (iv) the reduced expression and/or activity level of the endogenous CD38; and/or
- the engineered NK cell comprises (v) the reduced expression and/or activity of the immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
- the engineered NK cell comprises (vi) the reduced expression and/or activity of the hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;
- the hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR,
- the engineered NK cell comprises (vii) the safety switch;
- the engineered NK cell comprises (viii) the chimeric polypeptide receptor;
- the engineered NK cell comprises two or more members selected from the group consisting of (i) , (ii) , (iii) , (iv) , (v) , (vi) , (vii) , and (viii) ; and/or
- the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking reduced expression or activity level of the SOCS protein;
- the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking reduced expression or activity level of the SOCS protein;
- the SOCS protein is an endogenous protein
- the SOCS protein is selected from the group consisting of CIS, SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, and SOCS-7; and/or
- the SOCS protein is SOCS2;
- DAP dead-associated protein
- the activating NK receptor comprises NKG2D, NKP30, NKP44, NKP46, NKP80, DNAM1, a modification thereof, a functional variant thereof, or a combination thereof; and/or
- the activating NK receptor comprises NKG2D or a modification thereof;
- the activating NK receptor comprises NKP30 or a modification thereof;
- the activating NK receptor comprises NKP44 or a modification thereof;
- the activating NK receptor comprises NKP46 or a modification thereof;
- the activating NK receptor comprises NKP80 or a modification thereof;
- the activating NK receptor comprises DNAM1 or a modification thereof;
- the activating NK receptor is heterologous to the engineered immune cell;
- the activating NK receptor is a chimeric polypeptide receptor comprising at least an extracellular portion of NKG2D, NKP30, NKP44, or NKP46, NKP80, or DNAM1; and/or
- the activating NK receptor is endogenous to the engineered immune cell
- the heterologous IL cytokine and/or receptor comprises IL-15, IL-15R, and/or a fragment thereof;
- the antigen is not a NKP30 ligand, a NKP44 ligand, and/or a NKP46 ligand, NKP80 ligand, and/or DNAM1 ligand; and/or
- the antigen comprises BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10; and/or
- the engineered NK cell exhibits enhanced cytotoxic activity against a population of target cells as compared to the control NK cell;
- the enhanced cytotoxic activity against the population of target cells is ascertained by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%decrease in a size of the population of target cells as compared to the control NK cell; and/or
- the engineered NK cell exhibits reduction in tumor size as compared to as compared to the control NK cell;
- the tumor size is reduced by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%as compared to the control NK cell; and/or
- the engineered NK cell induces reduced immune response in a host cell as compared to the control NK cell;
- the engineered NK cell is for use in treating a subject in need thereof;
- the engineered NK cell is allogeneic to the subject.
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell;
- the engineered NK cell is derived from a cord blood natural killer cell (CBNK) or a peripheral blood natural killer cell (PBNK) ; and/or
- the engineered NK cell is for use in a method for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell; and/or
- the engineered NK cell is for use in a method for treating a subject in need thereof, wherein the subject has or is suspected of having a condition, optionally wherein:
- the condition is cancer or tumor;
- the engineered NK cell is either autologous or allogeneic to the subject;
- the engineered NK cell is for the manufacture of medicament for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell; and/or
- the engineered NK cell is for the manufacture of medicament for treating a subject in need thereof, wherein the subject has or is suspected of having a condition, optionally wherein the condition is cancer or tumor; and/or
- the engineered NK cell is either autologous or allogeneic to the subject.
- Embodiment 9 A composition comprising the engineered NK cell of any one of the Embodiments provided herein,
- composition further comprises a separate therapeutic agent, further optionally wherein the separate therapeutic agent is a chemotherapeutic agent.
- Embodiment 10 A method comprising:
- Embodiment 11 A method comprising:
- the contacting is sufficient to induce the killing of the target cell.
- Embodiment 12 A method of treating a subject in need thereof, comprising administering the engineered NK cell of any any one of the Embodiments provided herein,
- the method further comprises administering a separate therapeutic agent, further optionally wherein the separate therapeutic agent is a chemotherapeutic agent.
- Embodiment 13 A method of converting a stem cell to the engineered NK cell of any one of the Embodiments provided herein, comprising:
- the stem cell contacting in vitro the stem cell with a transgenic nucleic acid encoding the activating NK receptor, wherein the stem cell is an isolated stem cell or an induced stem cell, for conversion of the stem cell to the engineered NK cell,
- the engineered NK cell upon the contacting, exhibits enhanced expression or activity level of the activating NK receptor as compared to a control NK cell.
- compositions of matter including the engineered immune cells of the present disclosure may be utilized in the method section including methods of use and production disclosed herein, or vice versa.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided are immune cells that can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). The immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell, can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo and are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors).
Description
CROSS-REFERENCE
This application claims the benefit International Application No. PCT/CN2021/128464, filed November 03, 2021, and International Application No. PCT/CN2022/124454, filed October 10, 2022, which are entirely incorporated herein by reference.
Cancer (e.g., neoplasm, tumor) is a leading cause of death worldwide, accounting for about 10 million deaths annually. Cancer continues to bring increasing health, economic, and emotional burden on individuals, families, communities, and countries. Increase understanding of cancer biology (e.g., specifically cancer immune biology) and genetic engineering has encouraged development of adoptive cell therapies (e.g., cellular immunotherapy) , with a goal to treat or control a number of different cancers.
SUMMARY
The present disclosure provides methods and systems for treating cancer. Some aspects of the present disclosure provide engineered immune cells (e.g., engineered natural killer (NK) cells) and methods of use thereof for treatment of cancer, such as, e.g., as hematologic malignancies or solid tumors.
In an aspect, the present disclosure provides an engineered NK cell, comprising: (1) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell; and (2) one or more members selected from the group consisting of:
(i) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a NKG2D ligand;
(ii) reduced expression and/or activity level of an endogenous CD38 as compared to the control NK cell;
(iii) a reduced expression of one or more genes selected from the group consisting ofBCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, CD70;
(iv) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
(v) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
(vi) a safety switch capable of effecting death of the engineered NK cell.
In another aspect, the present disclosure provides an engineered NK cell, comprising enhanced expression or activity level of an activating NK receptor as compared to a control NK cell, wherein the activating NK receptor is configured to bind an antigen of NKG2D, NKP30, NKP44, NKP46, NKP80, and/or DNAM1, and wherein the activating NK receptor does not comprise a heterologous intracellular signaling domain.
In another aspect, the present disclosure provides an engineered NK cell, comprising a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is selected from the group consisting of CD70, CLEC12A, TIM-3, CD9, CD26, TRAIL-R4 (DCR2) , and NKG2D ligand, wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the chimeric polypeptide receptor.
In another aspect, the present disclosure provides an engineered NK cell, comprising: (1) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is CD38 and/or BCMA; and (2) one or more members selected from the group consisting of:
(i) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell;
(ii) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
(iii) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
(iv) a safety switch capable of effecting death of the engineered NK cell,
wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the one or more members.
In another aspect, the present disclosure provides an engineered NK cell, comprising: (1) reduced expression or activity level of a suppressor of cytokine (SOCS) protein; and (2) one or more members selected from the group consisting of:
(i) enhanced expression or activity level of endogenous activating NK receptor as compared to a control NK cell;
(ii) a heterologous interleukin (IL) cytokine and/or receptor for enhanced interleukin signaling as compared to the control NK cell;
(iii) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a NKG2D ligand;
(iv) reduced expression and/or activity level of an endogenous CD38 as compared to the control NK cell;
(v) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
(vi) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;
(vii) a safety switch capable of effecting death of the engineered NK cell; and
(viii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
In some embodiments of any one of the compositions disclosed herein, the engineered NK cell exhibits enhanced cytotoxicity against a target cell as compared to a control cell. In some embodiments of any one of the compositions disclosed herein, the engineered NK cell induces reduced immune response in a host cell as compared to a control cell.
In some embodiments of any one of the compositions disclosed herein, the host cell is an immune cell.
In another aspect, the present disclosure provides a method comprising: administering to a subject in need thereof a subject composition of any one of the compositions disclosed herein. In some embodiments, the separate therapeutic agent comprises a chemotherapeutic agent.
Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
INCORPORATION BY REFERENCE
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG. ” herein) , of which:
FIG. 1 illustrates nucleic acid vectors encoding one or more genes, such as an activating NK receptor.
FIG. 2A illustrates nucleic acid vectors encoding an activating NK receptor and/or a DAP protein. FIGs. 2B and 2C illustrate expression level of the activating NK receptor in cells treated with one of the nucleic acid vectors from FIG. 2A.
FIG. 3A illustrates nucleic acid vectors encoding a chimeric polypeptide receptor (e.g., a chimeric antigen receptor) exhibiting specific binding to an antigen, such as CLL-1. FIG. 3B illustrates examples of transgenes encoding a CD16 variant that can be inserted into the genome of a host cell. FIG. 3C illustrates different endogenous genes that can be suppressed in an engineered immune cell for immunotherapies.
FIG. 4A illustrates a structural of anti-CLL-1 chimeric polypeptide receptor (e.g., anti-CLL-1 chimeric antigen receptor (CAR) ) . FIG. 4B shows cytotoxicity level of anti-CLL-1 CAR NK cells and non-modified control NK cells, against CLL-1 expressing HL60 tumor cells. FIG. 4C shows expression level of CD107A in anti-CLL-1 CAR NK cells and non-modified control NK cells, upon being in contact with the CLL-1 expressing HL60 tumor cells.
FIG. 5A shows CD56 expression of engineered NK cells from iPSCs engineered to enhance expression and/or activity level of an activating NK receptor. FIG. 5B shows FACS fluoresces intensity of engineered NK cells overexpressing an activating NK receptor.
FIG. 6A shows cytotoxicity analysis of engineered NK cells with enhanced NK receptor and NK cells derived from
iPSCs, against solid tumor cells, Calu-3. FIG. 6B shows serial cytotoxicity analysis with engineered NK cells and NK cells derived from
iPSCs against THP1 and SKOV3. FIG. 6C shows cytotoxicity analysis with engineered NK cells and non-modified control NK cells against THP1 and MOLM13. FIG. 6D shows expression profile of NKG2D and NKP30 in engineered NK cells compared to NK cells derived from
iPSCs during in vitro killing assay.
FIG. 7 shows tumor burden of mice injected with engineered NK cells expressing NK receptors compared to mice injected NK cells without engineering.
FIG. 8A shows change in mice body weight post injection of engineered NK cells expressing NK receptors using SKOV3 tumor model. FIG. 8B shows survival proportions of mice harboring SKOV3 tumor with or without injection of engineered NK cells. FIG. 8C shows pharmacokinetics of hCD56+ cells in peripheral blood of mice injected with engineered NK cells. FIG. 8D shows tumor burden of mice with SKOV3 injected with different dose of engineered NK cells.
FIG. 9A shows cytotoxicity analysis of NK cells with TGFb-R2 knock out and control NK cells incubated with GFP labeled THP1 cells, with different TGF-b dosage at 24 hours and 72 hours. FIG. 9B shows serial cytotoxicity analysis of NK cells with TGFb-R2 knock out and control NK cells incubated with GFP labeled THP1 cells with different TGF-b dosage.
FIG. 10A shows knockout efficiency of TGFb-R2 in NK cells. FIG. 10B shows FACS analysis of NKG2D and NKP30 expression in NK cells with TGFb-R2 knocked out, with or without TGF-b treatment.
FIG. 11A shows cytotoxicity analysis of cord blood natural killer (CBNK) incubated with different ratio of wild type K562 or HLA-E K562. FIG. 11B shows result of CD107a assay of CBNK incubated with different ratio of K562, HLA-E K562, or CBNK alone. FIG. 11C shows FACS analysis of NKG2A expression in CBNK with knockout of NKG2A and with HS2 knockout as control. FIG. 11D shows cytotoxicity analysis of CBNK with NKG2A knockout and CBNK with H2S knockout incubated different ratio of wild type K562 or HLA-E K562.
FIG. 12A shows quantification of CD45+/CD46+ NK cells differentiated from iPSCs engineered with SOCS2 knockout. FIG. 12B shows FACS fluorescence intensity of engineered NK cells with SOCS2 knockout. FIG. 12C shows number of hCD56+/hC45+ NK cells cultured in presence of peripheral blood cells with IL-2 or IL-15 supplementation, to compare persistency level of NK cells with SOCS2 knockout, that of unmodified NK cells, and that of NK cells with CISH knockout.
FIG. 13 illustrates nucleic acid vectors encoding an DNAM1 and TIGIT and shows FACS analysis of TIGIT expression in 293T cells transfected with the nucleic acid vectors.
FIG. 14 illustrates nucleic acid vector encoding NKP80 and shows FACS analysis of NKP80 expression in iPSCs transfected with the nucleic acid vector.
While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
As used in the specification and claims, the singular forms “a, ” “an, ” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “achimeric transmembrane receptor” includes a plurality of chimeric transmembrane receptors.
The term “about” or “approximately” generally mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1%of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” meaning within an acceptable error range for the particular value should be assumed.
The use of the alternative (e.g., “or” ) should be understood to mean either one, both, or any combination thereof of the alternatives. The term “and/or” should be understood to mean either one, or both of the alternatives.
The term “cell” generally refers to a biological cell. A cell can be the basic structural, functional and/or biological unit of a living organism. A cell can originate from any organism having one or more cells. Some non-limiting examples include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g. cells from plant crops, fruits, vegetables, grains, soy bean, corn, maize, wheat, seeds, tomatoes, rice, cassava, sugarcane, pumpkin, hay, potatoes, cotton, cannabis, tobacco, flowering plants, conifers, gymnosperms, ferns, clubmosses, hornworts, liverworts, mosses) , an algal cell, (e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like) , seaweeds (e.g. kelp) , a fungal cell (e.g., a yeast cell, a cell from a mushroom) , an animal cell, a cell from an invertebrate animal (e.g. fruit fly, cnidarian, echinoderm, nematode, etc. ) , a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal) , a cell from a mammal (e.g., a pig, a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, a human, etc. ) , and etcetera. Sometimes a cell is not originating from a natural organism (e.g. a cell can be a synthetically made, sometimes termed an artificial cell) .
The term “reprogramming, ” “dedifferentiation, ” “increasing cell potency, ” or “increasing developmental potency, ” as used interchangeable herein, generally refers to a method of increasing the potency of a cell or dedifferentiating the cell to a less differentiated state. For example, a cell that has an increased cell potency has more developmental plasticity (i.e., can differentiate into more cell types) compared to the same cell in the non-reprogrammed state. In other words, a reprogrammed cell is one that is in a less differentiated state than the same cell in a non-reprogrammed state.
The term “differentiation” generally refers to a process by which an unspecialized ( “uncommitted” ) or less specialized cell acquires the features of a specialized cell such as, e.g., an immune cell. A differentiated or differentiation-induced cell is one that has taken on a more specialized ( “committed” ) position within the lineage of a cell. The term “committed” generally refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type.
The term “pluripotent” generally refers to the ability of a cell to form all lineages of the body or soma (i.e., the embryo proper) . For example, embryonic stem cells are a type of pluripotent stem cells that are able to form cells from each of the three germs layers, the ectoderm, the mesoderm, and the endoderm. Pluripotency can be a continuum of developmental potencies ranging from the incompletely or partially pluripotent cell (e.g., an epiblast stem cell) , which is unable to give rise to a complete organism to the more primitive, more pluripotent cell, which is able to give rise to a complete organism (e.g., an embryonic stem cell) .
The term “induced pluripotent stem cells” (iPSCs) generally refers to stem cells that are derived from differentiated cells (e.g., differentiated adult, neonatal, or fetal cells) that have been induced or changed (i.e., reprogrammed) into cells capable of differentiating into tissues of all three germ or dermal layers: mesoderm, endoderm, and ectoderm. The iPSCs produced do not refer to cells as they are found in nature. In some cases, iPSCs can be engineered to differentiation directly into committed cells (e.g., natural killer (NK) cells. In some cases, iPSCs can be engineered to differentiate first into tissue-specific stem cells (e.g., hematopoietic stem cells (HSCs) ) , which can be further induced to differentiate into committed cells (e.g., NK cells) .
The term “embryonic stem cell” (ESCs) generally refers to naturally occurring pluripotent stem cells of the inner cell mass of the embryonic blastocyst. Embryonic stem cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In some cases, ESCs can be engineered to differentiation directly into committed cells (e.g., NK cells) . In some cases, ESCs can be engineered to differentiate first into tissue-specific stem cells (e.g., HSCs) , which can be further induced to differentiate into committed cells (e.g., NK cells) .
The term “isolated stem cells” generally refers to any type of stem cells disclosed herein (e.g., ESCs, HSCs, mesenchymal stem cells (MSCs) , etc. ) that are isolated from a multicellular organism. For example, HSCs can be isolated from a mammal’s body, such as a human body. In another example, an embryonic stem cells can be isolated from an embryo.
The term “isolated” generally refers to a cell or a population of cells, which has been separated from its original environment. For example, a new environment of the isolated cells is substantially free of at least one component as found in the environment in which the “un-isolated” reference cells exist. An isolated cell can be a cell that is removed from some or all components as it is found in its natural environment, for example, isolated from a tissue or biopsy sample. The term also includes a cell that is removed from at least one, some or all components as the cell is found in non-naturally occurring environments, for example, isolated form a cell culture or cell suspension. Therefore, an isolated cell is partly or completely separated from at least one component, including other substances, cells or cell populations, as it is found in nature or as it is grown, stored or subsisted in non-naturally occurring environments.
The term “hematopoietic stem and progenitor cells, ” “hematopoietic stem cells, ” , “hematopoietic progenitor cells, ” or “hematopoietic precursor cells, ” as used interchangeably herein, generally refers to cells which are committed to a hematopoietic lineage but are capable of further hematopoietic differentiation (e.g., into NK cells) and include, multipotent hematopoietic stem cells (hematoblasts) , myeloid progenitors, megakaryocyte progenitors, erythrocyte progenitors, and lymphoid progenitors. Hematopoietic stem and progenitor cells (HSCs) are multipotent stem cells that give rise to all the blood cell types including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells) , and lymphoid lineages (T cells, B cells, NK cells) . In some cases, HSCs can be CD34+ hematopoietic cells capable of giving rise to both mature myeloid and lymphoid cell types including T cells, NK cells and B cells.
The term “immune cell” generally refers to a differentiated hematopoietic cell. Non-limiting examples of an immune cell can include an NK cell, a T cell, a monocyte, an innate lymphocyte, a tumor-infiltrating lymphocyte, a macrophage, a granulocyte, etc.
The term “NK cell” or “Natural Killer cell” generally refers to a subset of peripheral blood lymphocytes defined by the expression of CD56 or CD16 and the absence of the T cell receptor (CD3) . In some cases, NK cells that are phenotypically CD3-and CD56+, expressing at least one of NKG2C and CD57 (e.g., NKG2C, CD57, or both in same or different degrees) , and optionally, CD16, but lack expression of one or more of the following: PLZF, SYK, FceRγ, and EAT-2. In some cases, isolated subpopulations of CD56+ NK cells can exhibit expression of CD16, NKG2C, CD57, NKG2D, NCR ligands, NKp30, NKp40, NKp46, activating and inhibitory KIRs, NKG2A and/or DNAM-1.
The term “nucleotide, ” as used herein, generally refers to a base-sugar-phosphate combination. A nucleotide can comprise a synthetic nucleotide. A nucleotide can comprise a synthetic nucleotide analog. Nucleotides can be monomeric units of a nucleic acid sequence (e.g. deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) ) . The term nucleotide can include ribonucleoside triphosphates adenosine triphosphate (ATP) , uridine triphosphate (UTP) , cytosine triphosphate (CTP) , guanosine triphosphate (GTP) and deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives can include, for example, [αS] dATP, 7-deaza-dGTP and 7-deaza-dATP, and nucleotide derivatives that confer nuclease resistance on the nucleic acid molecule containing them. The term nucleotide as used herein can refer to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrative examples of dideoxyribonucleoside triphosphates can include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. A nucleotide may be unlabeled or detectably labeled by well-known techniques. Labeling can also be carried out with quantum dots. Detectable labels can include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels. Fluorescent labels of nucleotides may include but are not limited fluorescein, 5-carboxyfluorescein (FAM) , 2′7′-dimethoxy-4′5-dichloro-6-carboxyfluorescein (JOE) , rhodamine, 6-carboxyrhodamine (R6G) , N, N, N′, N′-tetramethyl-6-carboxyrhodamine (TAMRA) , 6-carboxy-X-rhodamine (ROX) , 4-(4′dimethylaminophenylazo) benzoic acid (DABCYL) , Cascade Blue, Oregon Green, Texas Red, Cyanine and 5- (2′-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS) . Specific examples of fluorescently labeled nucleotides can include [R6G] dUTP, [TAMRA] dUTP, [R110] dCTP, [R6G] dCTP, [TAMRA] dCTP, [JOE] ddATP, [R6G] ddATP, [FAM] ddCTP, [R110] ddCTP, [TAMRA] ddGTP, [ROX] ddTTP, [dR6G] ddATP, [dR110] ddCTP, [dTAMRA] ddGTP, and [dROX] ddTTP available from Perkin Elmer, Foster City, Calif. FluoroLink DeoxyNucleotides, FluoroLink Cy3-dCTP, FluoroLink Cy5-dCTP, FluoroLink Fluor X-dCTP, FluoroLink Cy3-dUTP, and FluoroLink Cy5-dUTP available from Amersham, Arlington Heights, Ill.; Fluorescein-15-dATP, Fluorescein-12-dUTP, Tetramethyl-rodamine-6-dUTP, IR770-9-dATP, Fluorescein-12-ddUTP, Fluorescein-12-UTP, and Fluorescein-15-2′-dATP available from Boehringer Mannheim, Indianapolis, Ind.; and Chromosome Labeled Nucleotides, BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP, BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade Blue-7-UTP, Cascade Blue-7-dUTP, fluorescein-12-UTP, fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine Green-5-UTP, Rhodamine Green-5-dUTP, tetramethylrhodamine-6-UTP, tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP, and Texas Red-12-dUTP available from Molecular Probes, Eugene, Oreg. Nucleotides can also be labeled or marked by chemical modification. A chemically-modified single nucleotide can be biotin-dNTP. Some non-limiting examples of biotinylated dNTPs can include, biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP) , biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP) , and biotin-dUTP (e.g. biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP) .
The term “polynucleotide, ” “oligonucleotide, ” or “nucleic acid, ” as used interchangeably herein, generally refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof, either in single-, double-, or multi-stranded form. A polynucleotide can be exogenous or endogenous to a cell. A polynucleotide can exist in a cell-free environment. A polynucleotide can be a gene or fragment thereof. A polynucleotide can be DNA. A polynucleotide can be RNA. A polynucleotide can have any three dimensional structure, and can perform any function, known or unknown. A polynucleotide can comprise one or more analogs (e.g. altered backbone, sugar, or nucleobase) . If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, florophores (e.g. rhodamine or flurescein linked to the sugar) , thiol containing nucleotides, biotin linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudourdine, dihydrouridine, queuosine, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA) , transfer RNA (tRNA) , ribosomal RNA (rRNA) , short interfering RNA (siRNA) , short-hairpin RNA (shRNA) , micro-RNA (miRNA) , ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA) , nucleic acid probes, and primers. The sequence of nucleotides can be interrupted by non-nucleotide components.
The term “gene” generally refers to a nucleic acid (e.g., DNA such as genomic DNA and cDNA) and its corresponding nucleotide sequence that is involved in encoding an RNA transcript. The term as used herein with reference to genomic DNA includes intervening, non-coding regions as well as regulatory regions and can include 5′and 3′ends. In some uses, the term encompasses the transcribed sequences, including 5′and 3′untranslated regions (5′-UTR and 3′-UTR) , exons and introns. In some genes, the transcribed region will contain “open reading frames” that encode polypeptides. In some uses of the term, a “gene” comprises only the coding sequences (e.g., an “open reading frame” or “coding region” ) necessary for encoding a polypeptide. In some cases, genes do not encode a polypeptide, for example, ribosomal RNA genes (rRNA) and transfer RNA (tRNA) genes. In some cases, the term “gene” includes not only the transcribed sequences, but in addition, also includes non-transcribed regions including upstream and downstream regulatory regions, enhancers and promoters. A gene can refer to an “endogenous gene” or a native gene in its natural location in the genome of an organism. A gene can refer to an “exogenous gene” or a non-native gene. A non-native gene can refer to a gene not normally found in the host organism but which is introduced into the host organism by gene transfer. A non-native gene can also refer to a gene not in its natural location in the genome of an organism. A non-native gene can also refer to a naturally occurring nucleic acid or polypeptide sequence that comprises mutations, insertions and/or deletions (e.g., non-native sequence) .
The term “expression” generally refers to one or more processes by which a polynucleotide is transcribed from a DNA template (such as into an mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides can be collectively referred to as “gene product. ” If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell. “Up-regulated, ” with reference to expression, generally refers to an increased expression level of a polynucleotide (e.g., RNA such as mRNA) and/or polypeptide sequence relative to its expression level in a wild-type state while “down-regulated” generally refers to a decreased expression level of a polynucleotide (e.g., RNA such as mRNA) and/or polypeptide sequence relative to its expression in a wild-type state. Expression of a transfected gene can occur transiently or stably in a cell. During “transient expression” the transfected gene is not transferred to the daughter cell during cell division. Since its expression is restricted to the transfected cell, expression of the gene is lost over time. In contrast, stable expression of a transfected gene can occur when the gene is co-transfected with another gene that confers a selection advantage to the transfected cell. Such a selection advantage may be a resistance towards a certain toxin that is presented to the cell.
The term “peptide, ” “polypeptide, ” or “protein, ” as used interchangeably herein, generally refers to a polymer of at least two amino acid residues joined by peptide bond (s) . This term does not connote a specific length of polymer, nor is it intended to imply or distinguish whether the peptide is produced using recombinant techniques, chemical or enzymatic synthesis, or is naturally occurring. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers comprising at least one modified amino acid. In some cases, the polymer can be interrupted by non-amino acids. The terms include amino acid chains of any length, including full length proteins, and proteins with or without secondary and/or tertiary structure (e.g., domains) . The terms also encompass an amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulation such as conjugation with a labeling component. The terms “amino acid” and “amino acids, ” as used herein, generally refer to natural and non-natural amino acids, including, but not limited to, modified amino acids and amino acid analogues. Modified amino acids can include natural amino acids and non-natural amino acids, which have been chemically modified to include a group or a chemical moiety not naturally present on the amino acid. Amino acid analogues can refer to amino acid derivatives. The term “amino acid” includes both D-amino acids and L-amino acids.
The term “derivative, ” “variant, ” or “fragment, ” as used herein with reference to a polypeptide, generally refers to a polypeptide related to a wild type polypeptide, for example either by amino acid sequence, structure (e.g., secondary and/or tertiary) , activity (e.g., enzymatic activity) and/or function. Derivatives, variants and fragments of a polypeptide can comprise one or more amino acid variations (e.g., mutations, insertions, and deletions) , truncations, modifications, or combinations thereof compared to a wild type polypeptide.
The term “engineered, ” “chimeric, ” or “recombinant, ” as used herein with respect to a polypeptide molecule (e.g., a protein) , generally refers to a polypeptide molecule having a heterologous amino acid sequence or an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the polypeptide molecule, as well as cells or organisms which express the polypeptide molecule. The term “engineered” or “recombinant, ” as used herein with respect to a polynucleotide molecule (e.g., a DNA or RNA molecule) , generally refers to a polynucleotide molecule having a heterologous nucleic acid sequence or an altered nucleic acid sequence as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion. In some cases, an engineered or recombinant polynucleotide (e.g., a genomic DNA sequence) can be modified or altered by a gene editing moiety.
The term “gene editing moiety” generally refers to a moiety which can edit a nucleic acid sequence, whether exogenous or endogenous to a cell comprising the nucleic acid sequence. In some embodiments, a gene editing moiety regulates expression of a gene by editing a nucleic acid sequence. In some cases, a gene editing moiety can regulate expression of a gene by editing genomic DNA sequence. In some cases, a gene editing moiety can regulate expression of a gene by editing an mRNA template. Editing a nucleic acid sequence can, in some cases, alter the underlying template for gene expression.
Alternatively or in addition to, a gene editing moiety can be capable of regulating expression or activity of a gene by specifically binding to a target sequence operatively coupled to the gene (or a target sequence within the gene) , and regulating the production of mRNA from DNA, such as chromosomal DNA or cDNA. In some cases, a gene editing moiety can recruit or comprise at least one transcription factor that binds to a specific DNA sequence, thereby controlling the rate of transcription of genetic information from DNA to mRNA. A gene editing moiety can itself bind to DNA and regulate transcription by physical obstruction, for example preventing proteins such as RNA polymerase and other associated proteins from assembling on a DNA template. A gene editing moiety can regulate expression of a gene at the translation level, for example, by regulating the production of protein from mRNA template. In some cases, a gene editing moiety can regulate gene expression by affecting the stability of an mRNA transcript.
The term “antibody” generally refers to a proteinaceous binding molecule with immunoglobulin-like functions. The term antibody includes antibodies (e.g., monoclonal and polyclonal antibodies) , as well as derivatives, variants, and fragments thereof. Antibodies include, but are not limited to, immunoglobulins (Ig's) of different classes (i.e. IgA, IgG, IgM, IgD and IgE) and subclasses (such as IgG1, IgG2, etc. ) . A derivative, variant or fragment thereof can refer to a functional derivative or fragment which retains the binding specificity (e.g., complete and/or partial) of the corresponding antibody. Antigen-binding fragments include Fab, Fab′, F (ab′) 2, variable fragment (Fv) , single chain variable fragment (scFv) , minibodies, diabodies, and single-domain antibodies ( “sdAb” or “nanobodies” or “camelids” ) . The term antibody includes antibodies and antigen-binding fragments of antibodies that have been optimized, engineered or chemically conjugated. Examples of antibodies that have been optimized include affinity-matured antibodies. Examples of antibodies that have been engineered include Fc optimized antibodies (e.g., antibodies optimized in the fragment crystallizable region) and multispecific antibodies (e.g., bispecific antibodies) .
The term “chimeric polypeptide receptor” generally refers to a non-natural polypeptide receptor comprising one or more antigen binding moieties, each antigen binding moiety capable of binding to a specific antigen. A chimeric polypeptide receptor can be monospecific (i.e., capable of binding to one type of specific antigen) . Alternatively, a chimeric polypeptide receptor can be multi-specific (i.e., capable of binding to two or more different types of specific antigens) . A chimeric polypeptide receptor can be monovalent (i.e., comprising a single antigen binding moiety) . Alternatively, a chimeric polypeptide receptor can be multivalent (i.e., comprising a plurality of antigen binding moieties) . In some cases, a chimeric polypeptide receptor can comprise a T-cell receptor (TCR) fusion protein (TFP) or a chimeric antigen receptor (CAR) .
The term “antigen binding domain” generally refers to a construct exhibiting preferential binding to a specific target antigen. An antigen binding domain can be a polypeptide construct, such as an antibody, modification thereof, fragment thereof, or a combination thereof. The antigen binding domain can be any antibody as disclosed herein, or a functional variant thereof. Non-limiting examples of an antigen binding domain can include a murine antibody, a human antibody, a humanized antibody, a camel Ig, a shark heavy-chain-only antibody (VNAR) , Ig NAR, a chimeric antibody, a recombinant antibody, or antibody fragment thereof. Non-limiting examples of antibody fragment include Fab, Fab′, F (ab) ′2, F (ab) ′3, Fv, single chain antigen binding fragment (scFv) , (scFv) 2, disulfide stabilized Fv (dsFv) , minibody, diabody, triabody, tetrabody, single-domain antigen binding fragments (sdAb, Nanobody) , recombinant heavy-chain-only antibody (VHH) , and other antibody fragments that maintain the binding specificity of the whole antibody.
The term “safety switch” generally refers to an engineered polypeptide construct designed to prevent potential toxicity or otherwise adverse effects of a cell therapy. When expressed in a cell, the safety switch can induce death of the host cell, thereby inactivating activity of the cell in a host (e.g., in a subject’s body) . Thus, the safety switch can be a suicide moiety. In some cases, the cell can be programmed to express the suicide moiety at certain stage of its life-cycle (e.g., time-programmed) . In some cases, expression of the suicide moiety in a cell can be conditional or inducible. In some examples, conditional regulation (e.g., expression) of a suicide moiety can include control through a small molecule-mediated post-translational activation and tissue-specific and/or temporal transcriptional regulation. Thus, the safety switch can be an inducible suicide moiety. A safety switch can mediate induction of apoptosis, inhibition of protein synthesis, DNA replication, growth arrest, transcriptional and post-transcriptional genetic regulation, and/or antibody-mediated depletion. In some cases, a safety switch can be activated by an exogenous molecule (e.g., a drug or a prodrug) that, when activated, triggers apoptosis and/or cell death of a cell (e.g., engineered NK cell as disclosed herein) .
The term “hypo-immunity regulator” generally refers to a polypeptide construct in a cell, wherein either enhanced expression (e.g., via knock-in of a heterologous gene) or reduced expression (e.g., via knock-out or knock-down of an endogenous gene) of the hypo-immunity regulator in the cell can help the cell to reduce or avoid immune response (e.g., immune attack, such as adaptive immune rejection) from a host’s body upon administration to the host’s body. In some cases, cells (e.g., engineered NK cells as disclosed herein) can be modified to exhibit either enhanced expression or reduced expression of the hypo-immunity regulator, such that the cells can evade the host immune attack upon second or further infusion of the cells into the host (i.e., recipient) . As such, the cells (i) would not be rejected by the host’s immune system (e.g., antibody-mediated complement cytotoxicity, or antibody-dependent cellular cytotoxicity (ADCC) ) and/or (ii) would be rejected at a slower rate by the host’s immune system as compared with a control cell without the enhanced expression or reduced expression of the hypo-immunity regulator. A cell exhibiting the enhanced expression or reduced expression of the hypo-immunity regulator can be referred to as exhibiting “hypo-immunity” or being “immune-privileged. ” For example, enhanced hypo-immunity (e.g., enhanced resistance against ADCC) of a population of engineered immune cells (e.g., a population of engineered NK cells) as disclosed herein can be ascertained in vitro (e.g., in the presence of human serum or human complement and an antibody (e.g., SSEA-4 antibody) ) or in vivo (e.g., upon administration to a subject’s bloodstream) .
In some cases, engineering of an immune cell (e.g., NK cells) as disclosed herein can enhance the immune cell’s resistance against immune rejection (e.g., ADCC) by at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, at least or up to about 80%, at least or up to about 85%, at least or up to about 90%, at least or up to about 95%, at least or up to about 100%, at least or up to about 150%, at least or up to about 200%, at least or up to about 300%, at least or up to about 400%, or at least or up to about 500%.
In some cases, the enhanced resistance against immune rejection (e.g., ADCC) can be ascertained in vitro in a medium comprising at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, or at least or up to about 80%, human complement.
The term “immune checkpoint inhibitor” generally refers to a group of molecules presented on a cell surface of an immune cell (e.g., T cells, myeloid cells, NK cells, B cells, etc. ) that can modulate immune response of the cell by down-regulating or inhibiting the immune response of the immune cell against a target cell, such as a cancer cell (i.e., anti-cancer or anti-tumor immune response) . The target cell can express a receptor or a ligand of the immune checkpoint inhibitor presented on the surface of the immune cell, to engage with the immune checkpoint inhibitor and down-regulate or inhibit the immune response of the immune cells against the target cell. As such, down-regulating or inhibiting expression of the immune checkpoint inhibitor in the immune cell can, in some cases, enhance or prolong the immune response of the immune cell against a target cell.
An exogenous interleukin, as disclosed herein, can comprise an interleukin that is not secreted by the cell or the population of cells (e.g., the engineered immune cell (s) , such as the engineered NK cells as disclosed herein) , and can be artificially added to the environment. In an in vitro environment, an exogenous interleukin may comprise a recombinant interleukin protein that is added to a medium. In an in vivo environment (e.g., in plasma) , an exogenous interleukin may comprise a recombinant interleukin protein that is administered to a subject in need thereof.
The term “persistence” as used herein may generally refer to a presence of at least a portion of a population of cells (e.g., a population of engineered immune cells, such as a population of engineered NK cells as disclosed herein) remaining in an environment after introducing the population of cells to the environment (e.g., in an in vitro medium, in the serum after intravenous (IV) administration, etc. ) . A persistence may be ascertained by a duration of time that at least a portion of the population of cells remain in the environment at a detectable level. In some examples, persistence of a population of cells may correlate to the half-life of the population of cells in the environment (e.g., medium, blood stream, etc. ) . In some cases, a population of cells of interest (e.g., ., a population of engineered immune cells, such as a population of engineered NK cells) may not grow (e.g., proliferate) over time, and a persistence level of the population of cells as disclosed herein can be ascertained by measuring a decrease (or a rate thereof) in a size of the population of cells over time. For example, a population of cells having a greater persistence level (e.g., at least 5%greater) in an environment after a period of time (e.g., after at least about 5 days) than a control population of cells in a comparable environment after a comparable period of time may indicate that a greater proportion (e.g., at least 5%greater) of the size of the population of cells have survived as compared to the control population of cells.
The term “immune response” generally refers to T cell mediated and/or B cell mediated immune responses from a host’s immune system to an object (e.g., a foreign object) . An example of an immune response include T cell responses, e.g., cytokine production and cellular cytotoxicity. IN some cases, an immune response can be indirectly effected by T cell activation, e.g., antibody production (humoral responses) and activation of cytokine responsive cells, such as macrophages.
The term “enhanced expression, ” “increased expression, ” or “upregulated expression” generally refers to production of a moiety of interest (e.g., a polynucleotide or a polypeptide) to a level that is above a normal level of expression of the moiety of interest in a host strain (e.g., a host cell) . The normal level of expression can be substantially zero (or null) or higher than zero. The moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain. The moiety of interest can comprise a heterologous gene or polypeptide construct that is introduced to or into the host strain. For example, a heterologous gene encoding a polypeptide of interest can be knocked-in (KI) to a genome of the host strain for enhanced expression of the polypeptide of interest in the host strain.
The term “enhanced activity, ” “increased activity, ” or “upregulated activity” generally refers to activity of a moiety of interest (e.g., a polynucleotide or a polypeptide) that is modified to a level that is above a normal level of activity of the moiety of interest in a host strain (e.g., a host cell) . The normal level of activity can be substantially zero (or null) or higher than zero. The moiety of interest can comprise a polypeptide construct of the host strain. The moiety of interest can comprise a heterologous polypeptide construct that is introduced to or into the host strain. For example, a heterologous gene encoding a polypeptide of interest can be knocked-in (KI) to a genome of the host strain for enhanced activity of the polypeptide of interest in the host strain.
The term “reduced expression, ” “decreased expression, ” or “downregulated expression” generally refers to a production of a moiety of interest (e.g., a polynucleotide or a polypeptide) to a level that is below a normal level of expression of the moiety of interest in a host strain (e.g., a host cell) . The normal level of expression is higher than zero. The moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain. In some cases, the moiety of interest can be knocked-out or knocked-down in the host strain. In some examples, reduced expression of the moiety of interest can include a complete inhibition of such expression in the host strain.
The term “reduced activity, ” “decreased activity, ” or “downregulated activity” generally refers to activity of a moiety of interest (e.g., a polynucleotide or a polypeptide) that is modified to a level that is below a normal level of activity of the moiety of interest in a host strain (e.g., a host cell) . The normal level of activity is higher than zero. The moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain. In some cases, the moiety of interest can be knocked-out or knocked-down in the host strain. In some examples, reduced activity of the moiety of interest can include a complete inhibition of such activity in the host strain.
The term “subject, ” “individual, ” or “patient, ” as used interchangeably herein, generally refers to a vertebrate, preferably a mammal such as a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
The term “treatment” or “treating” generally refers to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit. For example, a treatment can comprise administering a system or cell population disclosed herein. By therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. For prophylactic benefit, a composition can be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.
The term “effective amount” or “therapeutically effective amount” generally refers to the quantity of a composition, for example a composition comprising immune cells such as lymphocytes (e.g., T lymphocytes and/or NK cells) comprising a system of the present disclosure, that is sufficient to result in a desired activity upon administration to a subject in need thereof. Within the context of the present disclosure, the term “therapeutically effective” generally refers to that quantity of a composition that is sufficient to delay the manifestation, arrest the progression, relieve or alleviate at least one symptom of a disorder treated by the methods of the present disclosure.
A. Overview
T cells are part of the adaptive immune system and can be primed to recognize a specific threat by recognizing immune proteins (i.e., antigens) on a foreign cell surface. In contrast, NK cells are part of the innate immune response and can respond to a broad range of objects that consider to be “non-self. ” Generally, unlike T cells, NK cells can attack their target cells without sensitization (i.e., antigen-specific priming) to eliminate foreign substances.
Unmodified NK cells derived from a subject (e.g., derived from HSCs of the subject) can be cultured and expanded ex vivo, then administered to the subject as a treatment to attack their target cells, e.g., cancer cells. However, NK cell-based therapies can be limited due to short half-life and/or poor proliferation of NK cells ex vivo or in vivo. In addition, unmodified NK cells can be ineffective in targeting harder-to-treat cancers, such as myeloma or solid tumors. Furthermore, ex vivo production of NK cells based on blood-derived stem cells (e.g., HSCs) can yield a limited supply of NK cells for effective adoptive immunotherapy.
Thus, there remains a significant unmet need for immune cells (e.g., NK cells, T cells, etc. ) sourced and engineered to exhibit, for example, enhanced proliferation, half-life, and cytotoxic activity against target cells.
B. Engineered immune cells
The present disclosure describes systems and methods for immunotherapies. Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell) . Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) . The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.
In some cases, engineered immune cells (e.g., engineered NK cells) disclosed herein can be derived from an isolated stem cell (e.g., isolated ESCs) . In some cases, engineered immune cells disclosed herein can be derived from induced stem cells (e.g., iPSCs) .
In some cases, the stem cell disclosed herein (e.g., isolated stem cell, induced stem cell) can be an autologous cell or derived from the autologous cell. The autologous cell can be obtained from a subject having a condition or is suspected of having the condition. Alternatively, the autologous cell can be obtained from the subject before the subject is found to have the condition. In some cases, the autologous cell can be an allogeneic cell, e.g., a universal stem cell with reduced immunogenicity and with reduced amount or no need for immunosuppressive drugs. The autologous cell can be obtained from a healthy donor.
In some cases, the engineered immune cell (e.g., engineered NK cell) can be an autologous cell. The engineered immune cell can be obtained from a subject having a condition or is suspected of having the condition. Alternatively, the engineered immune cell can be obtained from the subject before the subject is found to have the condition. In some cases, the engineered immune cell can be an allogeneic cell, e.g., for a universal allogenic immunotherapy with reduced immunogenicity and with reduced amount or no need for immunosuppressive drugs. The engineered immune cell can be obtained from a healthy donor.
In some aspects, T cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered T cell) . T cells can be engineered to exhibit enhanced proliferation as compared to a control cell. T cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered T cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered T cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) . The engineered T cells can be autologous to the subject. Alternatively, the engineered T cells can be allogeneic to the subject.
In some aspects, NK cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered NK cell) . NK cells can be engineered to exhibit enhanced proliferation as compared to a control cell. NK cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered NK cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered NK cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) . The engineered NK cells can be autologous to the subject. Alternatively, the engineered NK cells can be allogeneic to the subject.
In one aspect, the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) . The engineered immune cell can comprise or exhibit one or more members of the following:
(#1) an enhanced expression and/or activity level of an activating NK receptor as compared to a control NK cell; and/or
(#2) a chimeric polypeptide receptor (e.g., a chimeric antigen receptor (CAR) , an engineered T cell receptor (TCR) , etc. ) comprising an antigen binding moiety capable of binding to an antigen, (e.g., optionally wherein the antigen is not a NKG2D ligand) ; and/or
(#3) a reduced expression and/or activity level of a suppressor of cytokine (SOCS) protein; and/or
(#4) an enhanced expression and/or activity level of a dead-associated protein (DAP) ; and/or
(#5) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a ligand of the activating NK receptor (e.g., NKG2D ligand) ; and/or
(#6) a reduced expression and/or activity level of endogenous CD38 as compared to the control NK cell; and/or
(#7) reduced expression and/or activity level of an immune checkpoint inhibitor (e.g., PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, 2B4, etc. ) ; and/or
(#8) reduced expression and/or activity level of a hypo-immunity regulator (e.g., B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, CD59, etc. ) ; and/or
(#9) a safety switch capable of effecting death of the engineered NK cell (e.g., upon a stimulus, such as exposure to an activating moiety, such as light or antibody) ; and/or
(#10) a heterologous cytokine (e.g., interleukin (IL) ) and/or a heterologous receptor thereof for enhanced cytokine signaling as compared to the control NK cell.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#1) . The engineered immune cell can exhibit (#1) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#1) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#2) . The engineered immune cell can exhibit (#2) and one or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and two or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and three or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and four or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and five or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and six or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and seven or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and eight or more members selected from the group consisting of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#2) and all members of (#1) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#3) . The engineered immune cell can exhibit (#3) and one or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and two or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and three or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and four or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and five or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and six or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and seven or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and eight or more members selected from the group consisting of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#3) and all members of (#2) , (#1) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#4) . The engineered immune cell can exhibit (#4) and one or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and two or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and three or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and four or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and five or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and six or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and seven or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and eight or more members selected from the group consisting of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#4) and all members of (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#5) . The engineered immune cell can exhibit (#5) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#5) and all members of (#2) , (#3) , (#4) , (#1) , (#6) , (#7) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#6) . The engineered immune cell can exhibit (#6) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#6) and all members of (#2) , (#3) , (#4) , (#5) , (#1) , (#7) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#7) . The engineered immune cell can exhibit (#7) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) . The engineered immune cell can exhibit (#7) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#1) , (#8) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#8) . The engineered immune cell can exhibit (#8) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) . The engineered immune cell can exhibit (#8) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#1) , (#9) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#9) . The engineered immune cell can exhibit (#9) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) . The engineered immune cell can exhibit (#9) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#1) , and (#10) .
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise or exhibit at least (#10) . The engineered immune cell can exhibit (#1) and one or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and two or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and three or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and four or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and five or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and six or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and seven or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and eight or more members selected from the group consisting of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) . The engineered immune cell can exhibit (#10) and all members of (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#1) .
An engineered immune cell (e.g., an engineered NK cell) comprising one or more members selected from the group constating of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced the activity (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc. ) , as compared to a control immune cell lacking at least one of the one or more members. For example, an engineered NK cell can comprise at least the enhanced expression and/or activity level of the activating NK receptor, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking enhanced expression/activity level of the activating NK receptor. In another example, an engineered NK cell can comprise a chimeric antigen receptor (e.g., a CAR) comprising an antigen binding moiety capable of binding CD70, CLEC12A, CD9, CD26, TRAIL-R4 (DCR2) , NKG2D ligand, and/or TIM-3, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking the CAR.
An engineered immune cell (e.g., an engineered NK cell) comprising two or more members selected from the group constating of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced activity (e.g., persistence of viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc. ) , as compared to a control immune cell lacking at least one of the two or more members. For example, an engineered NK cell can comprise (A) the enhanced expression and/or activity level of the activating NK receptor and (B) at least one or more members selected from the group consisting of (#5) , (#6) , (#7) , and (#8) , as disclosed herein, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking (A) and/or (B) . In another example, an engineered NK cell can comprise (A) a chimeric antigen receptor (e.g., a CAR) comprising an antigen binding moiety capable of binding CD70, CLEC12A, and/or TIM-and (B) at least one or more members selected from the group consisting of (#1) , (#7) , (#8) , and (#9) , as disclosed herein, and the engineered NK cell can exhibit enhanced cytotoxicity against a cancer or tumor cell, as compared to a control cell lacking (A) and/or (B) .
Any combination of two or more members selected from the group constating of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can induce a synergistic effect on (e.g., can synergistically enhance) an activity of the engineered immune cell (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, maintenance of stemness, etc. ) , as compared to (i) an individual effect on (e.g., an individual enhancement of) the activity of a control immune cell comprising only one of the two or more members, and/or (ii) a sum of the individual effect on (e.g., the sum of the individual enhancements of) the activity thereof. For example, an engineered NK cell can exhibit at least (#1) the enhanced expression and/or activity level of an activating NK receptor and (#2) the chimeric polypeptide receptor (e.g., a CAR) comprising one or more antigen binding moieties capable of binding to an antigen that is, optionally, not a NKG2D ligand, such as BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10. In such example, (#1) and (#2) can yield a synergistic effect in the engineered NK cell, such that an activity of the engineered NK cell (e.g., cytotoxicity against a cancer cell) is greater than that of (i) an individual enhancement of the activity in a control NK cell engineered to comprise only one of (#1) and (#2) and/or (ii) a sum of the individual enhancements thereof.
Non-limiting examples of the enhanced activity of the engineered immune cell (e.g., the engineered NK cell) , as disclosed herein, can include viability of the engineered immune cell, proliferation (or growth rate) of the engineered immune cell, survival of the engineered immune cell, cytotoxicity against a target cell such as a cancer cell, and maintenance of stemness of the engineered immune cell (e.g., stem-like T cells) . Such enhancement in activity can occur (or can be ascertained) in vitro, ex vivo, or in vivo. The enhanced activity can be at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more, as compared to that in a control immune cell. The enhanced activity can be at most about 100%, at most about 99%, 95%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 60%, at most about 50%, at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, at most about 2%, at most about 1%, or less, as compared to that in a control immune cell. The enhanced activity can be at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more, as compared to a control immune cell. The enhanced activity can be at most about 500-fold, at most about 200-fold, at most about 100-fold, at most about 50-fold, at most about 40-fold, at most about 30-fold, at most about 25-fold, at most about 20-fold, at most about 15-fold, at most about 10-fold, at most about 9-fold, at most about 8-fold, at most about 7-fold, at most about 6-fold, at most about 5-fold, at most about 4-fold, at most about 3-fold, at most about 2-fold, at most about 1-fold, at most about 0.5-fold, at most about 0.2-fold, at most about 0.1-fold, or less, as compared to a control immune cell.
The synergistic effect as disclosed herein (e.g., via any combination of (#1) - (#10) ) can be greater than (i) and/or (ii) by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more. The synergistic effect can be greater than (i) and/or (ii) by at most about 100%, at most about 99%, 95%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 60%, at most about 50%, at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, at most about 2%, at most about 1%, or less. The synergistic effect can be greater than (i) and/or (ii) by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more. The synergistic effect can be greater than (i) and/or (ii) by at most about 500-fold, at most about 200-fold, at most about 100-fold, at most about 50-fold, at most about 40-fold, at most about 30-fold, at most about 25-fold, at most about 20-fold, at most about 15-fold, at most about 10-fold, at most about 9-fold, at most about 8-fold, at most about 7-fold, at most about 6-fold, at most about 5-fold, at most about 4-fold, at most about 3-fold, at most about 2-fold, at most about 1-fold, at most about 0.5-fold, at most about 0.2-fold, at most about 0.1-fold, or less.
Any combination of two or more members selected from the group constating of (#1) , (#2) , (#3) , (#1) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can induce a synergistic effect on (e.g., can synergistically enhance) each other (e.g., A having a synergistic effect on B, B having as synergistic effect on A, or both) . An engineered immune cell (e.g., an engineered NK cell) can comprise at least a first member and a second member (e.g., that is different than the first member) selected from the group constating of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein. The synergistic effect between the first member and the second member can be such that the engineered immune cell exhibit first member in a greater degree than (i) an individual degree of the first member in a control cell comprising only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof. Alternatively or in addition to, the synergistic effect between the first member and the second member can be such that the engineered immune cell exhibit first member in a greater degree than (i) an individual degree of the first member in a control cell comprising only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof. The degree of the first member and/or the second member can be a degree of enhancement in a target moiety’s expression, activity, and/or signaling thereof (e.g., (#1) , (#4) , (#5) , and/or (#10) , as disclosed herein) . The degree of the first member and/or the second member, as disclosed herein, can be a degree of reduction in a target moiety’s expression, activity, and/or signaling thereof (e.g., (#3) , (#6) , (#7) , and/or (#8) , as disclosed herein) . The degree of the first member and/or the second member, as disclosed herein, can be a degree of expression and/or activity of a target moiety (e.g., (#2) , (#5) , (#9) , and/or (#10) , as disclosed herein) .
For example, an engineered NK cell as disclosed herein can comprise the enhanced expression and/or activity level of the activating NK receptor (first member) and the enhanced expression and/or activity level of DAP (second member) . The synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of enhancement in the expression and/or activity level of the activating NK receptor, as compared to (i) an individual degree of enhancement in the expression and/or activity level of the activating NK receptor in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof. Alternatively or in addition to, the synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of enhancement in the expression and/or activity level of the DAP, as compared to (i) an individual degree of enhancement of the expression and/or activity level in the DAP in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
In another example, an engineered NK cell as disclosed herein can comprise the enhanced expression and/or activity level of the activating NK receptor (first member) and the reduced expression and/or activity level of the SOCS protein (second member) . The synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of enhancement of the expression and/or activity level of the activating NK receptor, as compared to (i) an individual degree of enhancement in the expression and/or activity level of the activating NK receptor in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof. Alternatively or in addition to, the synergistic effect between the first member and the second member can be such that the engineered NK cell exhibits a greater degree of reduction in the expression and/or activity level of the SOCS protein, as compared to (i) an individual degree of reduction in the expression and/or activity level of the SOCS protein in a control NK cell engineered to exhibit only one of the first member and the second member and/or (ii) a sum of the individual degrees thereof.
The degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more. The degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at most about 100%, at most about 99%, 95%, at most about 90%, at most about 85%, at most about 80%, at most about 75%, at most about 70%, at most about 60%, at most about 50%, at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 5%, at most about 2%, at most about 1%, or less. The degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15- fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more. The degree of the synergistic effect on each other between two members (or among two or more members) as disclosed herein can be greater than (i) and/or (ii) by at most about 500-fold, at most about 200-fold, at most about 100-fold, at most about 50-fold, at most about 40-fold, at most about 30-fold, at most about 25-fold, at most about 20-fold, at most about 15-fold, at most about 10-fold, at most about 9-fold, at most about 8-fold, at most about 7-fold, at most about 6-fold, at most about 5-fold, at most about 4-fold, at most about 3-fold, at most about 2-fold, at most about 1-fold, at most about 0.5-fold, at most about 0.2-fold, at most about 0.1-fold, or less.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise/exhibit the enhanced expression and/or activity level of the activating NK receptor as compared to a control NK cell, as disclosed herein. The activating NK receptor can comprise NKG2D, NKP30 (e.g., NKP30A and/or NKP30B isoforms) , NKP44, NKP46, a modification thereof, a functional variant thereof, and/or a combination thereof. The activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKG2D or a modification thereof. The activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKP30 or a modification thereof. The activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKP44 or a modification thereof. The activating NK receptor can comprise at least a portion of (e.g., some of the entirety of) NKP46 or a modification thereof.
In some cases, the activating NK receptor as disclosed herein may not comprise NKG2C. Alternatively, the activating NK receptor may comprise NKG2C.
Without wishing to be bound by theory, in some cases, the activating NK receptor as disclosed herein may comprise CD100 (SEMA4D) , CD16 (FcgRIIIA) , CD160 (BY55) , CD244 (2B4, SLAMF4) , CD27, CD94–NKG2C, CD94–NKG2E, CD94-NKG2H, CD96, CRTAM, DAP12, DNAM1 (CD226) , KIR2DL4, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1, Ly49, NCR, NKG2D (KLRK1, CD314) , NKp30 (NCR3) , NKp44 (NCR2) , NKp46 (NCR1) , NKp80 (KLRF1, CLEC5C) , NTB-A (SLAMF6) , PSGL1, SLAMF7 (CRACC, CS1, CD319) , CD161 (NKR-P1A, NK1.1) , CD94–NKG2A, CD96, CEACAM1, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, KLRG1, LAIR1, LIR1 (ILT2, LILRB1) , Ly49a, Ly49b, NKR-P1A (KLRB1) , SIGLEC-10, SIGLEC-11, SIGLEC-14, SIGLEC-16, SIGLEC-3 (CD33) , SIGLEC-5 (CD170) , SIGLEC-6 (CD327) , SIGLEC-7 (CD328) , SIGLEC-8, SIGLEC-9 (CD329) , SIGLEC-E, SIGLEC-F, SIGLEC-G, SIGLEC-H, TIGIT, a modification thereof, a functional variant thereof, and/or a combination thereof.
In some cases, the activating NK receptor can be an endogenous activating NK receptor. For example, an endogenous gene encoding the activating NK receptor can be activated (e.g., via a CRISPR-Cas system as disclosed herein) to enhance the expression and/or activity of the NK receptor. In some cases, the activating NK receptor can be a heterologous receptor. The heterologous activating NK receptor can be delivered to the engineered immune cell, and/or a heterologous gene (or a heterologous polynucleotide sequence) encoding an activating NK receptor can be delivered to the engineered immune cell. Such heterologous gene may or may not be integrated into the genome of the engineered immune cell. In some cases, the activating NK receptor may be a fusion protein, e.g., at least a portion (or all) of the activating NK receptor can be fused with at least a portion (or all) of a heterologous protein. For example, the activating NK receptor can comprise a chimeric antigen receptor (CAR) comprising (i) at least a portion of an antigen binding domain of the activating NK receptor (e.g., at least a portion of an extracellular domain of the activating NK receptor) and (ii) an intracellular signaling domain of a CAR (e.g., a first-, second-, or third-regeneration CAR) . In some cases, the activating NK receptor may not be a fusion protein. In some cases, the activating NK receptor may not comprise (i) a heterologous transmembrane and/or (ii) a heterologous signaling domain (e.g., a heterologous intracellular signaling domain) .
In some embodiments, the activating NK receptor can be configured to bind (or capable of binding to) an antigen or ligand of NKG2D, NKP30, NKP44, and/or NKP46, NKP80, and/or DNAM1. Non-limiting examples of a ligand of NKG2D can include a MIC family protein (e.g., MICA, MICB, etc. ) and RAET1/ULBP family protein (e.g., RAET1E/ULBP4, RAET1G/ULBP5, RAET1H/ULBP2, RAET1/ULBP1, RAET1L/ULBP6, RAET1N/ULBP3, Rae-1, H60, MULT-1, etc. ) . Non-limiting examples of a ligand of NKP30 can include BAT3, BAG6, B7-H6, and galectin (e.g., galenctin-3) . Non-limiting examples of a ligand of NKP44 can include mixed-lineage leukemia protein (MLL) (e.g., MLL5, such as 21spe-MLL5) , heparan sulfate (HS) proteoglycans (HSPG) , Nidogen glycoprotein (NID) (e.g., NID1) , Proliferating Cell Nuclear Antigen (PCNA) , Platelet-Derived Growth Factor (PDGF) (e.g., PDGF-DD) , and exosomes. Non-limiting examples of a ligand of NKP46 can include a cytokine such as interleukin (IL) (e.g., IL-2, IL-15, etc. ) , glycoproteins such as HSPG and/or complement factor P (CFP) . Non-limiting examples of a ligand of NKP80 can include AICL and CLEC2B. Non-limiting examples of a ligand of DNAM1 can include CD112 and CD155.
The enhanced expression and/or activity level of the activating NK receptor in the engineered immune cell (e.g., the engineered NK cell) can be greater than that in a control immune cell by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 120%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more. The enhanced expression and/or activity level of the activating NK receptor in the engineered immune cell (e.g., the engineered NK cell) can be greater than that in the control immune cell by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more. The control immune cell can be an immune cell (e.g., an NK cell) that is not induced to exhibit an endogenous gene encoding the activating NK receptor. The control immune cell can be an immune cell (e.g., an NK cell) that does not comprise a heterologous activating NK receptor or a gene encoding thereof.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise/exhibit the chimeric polypeptide receptor (e.g., CAR, engineered TCR, etc. ) comprising the antigen binding moiety capable of binding to the antigen. In some embodiments, the antigen may not be a ligand of the activating NK receptor as disclosed herein. For example, the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKG2D. In another example, the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKP30. In another example, the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKP44. In another example, the antigen of the antigen binding moiety of the chimeric polypeptide receptor may not be a ligand of NKP46.
In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10.
In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can be selected from the group consisting of CD70, C-type lectin domain family protein (e.g., CLEC12A) , TIM-3, CD38, CD9, CD26, TRAIL-R4 (DCR2) , NKG2D ligand, and BCMA.
In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise CD70. In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise a C-type lectin domain family protein, e.g., C-type lectin domain family 12 member A (CLEC12A or CLL-1) . In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise TIM-3. In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise CD38. In some embodiments, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein comprise BCMA.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can exhibit the reduced expression and/or activity level of the SOCS protein. Non-limiting examples of the SOCS protein can include CIS, SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, and SOCS-7. For example, the SOCS protein can comprise SOCS2. The SOCS protein can be an endogenous protein. For example, an endogenous gene encoding the SOCS protein can be hindered or modified (e.g., via a CRISPR-Cas system as disclosed herein, or via a small molecule or protein inhibitor of the SOCS2 protein itself) to reduce the expression and/or activity of SOCS protein.
The reduced expression and/or activity level of the SOCS protein (e.g., SOCS2) in the engineered immune cell (e.g., the engineered NK cell) can be less than that in a control immune cell (e.g., that is not contacted by a CRISPR/Cas protein to hinder or modify a gene encoding the SOCS protein) by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 00%, or about 100%. The reduced expression and/or activity level of the SOCS protein (e.g., SOCS2) in the engineered immune cell (e.g., the engineered NK cell) can be less than that in the control immune cell by at least about 0.1-fold, at least about 0.2-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or more.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise (or exhibit) the enhanced expression and/or activity level of DAP. Non-limiting examples of the DAP can include DAP-10 and DAP-12. In some cases, the DAP can be an endogenous DAP, and the engineered immune cell can be induced (e.g., via action of a nuclease system) to exhibit the enhanced expression or activity level of the endogenous DAP. For example, the engineered immune cell can be contacted with (e.g., transfected or transduced with) as a CRISPR-Cas system comprising a Cas protein and a guide nucleic acid molecule that are configured to form a complex capable of binding a gene that (i) encodes the endogenous DAP or (ii) controls expression and/or activity of the endogenous DAP. In some cases, the DAP can be a heterologous DAP. The heterologous DAP or a gene encoding thereof can be delivered (e.g., via transfection, viral delivery vehicles, non-viral delivery vehicles, etc. ) to the engineered immune cell.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise (or exhibit) the heterologous cytokine (e.g., IL) and/or the heterologous receptor thereof for enhanced signaling of the cytokine in the engineered immune cell, as compared to that in a control NK cell.
The heterologous cytokine (e.g., the heterologous IL) and/or the heterologous receptor thereof, as disclosed herein, can be of the same species as that of the engineered immune cell (e.g., the engineered NK cell) . For example, both the heterologous cytokine (and/or the heterologous receptor thereof) and the engineered immune cell can be of human origin. Alternatively, the heterologous cytokine (and/or the heterologous receptor thereof) can be of a different species than that of the engineered immune cell.
A heterologous cytokine (e.g., the heterologous IL) and/or the heterologous receptor thereof, as disclosed herein, can be introduced to the engineered immune cell (e.g., engineered NK cell) by contacting a heterologous polynucleotide encoding the heterologous cytokine and/or the heterologous receptor thereof to the engineered immune cell. The heterologous polynucleotide can be integrated into the engineered immune cell’s chromosome (e.g., nuclear chromosome) . Alternatively, the heterologous polynucleotide may not and need not be integrated into the chromosome of the engineered immune cell. In an example, a mRNA encoding a heterologous cytokine can be introduced (or inserted into) the engineered immune cell.
In some cases, the cytokine as disclosed herein can be IL. An IL as disclosed herein can comprise at least 1, 2, 3, 4, 5, or more different types of ILs. An IL as disclosed herein can comprise at most 5, 4, 3, or 2 different type of ILs. Alternatively, the IL can be a single type of IL. Non-limiting examples of the IL can include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36. In some examples, the IL can comprise one or more members selected from the group consisting of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and functional modifications thereof. For example, the engineered immune cell (e.g., an engineered NK cell) as disclosed herein can comprise at least a portion of heterologous variant of any one of the IL as disclosed herein, such as human IL-15 (or a gene encoding thereof) . In another example, the engineered immune cell (e.g., an engineered NK cell) as disclosed herein can comprise at least a portion of heterologous variant of a receptor of any one of the IL as disclosed herein, such as human IL-15 receptor (IL-15R) (or a gene encoding thereof) .
The heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be a secretory cytokine. Alternatively, the heterologous cytokine may not and need not be secreted by the engineered immune cell. In such a case, for example, the heterologous cytokine can be bound to a cell surface of the engineered immune cell.
In some cases, the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be a secretory cytokine. An expression cassette encoding the heterologous cytokine can be introduced to the engineered immune cell. The expression cassette can further encode an additional heterologous polypeptide, e.g., a heterologous receptor. Within the expression cassette, a first polynucleotide sequence encoding the heterologous cytokine and a second polynucleotide sequence encoding the additional heterologous polypeptide (e.g., the heterologous receptor) can be coupled to each other via a polynucleotide linker encoding a cleavage linker. In some examples, the heterologous receptor can be a respective receptor of the heterologous cytokine (e.g., heterologous IL-15α or IL-15β for heterologous IL-15) . Alternatively, the expression cassette may not and need not encode any additional heterologous polypeptide other than the heterologous cytokine.
A cleavable linker as disclosed herein can comprise a self-cleaving peptide, such as a self-cleaving 2A peptide. Self-cleaving peptides can be found in members of the Picornaviridae virus family, including aphthoviruses such as foot-and-mouth disease virus (FMDV) , equine rhinitis A virus (ERAV) , Thosea asigna virus (TaV) and porcine tescho virus-1 (PTV-I) , and cardioviruses such as Theilovirus (e.g., Theiler's murine encephalomyelitis) and encephalomyocarditis viruses. Non-limiting examples of the self-cleaving 2A peptide can include “F2A” , “E2A” , “P2A” , “T2A” , and functional variants thereof.
In some cases, the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be bound to a cell surface the engineered immune cell (e.g., the engineered NK cell) . In some examples, the engineered immune cell can be genetically modified such that a heterologous polynucleotide sequence encoding the heterologous cytokine is coupled to a gene encoding an endogenous transmembrane protein of the engineered immune cell. In an example, the endogenous transmembrane protein can be a respective receptor of the heterologous cytokine (e.g., heterologous IL-15α or IL-15β for heterologous IL-15) . In some examples, an expression cassette encoding a heterologous fusion polypeptide comprising (i) the heterologous cytokine that is coupled to (ii) a heterologous receptor can be introduced to the engineered immune cell. Here, the heterologous cytokine may not and need not be cleavable from the heterologous receptor. Non-limiting examples of the heterologous receptor can include a respective receptor of the heterologous cytokine (e.g., heterologous IL-15α or IL-15β for heterologous IL-15) , or a different receptor such as a common gamma chain (γ
C) receptor or a modification thereof.
An expression cassette as disclosed herein can be integrated into the genome of the engineered cell (e.g., the engineered NK cell) via action of a gene editing moiety as disclosed herein. Alternatively, the expression cassette may not and need not be integrated into the genome of the engineered cell.
The engineered immune cell (e.g., the engineered NK cell) as disclosed herein can exhibit enhanced signaling of an endogenous signaling pathway that involves the heterologous cytokine (e.g., the heterologous IL, such as the heterologous IL-15) and/or the heterologous receptor (e.g., the heterologous IL receptor, such as the heterologous IL-15R) as disclosed herein. The enhanced signaling of the endogenous signaling pathway as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., JAK3, STAT3, STAT5, etc. for IL-15/IL-15R) or (ii) expression of a downstream gene (e.g., Mcl1, Cdk4/6, Mki67, Tnf, Gzmb, Gzmc, Ifng, etc. for IL-15/IL-15R) via Western blotting or polymerase chain reaction (PCR) techniques.
In some cases, enhanced signaling of the endogenous signaling pathway that is induced by the heterologous cytokine and/or the heterologous receptor (e.g., induced by the heterologous cytokine and/or heterologous receptor, such as IL-15/IL-15R as disclosed herein) in the engineered immune cell of the present disclosure can be characterized by an increase in phosphorylation of a downstream signaling protein by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell.
In some cases, enhanced signaling of the endogenous signaling pathway that is induced by the heterologous cytokine and/or the heterologous receptor (e.g., induced by the heterologous cytokine and/or heterologous receptor, such as IL-15/IL-15R as disclosed herein) in the engineered immune cell of the present disclosure can be characterized by an increased expression of a downstream gene by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell.
Enhanced CD16 signaling (e.g., constitutively activated signaling of CD16) of the engineered immune cell (e.g., engineered NK cell) as disclosed herein can be achieved by having non-cleavable CD16 variant in the subject cell. CD16 (e.g., CD16a) is a transmembrane protein expressed by immune cells (e.g., NK cells) , which binds monomeric IgG attached to target cells to activate the immune cells and facilitate antibody-dependent cell-mediated cytotoxicity (ADCC) . In a non-engineered immune cell, the binding between CD16 and the monomeric IgG can induce cleavage of the CD16 protein at a cleavage site near the transmembrane domain, to regulates the cell surface density of CD16 upon immune cell activation. Thus, the endogenous CD16 of the engineered immune cell can be modified to enhance its signaling. Alternatively, an enhanced signaling variant of CD16 can be artificially introduced to the engineered immune cell.
In some cases, the engineered immune cell’s endogenous gene encoding CD16 can be genetically modified in its ectodomain (e.g., F176V) via action of a gene editing moiety as disclosed herein, such that the modified CD16 exhibits higher binding affinity to its target (e.g., monomeric IgG) as compared to a natural CD16. In some cases, a heterologous gene encoding such modified CD16 can be introduced to the cell.
In some cases, the engineered immune cell’s endogenous gene encoding CD16 can be genetically modified via action of a gene editing moiety as disclosed herein, such that the modified CD16 is non-cleavable and can induce enhanced CD16 signaling. In some examples, the cleavage site (e.g., position 195-198) in the membrane-proximal region (position 189-212) of CD16 can be modified or eliminated (e.g., CD16 S197P variant as a non-cleavable CD16 variant) . In some cases, a heterologous gene encoding such modified CD16 can be introduced to the cell.
In some cases, a heterologous gene encoding a heterologous CD16 variant that (i) exhibits higher binding affinity to its target (e.g., monomeric IgG) and (ii) is non-cleavable can be introduced to the cell (i.e., hnCD16) . In some examples, the heterologous CD16 variant can be a modified CD16 comprising, for example, F176V and S197P, as disclosed herein. In some examples, the heterologous CD variant can be a fusion receptor protein comprising (i) at least a portion of CD16 with an inactivated cleavage site and (ii) an ectodomain of a different cell surface protein, such as a glycoprotein (e.g., CD64) , that exhibits enhanced binding to the target (e.g., monomeric IgG) as compared to an unmodified CD16.
A heterologous gene as disclosed herein can be integrated into the genome of the engineered cell (e.g., the engineered NK cell) via action of a gene editing moiety as disclosed herein. Alternatively, the heterologous gene may not and need not be integrated into the genome of the engineered cell.
The enhanced CD16 signaling of the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., SHP-1) via Western blotting or (ii) expression of a downstream gene (e.g., CD25, IFN-gamma, TNF, etc. ) via Western blotting or PCR techniques.
In some cases, the CD16 signaling of the engineered immune cell (e.g., the engineered NK cell comprising hnCD16) of the present disclosure can be greater than CD16 signaling of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold.
In some cases, enhanced CD16 signaling of the engineered immune cell (e.g., the engineered NK cell comprising hnCD16) of the present disclosure can be characterized by an increase in phosphorylation of a downstream signaling protein by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell.
In some cases, enhanced CD16 signaling of the engineered immune cell (e.g., the engineered NK cell comprising hnCD16) of the present disclosure can be characterized by an increased expression of a downstream gene by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell.
In some cases, the CD16 signaling of the engineered immune cell (e.g., the engineered NK cell comprising hnCD16) of the present disclosure can be more prolonged (e.g., a longer duration of time of activated CD16 signaling) than CD16 signaling of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold.
The engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise reduced activity of endogenous cytokine signaling (e.g., endogenous IL signaling, such as endogenous IL-17 signaling) . The engineered immune cell can be derived from an isolated stem cell (e.g., an isolated ESC) . Alternatively, the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
In some cases, the engineered NK cell can be treated with inhibitors (e.g., small molecule inhibitors) of the endogenous cytokine signaling. In some cases, the engineered NK cell can comprise reduced expression of endogenous IL (e.g., endogenous IL-17) or endogenous receptor thereof (e.g., via indel or transgene mutation, via transient or permanent suppression, etc. ) . In some cases, the engineered NK cell can comprise reduced expression of endogenous IL-17. In some cases, the engineered NK cell can comprise reduced expression of endogenous IL-17R. In some cases, the engineered NK cell can comprise reduced expression of endogenous IL-17 and endogenous IL-17R.
In some cases, the endogenous cytokine as disclosed herein can be an endogenous IL. An endogenous IL as disclosed herein can comprise at least 1, 2, 3, 4, 5, or more different types of endogenous ILs. An endogenous IL as disclosed herein can comprise at most 5, 4, 3, or 2 different type of endogenous ILs. Alternatively, the endogenous IL can be a single type of endogenous IL. Non-limiting examples of the endogenous IL can include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36. In some examples, the endogenous IL can be IL-17. Non-limiting examples of endogenous Il-17 can include IL-17A, IL-17F, and natural mutations thereof. For example, the engineered immune cell (e.g., an engineered NK cell) as disclosed herein can exhibit reduced expression or activity of IL-17A or IL-17F.
In some cases, an endogenous gene encoding the endogenous cytokine (e.g., an endogenous IL, such as IL-17) as disclosed herein can be modified via action of a gene editing moiety as disclosed herein.
The endogenous receptor can be a respective receptor of any cytokine as disclosed herein (e.g., a respective receptor of any IL as disclosed herein) . In some cases, the endogenous receptor can be a respective receptor of IL (e.g., IL-17R for IL-7 signaling) . Non-limiting examples of IL-17R can include IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE, and variants thereof. In an example, the endogenous IL-17R comprises IL-17RA.
In some cases, the reduced expression or activity of the endogenous cytokine (e.g., an endogenous IL, such as IL-17) or endogenous receptor thereof as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., PI3K, Act1, MAP3K, MEK1/2, MKK3/6, MKK4/7, MKK3/6, ERK, p38, JNK, etc. for IL-17) or (ii) expression of a downstream gene via Western blotting or PCT techniques. In some examples, a downstream gene of IL cytokine, such as IL-17, can include a chemokine (e.g., CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, CCL2, CCL20, etc. ) , a cytokine (e.g., IL-6, TNFa, G-CSF, GM-CSF, etc. ) , an acute phase response molecule (e.g., SAA, CRP, lipocalin 2/24p3, etc. ) , and/or an enzyme (e.g., a metalloproteinase, such as MMP1, MMP3, MMP9, MMP13) .
In some cases, reduced expression or activity of the endogenous cytokine (e.g., the endogenous IL, such as IL-17) or endogenous receptor thereof in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can be characterized by a decrease in phosphorylation of a downstream signaling protein of the endogenous cytokine by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell.
In some cases, reduced expression or activity of the endogenous cytokine (e.g., the endogenous IL, such as IL-17) or endogenous receptor thereof in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can be characterized by a decrease in the expression of a downstream gene of the endogenous cytokine by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell.
In some cases, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can exhibit enhanced expression profile of a specific cell marker for a committed immune cell (e.g., a NK cell marker) as compared to a control cell that does not exhibit the reduced activity of the endogenous cytokine signaling (e.g., endogenous IL signaling, such as endogenous IL-17 signaling) as disclosed herein. For example, non-limiting examples of a specific cell marker for committed NK cells can include CD57 or killer immunoglobulin-like receptors (KIR) . KIR can comprise KIR2D and/or KIR3D. KIR2D can comprise KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, and/or KIR2DS5. KIR3D can comprise KIR3DL1, KIR3DL2, KIR3DL3, and/or KIR3DS1.
The enhanced expression profile of the specific cell marker for the committed immune cell (e.g., CD57 or KIR for NK cells) as disclosed herein can be ascertained by a number of methods, including, but are not limited to, Western blotting or PCR techniques.
In some cases, the expression of the specific cell marker for a committed immune cell (e.g., CD57 or KIR or NK cells) in the engineered immune cell of the present disclosure can be greater than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) comprising one or more members (e.g., two or more members) selected from the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can exhibit enhanced survival in the presence of tumor cells as compared to a control cell lacking at least one of the one or more members. In some case, the engineered immune cell can, in the presence of tumor cells, survive longer than the control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can exhibit reduced expression or activity of one or more immune checkpoint inhibitors (e.g., PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, 2B4, etc. ) . The one or more immune checkpoint inhibitors can be endogenous to the engineered immune cell. In an example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous PD1. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous CTLA-4. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous TIM-3. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous KIR2D. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous CD94. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous NKG2A. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous TIGIT. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous TGF beta receptor. In another example, the engineered immune cell (e.g., the engineered NK cell) can exhibit reduced expression and/or activity of endogenous 2B4.
In some cases, the reduced expression or activity of the immune checkpoint inhibitor (e.g., CD94, CD96, TGF beta receptor, etc. ) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can exhibit reduced expression or activity of one or more hypo-immunity regulators (e.g., one or more endogenous immune regulator polypeptides) , as disclosed herein. The one or more hypo-immunity regulators can be selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can exhibit reduced expression or activity of one or more endogenous polypeptides (e.g., endogenous immune regulating polypeptide) . The one or more endogenous polypeptides can comprise one or more members of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN2, PTPN6, and/or CD70. Alternatively or in addition to, the one or more endogenous polypeptides can comprise one or more members of NLRC5, RFXANK, RFXAP, CD80, CD7, TAP2, TAP1, TAPBP. For example, the reduced expression or activity of such one or more endogenous polypeptides in the engineered NK cell can enhance one or more characteristics of the engineered NK cell (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, etc. ) . For example, the reduced expression or activity of such one or more endogenous polypeptides in the engineered NK cell can enhance persistence of the engineered cell in a sub-optimal environment. In another example, the reduced expression or activity of such one or more endogenous polypeptides in the engineered NK cell can enhance resistance against immune rejection (e.g., ADCC cytotoxicity of the engineered NK cell) .
In some cases, the expression or activity of the hypo-immunity regulator (e.g., the endogenous hypo-immunity regulator) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than the same in a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as ascertained by Western blotting or PCT techniques, as disclosed herein.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can exhibit reduced expression or activity of endogenous CD38 as compared to a control cell. Such engineered immune cell may be used to treat a subject who has or is suspected of having white blood cell cancer, such as multiple myeloma (MM) .
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, expression or activity of endogenous CD38 of the engineered immune cell may not and need not be modified. Such engineered immune cell may be used to treat a subject who has or is suspected of having a disease (e.g., cancer, tumor) that is not multiple myeloma.
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) can comprise the chimeric polypeptide receptor (or at least one chimeric polypeptide receptor) comprising an antigen binding moiety capable of binding to an antigen, as provided in the present disclosure. In some examples, the engineered immune cell can comprise a plurality of different chimeric polypeptide receptors to specifically bind a plurality of different antigens. In some examples, the engineered immune cell can comprise at least one chimeric polypeptide receptor that comprises a plurality of antigen binding moieties to specifically bind a plurality of different antigens.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can comprise a safety switch capable of effecting death of the engineered immune cell. The engineered immune cell can comprise a gene encoding the safety switch (e.g., integrated into the genome of the immune cell) , via action of the gene editing moiety, as disclosed herein. In some cases, a prodrug can be introduced to the engineered immune cell (e.g., administered to a subject comprising the engineered immune cell) in the event of an adverse event or when the adaptive immunotherapy is no longer necessary, and the prodrug can be activated by the safety switch molecule to kill the subject immune cell. In some cases, the safety switch can comprise one or more members selected from the group consisting of caspase (e.g., caspase 3, 7, or 9) , thymidine kinase, cytosine deaminase, modified EGFR, B-cell CD20, and functional variants thereof. In some cases, the safety switch can be activated via an activator (e.g., a small molecule or a protein, such as an antibody) for post-translational, temporal, and/or site-specific regulation of death (or depletion) of the subject engineered immune cell. Non-limiting examples of a safety switch and its activator can include Caspase 9 (or caspase 3 or 7) and AP1903; thymidine kinase (TK) and ganciclovir (GCV) ; and cytosine deaminase (CD) and 5-fluorocytosine (5-FC) . Alternatively or in addition to, modified epidermal growth factor receptor (EGFR) containing epitope recognized by an antibody (e.g., anti-EGFR Ab, such as cetuximab) can be used to deplete the engineered immune cells when the subject cells are exposed to the antibody. In some cases, the engineered immune cells (e.g., the engineered NK cells) as disclosed herein can comprise a safety switch protein selected from the group consisting of caspase 9 (caspase 3 or 7) , thymidine kinase, cytosine deaminase, modified EGFR, and B-cell CD20.3
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can exhibit enhanced persistence or survival (e.g., in an environment substantially free of exogenous cytokine, such as IL-2 or IL-5; or in an environment with sub-optimal dose of such exogenous cytokine; in vitro environment; in vivo environment, etc. ) as compared to a control cell. In some cases, the engineered immune cell as disclosed herein can exhibit enhanced persistence or survival (e.g., in vitro, ex vivo, or in vivo) that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as ascertained by, e.g., tracking a change in the number of the engineered immune cells (e.g., the engineered NK cells) over time.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can exhibit enhanced proliferation or growth rate (e.g., in an environment substantially free of exogenous cytokine, such as IL-2 or IL-5; or in an environment with sub-optimal dose of such exogenous cytokine; in vitro environment; in vivo environment, etc. ) as compared to a control cell. In some cases, the engineered immune cell as disclosed herein can exhibit enhanced proliferation or growth rate (e.g., in vitro, ex vivo, or in vivo) that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as ascertained by, e.g., tracking a change in the number of the engineered immune cells (e.g., the engineered NK cells) over time.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can exhibit enhanced cytotoxicity against a target cell as compared to a control cell. In some cases, the engineered immune cell as disclosed herein can exhibit cytotoxicity (e.g., in vitro, ex vivo, or in vivo) against a target cell or a target population of cells that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as ascertained by, e.g., tracking a change in the number of the target population of cells.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can induce reduced immune response from separate immune cells (e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host) as compared to a control cell. In some cases, the engineered immune cell as disclosed herein can reduce the immune response from the separate immune cells by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to an immune response from the separate immune cells when exposed to a control cell, as ascertained by, e.g., measuring (i) a change in the number of the initial population of the engineered immune cells upon exposure to the separate immune cells or (ii) a change in cytokine release of the separate immune cells upon exposure to the initial population of the engineered immune cells.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can exhibit enhanced half-life upon exposure to separate immune cells (e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host) as compared to a control cell. In some cases, upon exposure to the separate immune cells (e.g., in vitro or in vivo) , the half-life of the engineered immune cells can be greater than that of the control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as ascertained by monitoring the number of the engineered immune cells over time (e.g., via FACS) .
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can effect enhanced function or pathological condition of a bodily tissue of a subject as compared to a control cell. In some cases, treatment with the engineered immune cell can effect enhanced function or pathological condition of a bodily tissue of a subject by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell or vehicle (i.e., no cells) .
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can effect delayed degeneration of function or pathological condition of a bodily tissue of a subject as compared to a control cell. In some cases, treatment with the engineered immune cell can effect delayed degeneration of function or pathological condition of a bodily tissue of a subject by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about 60-fold, at least or up to about 70-fold, at least or up to about 80-fold, at least or up to about 90-fold, at least or up to about 100-fold, at least or up to about 500-fold, at least or up to about 1,000-fold, at least or up to about 5,000-fold, or at least or up to about 10,000-fold, as compared to a control cell or vehicle (i.e., no cells) .
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the bodily tissue can comprise one or more members selected from the group consisting of blood, plasma, serum, urine, perilymph fluid, feces, saliva, semen, amniotic fluid, cerebrospinal fluid, bile, sweat, tears, sputum, synovial fluid, vomit, bone, heart, thymus, artery, blood vessel, lung, muscle, stomach, intestine, liver, pancreas, spleen, kidney, gall bladder, thyroid gland, adrenal gland, mammary gland, ovary, prostate gland, testicle, skin, adipose, eye, brain, infected tissue, diseased tissue, malignant tissue, calcified tissue, and healthy tissue.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, the engineered immune cell can induce immune response towards a target cell. The target can be, for example, a diseased cell, a cancer cell, a tumor cell, etc.
C. Additional aspects of the engineered immune cells
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein, a heterologous gene can be operatively coupled to (e.g., for knock-in) a constitutive, inducible, temporal, tissue-specific, and/or cell type-specific promoter. Non-limiting examples of a promoter of interest can include CMV, EF1a, PGK, CAG, and UBC. Non-limiting examples of an insertion site can include AAVS1, CCR5, ROSA26, collagen, HTRP, H11, B2M, GAPDH, TCR, RUNX1, TAP1, TAP2, tapasin, NLRC5, CIITA, RFXANK, CIITA, RFX5, RFXAP, TCR a or b constant region, NKG2A, NKG2D, CD38, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein can exhibit reduced expression or activity of one or more of the following endogenous genes for enhancing function of the engineered immune cell in a tumor microenvironment (i.e., tumor microenvironment gene or “TME” ) . In some cases, having reduced expression or activity of a TME can enhance the engineered immune cell’s immune activity against a target cell. In some cases, a TME gene may be an immune checkpoint inhibitor. Non-limiting examples of the TME can include: NKG2A, NKG2D, PD1, CTLA4, LAG3, TIM3, TIGIT, KIR2D, CD94, CD96, TGF beta receptor, 2B4, and SHIP2.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein can exhibit one or more heterologous genes (e.g., knocked-in) for, e.g., enhanced function: CD137, CD80, CD86, DAP10 (e.g., with or without point mutation) .
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein can exhibit reduced expression or activity of one or more of the following endogenous genes for, e.g., hypo-immunity: B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, and a NKG2DL (e.g., ULBP1) .
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein can exhibit one or more heterologous genes (e.g., knocked-in) for, e.g., hypo-immunity: HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
In some embodiments of any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein can exhibit one or more heterologous genes (e.g., knocked-in) : CD3, CD4, CD80, 41BBL, and CD131.
D. Chimeric antigen receptor
The engineered immune cell (e.g., the engineered NK cell) of the present disclosure can comprise a chimeric polypeptide receptor as disclosed herein (e.g., at least 1, 2, 3, 4, 5, or more different types of chimeric polypeptide receptors) . The engineered immune cell can be engineered to express a chimeric polypeptide receptor transiently or permanently. In some cases, a recombinant chimeric polypeptide receptor can be delivered to the engineered immune cell via, e.g., a liposome, and be incorporated into the engineered immune cell via membrane fusion. In some cases, a heterologous polynucleotide construct (e.g., DNA or RNA) encoding the chimeric polypeptide receptor can be delivered to the engineered immune cell. The heterologous polynucleotide construct (i.e., a gene) encoding the heterologous polynucleotide construct can be incorporated into the chromosome of the engineered immune cell (i.e., chromosomal gene) or, alternatively, may not or need not be integrated into the chromosome of the engineered immune cell as disclosed herein.
A chimeric polypeptide receptor can comprises a T cell receptor fusion protein (TFP) . The term “T cell receptor fusion protein” or “TFP” generally refers to a recombinant polypeptide construct comprising (i) one or more antigen binding moieties (e.g., monospecific or multispecific) , (ii) at least a portion of TCR extracellular domain, (iii) at least a portion of TCR transmembrane domain, and (iv) at least a portion of TCR intracellular domain.
In some cases, an endogenous T cell receptor (TCR) of the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be inactivated. In some examples, a function of the endogenous TCR of the engineered immune cell can be inhibited by an inhibitor. In some examples, a gene encoding a subunit of the endogenous TCR can be inactivated (e.g., edited via action of the gene editing moiety as disclosed herein) such that the endogenous TCR is inactivated. The gene encoding the subunit of endogenous TCR can be one or more of: TCRα, TCRβ, CD3ε, CD3δ, CD3γ, and CD3ζ.
A chimeric polypeptide receptor can comprises a chimeric antigen receptor (CAR) . The term “chimeric antigen receptor” or “CAR” generally refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as “an intracellular or intrinsic signaling domain” ) comprising a functional signaling domain derived from a stimulatory molecule. In some cases, the stimulatory molecule may be the zeta chain associated with the T cell receptor complex. In some cases, the intracellular signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule. In some cases, the costimulatory molecule may comprise 4-1BB (i.e., CD137) , CD27, and/or CD28. In one aspect, the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein. In one aspect, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen recognition domain, wherein the leader sequence is optionally cleaved from the antigen recognition domain (e.g., a scFv) during cellular processing and localization of the CAR to the cellular membrane.
A CAR may be a first-, second-, third-, or fourth-generation CAR system, a functional variant thereof, or any combination thereof. First-generation CARs (e.g., CD19R or CD19CAR) include an antigen binding domain with specificity for a particular antigen (e.g., an antibody or antigen-binding fragment thereof such as an scFv, a Fab fragment, a VHH domain, or a VH domain of a heavy-chain only antibody) , a transmembrane domain derived from an adaptive immune receptor (e.g., the transmembrane domain from the CD28 receptor) , and a signaling domain derived from an adaptive immune receptor (e.g., one or more (e.g., three) ITAM domains derived from the intracellular region of the CD3 ζ receptor or FcεRIγ) . Second-generation CARs modify the first-generation CAR by addition of a co-stimulatory domain to the intracellular signaling domain portion of the CAR (e.g., derived from co-stimulatory receptors that act alongside T-cell receptors such as CD28, CD137/4-1BB, and CD134/OX40) , which abrogates the need for administration of a co-factor (e.g., IL-2) alongside a first-generation CAR. Third-generation CARs add multiple co-stimulatory domains to the intracellular signaling domain portion of the CAR (e.g., CD3ζ-CD28-OX40, or CD3ζ-CD28-41BB) . Fourth-generation CARs modify second-or third-generation CARs by the addition of an activating cytokine (e.g., IL-12, IL-23, or IL-27) to the intracellular signaling portion of the CAR (e.g., between one or more of the costimulatory domains and the CD3ζ ITAM domain) or under the control of a CAR-induced promoter (e.g., the NFAT/IL-2 minimal promoter) . In some cases, a CAR may be a new generation CAR system that is different than the first-, second-, third-, or fourth-generation CAR system as disclosed herein.
A hinge domain (e.g., the linker between the extracellular antigen binding domain and the transmembrane domain) of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3c CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, NKp30, NKp44, NKp46, NKG2C, NKG2D, or T cell receptor polypeptide.
A transmembrane domain of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3c CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, NKp30, NKp44, NKp46, NKG2C, NKG2D, or T cell receptor polypeptide.
The hinge domain and the transmembrane domain of a CAR as disclosed herein (e.g., for the engineered immune cell, such as the engineered NK cell) can be derived from the same protein (e.g., CD8) . Alternatively, the hinge domain and the transmembrane domain of the CAR as disclosed herein can be derived from different proteins.
A signaling domain of a CAR can comprise at least or up to about 1 signaling domain, at least or up to about 2 signaling domains, at least or up to about 3 signaling domains, at least or up to about 4 signaling domains, at least or up to about 5 signaling domains, at least or up to about 6 signaling domains, at least or up to about 7 signaling domains, at least or up to about 8 signaling domains, at least or up to about 9 signaling domains, or at least or up to about 10 signaling domains.
A signaling domain (e.g., a signaling peptide of the intracellular signaling domain) of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of a polypeptide of CD3ζ, 2B4, DAP10, DAP12, DNAM1, CD137 (41BB) , IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, NKG2D, or any combination thereof.
Alternatively or in addition to (i.e., a co-stimulatory domain) , the signaling domain CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of a polypeptide of CD27, CD28, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D, or any combination thereof.
In some cases, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein comprises the chimeric polypeptide receptor (e.g., CAR) that comprises at least CD8 transmembrane domain and one or more of: (i) 2B4 signaling domain and (ii) DAP10 signaling domain. In some cases, the engineered cell (e.g., the engineered NK cell) as disclosed herein comprises the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises at least (i) CD8 transmembrane domain, (ii) 2B4 signaling domain, and (iii) DAP10 signaling domain. The 2B4 signaling domain can be flanked by the CD8 transmembrane domain and the DAP10 signaling domain. Alternatively, the DAP10 signaling domain can be flanked by the CD8 transmembrane domain and the 2B4 signaling domain. In some cases, the chimeric polypeptide receptor as disclosed herein can further comprise yet an additional signaling domain derived from CD3ζ.
An antigen (i.e., a target antigen) of an antigen binding moiety of a chimeric polypeptide receptor (e.g., TFP or CAR) as disclosed herein can be a cell surface marker, a secreted marker, or an intracellular marker.
Non-limiting examples of an antigen (i.e., a target antigen) of an antigen binding moiety of a chimeric polypeptide receptor (e.g., TFP or CAR) as disclosed herein can include ADGRE2, carbonic anhydrase IX (CA1X) , CCRI, CCR4, carcinoembryonic antigen (CEA) , CD3ζ, CD5, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD133, CD138, CD269 (BCMA) , CD S, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen) , epithelial glycoprotein2 (EGP 2) , epithelial glycoprotein-40 (EGP-40) , epithelial cell adhesion molecule (EpCAM) , EGFRvIII, receptor tyrosine-protein kinases erb-B2, 3, 4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP) , fetal acetylcholine receptor (AChR) , folate receptor-a, Ganglioside G2 (GD2) , Ganglioside G3 (GD3) , gp100, human Epidermal Growth Factor Receptor 2 (HER-2) , human telomerase reverse transcriptase (hTERT) , ICAM-1, Integrin B7, Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) , κ-light chain, kinase insert domain receptor (KDR) , Kappa, Lewis A (CA19.9) , Lewis Y (LeY) , L1 cell adhesion molecule (L1-CAM) , LILRB2, MART-1, melanoma antigen family A 1 (MAGE-A1) , MICA/B, Mucin 1 (Muc-1) , Mucin 16 (Muc-16) , Mesothelin (MSLN) , NKCSI, NKG2D ligand, c-Met, cancer-testis antigen NY-ESO-1, NY-ESO-2, oncofetal antigen (h5T4) , PRAIVIE, prostate stem cell antigen (PSCA) , PRAME prostate-specific membrane antigen (PSMA) , ROR1, tumor-associated glycoprotein 72 (TAG-72) , TIM-3, TRBCI, TRBC2, vascular endothelial growth factor R2 (VEGF-R2) , Wilms tumor protein (WT-1) , and various pathogen antigen (e.g., pathogen antigens derived from a virus, bacteria, fungi, parasite and protozoa capable of causing diseases) . In some examples, a pathogen antigen is derived from HIV, HBV, EBV, HPV, Lasse Virus, Influenza Virus, or Coronavirus.
Additional examples of the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include 1-40-β-amyloid, 4-1BB, 5AC, 5T4, activin receptor-like kinase 1, ACVR2B, adenocarcinoma antigen, AGS-22M6, alpha-fetoprotein, angiopoietin 2, angiopoietin 3, anthrax toxin, AOC3 (VAP-1) , B7-H3, Bacillus anthracis anthrax, BAFF, beta-amyloid, B-lymphoma cell, C242 antigen, C5, CA-125, Canis lupus familiaris IL31, carbonic anhydrase 9 (CA-IX) , cardiac myosin, CCL11 (eotaxin-1) , CCR4, CCR5, CD11, CD18, CD125, CD140a, CD147 (basigin) , CD15, CD152, CD154 (CD40L) , CD19, CD2, CD20, CD200, CD22, CD221, CD25 (α chain of IL-2receptor) , CD27, CD274, CD28, CD3, CD3 epsilon, CD30, CD33, CD37, CD38, CD4, CD40, CD40 ligand, CD41, CD44 v6, CD5, CD51, CD52, CD56, CD6, CD70, CD74, CD79B, CD80, CEA, CEA-related antigen, CFD, ch4D5, CLDN18.2, Clostridium difficile, clumping factor A, CSF1R, CSF2, CTLA-4, C-X-C chemokine receptor type 4, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL4, DPP4, DR5, E. coli shiga toxin type-1, E. coli shiga toxin type-2, EGFL7, EGFR, endotoxin, EpCAM, episialin, ERBB3, Escherichia coli, F protein of respiratory syncytial virus, FAP, fibrin II beta chain, fibronectin extra domain-B, folate hydrolase, folate receptor 1, folate receptor alpha, Frizzled receptor, ganglioside GD2, GD2, GD3 ganglioside, glypican 3, GMCSF receptor α-chain, GPNMB, growth differentiation factor 8, GUCY2C, hemagglutinin, hepatitis B surface antigen, hepatitis B virus, HER1, HER2/neu, HER3, HGF, HHGFR, histone complex, HIV-1, HLA-DR, HNGF, Hsp90, human scatter factor receptor kinase, human TNF, human beta-amyloid, ICAM-1 (CD54) , IFN-α, IFN-γ, IgE, IgE Fc region, IGF-1 receptor, IGF-1, IGHE, IL17A, IL17F, IL20, IL-12, IL-13, IL-17, IL-1β, IL-22, IL-23, IL-31RA, IL-4, IL-5, IL-6, IL-6 receptor, IL-9, ILGF2, influenza A hemagglutinin, influenza A virus hemagglutinin, insulin-like growth factor I receptor, integrin α4β7, integrin α4, integrin α5β1, integrin α7 β7, integrin αIIbβ3, integrin αvβ3, interferon α/β receptor, interferon gamma-induced protein, ITGA2, ITGB2 (CD18) , KIR2D, Lewis-Y antigen, LFA-1 (CD11a) , LINGO-1, lipoteichoic acid, LOXL2, L-selectin (CD62L) , LTA, MCP-1, mesothelin, MIF, MS4A1, MSLN, MUC1, mucin CanAg, myelin-associated glycoprotein, myostatin, NCA-90 (granulocyte antigen) , neural apoptosis-regulated proteinase 1, NGF, N-glycolylneuraminic acid, NOGO-A, Notch receptor, NRP1, Oryctolagus cuniculus, OX-40, oxLDL, PCSK9, PD-1, PDCD1, PDGF-R α, phosphate-sodium co-transporter, phosphatidylserine, platelet-derived growth factor receptor beta, prostatic carcinoma cells, Pseudomonas aeruginosa, rabies virus glycoprotein, RANKL, respiratory syncytial virus, RHD, Rhesus factor, RON, RTN4, sclerostin, SDC1, selectin P, SLAMF7, SOST, sphingosine-1-phosphate, Staphylococcus aureus, STEAP1, TAG-72, T-cell receptor, TEM1, tenascin C, TFPI, TGF-β 1, TGF-β 2, TGF-β, TNF-α, TRAIL-R1, TRAIL-R2, TRAIL-R4 (DCR2) , tumor antigen CTAA16.88, tumor specific glycosylation of MUC1, tumor-associated calcium signal transducer 2, TWEAK receptor, TYRP1 (glycoprotein 75) , VEGFA, VEGFR1, VEGFR2, vimentin, and VWF.
Additional examples of the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include 707-AP, a biotinylated molecule, a-Actinin-4, abl-bcr alb-b3 (b2a2) , abl-bcr alb-b4 (b3a2) , adipophilin, AFP, AIM-2, Annexin II, ART-4, BAGE, b-Catenin, bcr-abl, bcr-abl p190 (e1a2) , bcr-abl p210 (b2a2) , bcr-abl p210 (b3a2) , BING-4, CAG-3, CAIX, CAMEL, Caspase-8, CD171, CD19, CD20, CD22, CD24, CD30, CD33, CD38, CD44v7/8, CDC27, CDK-4, CEA, CLCA2, Cyp-B, DAM-10, DAM-6, DEK-CAN, EGFRvIII, EGP-2, EGP-40, ELF2, Ep-CAM, EphA2, EphA3, erb-B2, erb-B3, erb-B4, ES-ESO-1a, ETV6/AML, FBP, fetal acetylcholine receptor, FGF-5, FN, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, GD2, GD3, GnT-V, Gp100, gp75, Her-2, HLA-A*0201-R170I, HMW-MAA, HSP70-2 M, HST-2 (FGF6) , HST-2/neu, hTERT, iCE, IL-11Rα, IL-13Rα2, KDR, KIAA0205, K-RAS, L1-cell adhesion molecule, LAGE-1, LDLR/FUT, Lewis Y, MAGE-1, MAGE-10, MAGE-12, MAGE-2, MAGE-3, MAGE-4, MAGE-6, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A6, MAGE-B1, MAGE-B2, Malic enzyme, Mammaglobin-A, MART-1/Melan-A, MART-2, MC1R, M-CSF, mesothelin, MUC1, MUC16, MUC2, MUM-1, MUM-2, MUM-3, Myosin, NA88-A, Neo-PAP, NKG2D, NPM/ALK, N-RAS, NY-ESO-1, OA1, OGT, oncofetal antigen (h5T4) , OS-9, P polypeptide, P15, P53, PRAME, PSA, PSCA, PSMA, PTPRK, RAGE, ROR1, RU1, RU2, SART-1, SART-2, SART-3, SOX10, SSX-2, Survivin, Survivin-2B, SYT/SSX, TAG-72, TEL/AML1, TGFaRII, TGFbRII, TP1, TRAG-3, TRG, TRP-1, TRP-2, TRP-2/INT2, TRP-2-6b, Tyrosinase, VEGF-R2, WT1, α-folate receptor, and κ-light chain.
Additional examples of the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include an antibody, a fragment thereof, or a variant thereof. Such antibody can be a natural antibody (e.g., naturally secreted by a subject’s immune cell, such as B cells) , a synthetic antibody, or a modified antibody. In some cases, the antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include an Fc domain of an antibody from the group comprising 20- (74) - (74) (milatuzumab; veltuzumab) , 20-2b-2b, 3F8, 74- (20) - (20) (milatuzumab; veltuzumab) , 8H9, A33, AB-16B5, abagovomab, abciximab, abituzumab, zlintuzumab) , actoxumab, adalimumab, ADC-1013, ADCT-301, ADCT-402, adecatumumab, aducanumab, afelimomab, AFM13, afutuzumab, AGEN1884, AGS15E, AGS-16C3F, AGS67E, alacizumab pegol, ALD518, alemtuzumab, alirocumab, altumomab pentetate, amatuximab, AMG 228, AMG 820, anatumomab mafenatox, anetumab ravtansine, anifrolumab, anrukinzumab, APN301, APN311, apolizumab, APX003/SIM-BD0801 (sevacizumab) , APX005M, arcitumomab, ARX788, ascrinvacumab, aselizumab, ASG-15ME, atezolizumab, atinumab, ATL101, atlizumab (also referred to as tocilizumab) , atorolimumab, Avelumab, B-701, bapineuzumab, basiliximab, bavituximab, BAY1129980, BAY1187982, bectumomab, begelomab, belimumab, benralizumab, bertilimumab, besilesomab, Betalutin (177Lu-tetraxetan-tetulomab) , bevacizumab, BEVZ92 (bevacizumab biosimilar) , bezlotoxumab, BGB-A317, BHQ880, BI 836880, BI-505, biciromab, bimagrumab, bimekizumab, bivatuzumab mertansine, BIW-8962, blinatumomab, blosozumab, BMS-936559, BMS-986012, BMS-986016, BMS-986148, BMS-986178, BNC101, bococizumab, brentuximab vedotin, BrevaRex, briakinumab, brodalumab, brolucizumab, brontictuzumab, C2-2b-2b, canakinumab, cantuzumab mertansine, cantuzumab ravtansine, caplacizumab, capromab pendetide, carlumab, catumaxomab, CBR96-doxorubicin immunoconjugate, CBT124 (bevacizumab) , CC-90002, CDX-014, CDX-1401, cedelizumab, certolizumab pegol, cetuximab, CGEN-15001T, CGEN-15022, CGEN-15029, CGEN-15049, CGEN-15052, CGEN-15092, Ch.14.18, citatuzumab bogatox, cixutumumab, clazakizumab, clenoliximab, clivatuzumab tetraxetan, CM-24, codrituzumab, coltuximab ravtansine, conatumumab, concizumab, Cotara (iodine I-131 derlotuximab biotin) , cR6261, crenezumab, DA-3111 (trastuzumab biosimilar) , dacetuzumab, daclizumab, dalotuzumab, dapirolizumab pegol, daratumumab, Daratumumab Enhanze (daratumumab) , Darleukin, dectrekumab, demcizumab, denintuzumab mafodotin, denosumab, Depatuxizumab, Depatuxizumab mafodotin, derlotuximab biotin, detumomab, DI-B4, dinutuximab, diridavumab, DKN-01, DMOT4039A, dorlimomab aritox, drozitumab, DS-1123, DS-8895, duligotumab, dupilumab, durvalumab, dusigitumab, ecromeximab, eculizumab, edobacomab, edrecolomab, efalizumab, efungumab, eldelumab, elgemtumab, elotuzumab, elsilimomab, emactuzumab, emibetuzumab, enavatuzumab, enfortumab vedotin, enlimomab pegol, enoblituzumab, enokizumab, enoticumab, ensituximab, epitumomab cituxetan, epratuzumab, erlizumab, ertumaxomab, etaracizumab, etrolizumab, evinacumab, evolocumab, exbivirumab, fanolesomab, faralimomab, farletuzumab, fasinumab, FBTA05, felvizumab, fezakinumab, FF-21101, FGFR2 Antibody-Drug Conjugate, Fibromun, ficlatuzumab, figitumumab, firivumab, flanvotumab, fletikumab, fontolizumab, foralumab, foravirumab, FPA144, fresolimumab, FS102, fulranumab, futuximab, galiximab, ganitumab, gantenerumab, gavilimomab, gemtuzumab ozogamicin, Gerilimzumab, gevokizumab, girentuximab, glembatumumab vedotin, GNR-006, GNR-011, golimumab, gomiliximab, GSK2849330, GSK2857916, GSK3174998, GSK3359609, guselkumab, Hu14.18K322A MAb, hu3S193, Hu8F4, HuL2G7, HuMab-5B1, ibalizumab, ibritumomab tiuxetan, icrucumab, idarucizumab, IGN002, IGN523, igovomab, IMAB362, IMAB362 (claudiximab) , imalumab, IMC-CS4, IMC-D11, imciromab, imgatuzumab, IMGN529, IMMU-102 (yttrium Y-90 epratuzumab tetraxetan) , IMMU-114, ImmuTune IMP701 Antagonist Antibody, INCAGN1876, inclacumab, INCSHR1210, indatuximab ravtansine, indusatumab vedotin, infliximab, inolimomab, inotuzumab ozogamicin, intetumumab, Ipafricept, IPH4102, ipilimumab, iratumumab, isatuximab, Istiratumab, itolizumab, ixekizumab, JNJ-56022473, JNJ-61610588, keliximab, KTN3379, L19IL2/L19TNF, Labetuzumab, Labetuzumab Govitecan, LAG525, lambrolizumab, lampalizumab, L-DOS47, lebrikizumab, lemalesomab, lenzilumab, lerdelimumab, Leukotuximab, lexatumumab, libivirumab, lifastuzumab vedotin, ligelizumab, lilotomab satetraxetan, lintuzumab, lirilumab, LKZ145, lodelcizumab, lokivetmab, lorvotuzumab mertansine, lucatumumab, lulizumab pegol, lumiliximab, lumretuzumab, LY3164530, mapatumumab, margetuximab, maslimomab, matuzumab, mavrilimumab, MB311, MCS-110, MEDI0562, MEDI-0639, MEDI0680, MEDI-3617, MEDI-551 (inebilizumab) , MEDI-565, MEDI6469, mepolizumab, metelimumab, MGB453, MGD006/S80880, MGD007, MGD009, MGD011, milatuzumab, Milatuzumab-SN-38, minretumomab, mirvetuximab soravtansine, mitumomab, MK-4166, MM-111, MM-151, MM-302, mogamulizumab, MOR202, MOR208, MORAb-066, morolimumab, motavizumab, moxetumomab pasudotox, muromonab-CD3, nacolomab tafenatox, namilumab, naptumomab estafenatox, narnatumab, natalizumab, nebacumab, necitumumab, nemolizumab, nerelimomab, nesvacumab, nimotuzumab, nivolumab, nofetumomab merpentan, NOV-10, obiltoxaximab, obinutuzumab, ocaratuzumab, ocrelizumab, odulimomab, ofatumumab, olaratumab, olokizumab, omalizumab, OMP-131R10, OMP-305B83, onartuzumab, ontuxizumab, opicinumab, oportuzumab monatox, oregovomab, orticumab, otelixizumab, otlertuzumab, OX002/MEN1309, oxelumab, ozanezumab, ozoralizumab, pagibaximab, palivizumab, panitumumab, pankomab, PankoMab-GEX, panobacumab, parsatuzumab, pascolizumab, pasotuxizumab, pateclizumab, patritumab, PAT-SC1, PAT-SM6, pembrolizumab, pemtumomab, perakizumab, pertuzumab, pexelizumab, PF-05082566 (utomilumab) , PF-06647263, PF-06671008, PF-06801591, pidilizumab, pinatuzumab vedotin, pintumomab, placulumab, polatuzumab vedotin, ponezumab, priliximab, pritoxaximab, pritumumab, PRO 140, Proxinium, PSMA ADC, quilizumab, racotumomab, radretumab, rafivirumab, ralpancizumab, ramucirumab, ranibizumab, raxibacumab, refanezumab, regavirumab, REGN1400, REGN2810/SAR439684, reslizumab, RFM-203, RG7356, RG7386, RG7802, RG7813, RG7841, RG7876, RG7888, RG7986, rilotumumab, rinucumab, rituximab, RM-1929, RO7009789, robatumumab, roledumab, romosozumab, rontalizumab, rovelizumab, ruplizumab, sacituzumab govitecan, samalizumab, SAR408701, SAR566658, sarilumab, SAT 012, satumomab pendetide, SCT200, SCT400, SEA-CD40, secukinumab, seribantumab, setoxaximab, sevirumab, SGN-CD19A, SGN-CD19B, SGN-CD33A, SGN-CD70A, SGN-LIV1A, sibrotuzumab, sifalimumab, siltuximab, simtuzumab, siplizumab, sirukumab, sofituzumab vedotin, solanezumab, solitomab, sonepcizumab, sontuzumab, stamulumab, sulesomab, suvizumab, SYD985, SYM004 (futuximab and modotuximab) , Sym015, TAB08, tabalumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tanezumab, Tanibirumab, taplitumomab paptox, tarextumab, TB-403, tefibazumab, Teleukin, telimomab aritox, tenatumomab, teneliximab, teplizumab, teprotumumab, tesidolumab, tetulomab, TG-1303, TGN1412, Thorium-227-Epratuzumab Conjugate, ticilimumab, tigatuzumab, tildrakizumab, Tisotumab vedotin, TNX-650, tocilizumab, toralizumab, tosatoxumab, tositumomab, tovetumab, tralokinumab, trastuzumab, trastuzumab emtansine, TRBS07, TRC105, tregalizumab, tremelimumab, trevogrumab, TRPH 011, TRX518, TSR-042, TTI-200.7, tucotuzumab celmoleukin, tuvirumab, U3-1565, U3-1784, ublituximab, ulocuplumab, urelumab, urtoxazumab, ustekinumab, Vadastuximab Talirine, vandortuzumab vedotin, vantictumab, vanucizumab, vapaliximab, varlilumab, vatelizumab, VB6-845, vedolizumab, veltuzumab, vepalimomab, vesencumab, visilizumab, volociximab, vorsetuzumab mafodotin, votumumab, YYB-101, zalutumumab, zanolimumab, zatuximab, ziralimumab, and zolimomab aritox.
In some cases, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to an antigen comprising one or more members selected from the group comprising BCMA, CD20, CD22, CD30, CD33, CD38, CD70, Kappa, Lewis Y, NKG2D ligand, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and gp100. Non-limiting examples of the NKG2D ligand comprises one or more members selected from the group comprising of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6.
In some cases, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain capable of specifically binding an antigen of a target cell, and the engineered immune cell can exhibit reduced expression or activity of an endogenous gene encoding the same antigen of the chimeric polypeptide receptor. As such, a population of the engineered immune cells can avoid targeting and killing each other, e.g., upon administration to a subject in need thereof.
In some cases, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD38. In some cases, the engineered immune cell’s endogenous gene encoding CD38 can be modified to effect reduced expression or activity of the endogenous CD38. In some cases, the subject engineered immune cells comprising the chimeric polypeptide receptor against CD38 can be capable of targeting and effecting death (or degradation) of plasma cells.
In some cases, the engineered immune cell (e.g., the engineered NK cell) as disclosed herein can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD38. In some examples, the engineered immune cell is an engineered NK cell that is derived from an isolated ESC or an induced stem cell (e.g., iPSC) . In some cases, the engineered immune cell’s endogenous gene encoding CD38 can be modified to effect reduced expression or activity of the endogenous CD38.
E. Stem cells
Any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein can be derived from an isolated stem cell (e.g., an ESC) or an induced stem cell (iPSC) . The isolated stem cell or the induced stem cell can be modified (e.g., genetically modified) to generate the engineered immune cell.
In some cases, pluripotency of stem cells (e.g., ESCs or iPSCs) can be determined, in part, by assessing pluripotency characteristics of the cells. Pluripotency characteristics can include, but are not limited to: (i) pluripotent stem cell morphology; (ii) the potential for unlimited self-renewal; (iii) expression of pluripotent stem cell markers including, but not limited to SSEA1 (mouse only) , SSEA3/4, SSEA5, TRA1-60/81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133/prominin, CD140a, CD56, CD73, CD90, CD105, OCT4, NANOG, SOX2, CD30 and/or CD50; (iv) ability to differentiate to all three somatic lineages (ectoderm, mesoderm and endoderm) ; (v) teratoma formation consisting of the three somatic lineages; and (vi) formation of embryoid bodies consisting of cells from the three somatic lineages.
In some cases, stem cells (e.g., ESCs or iPSCs) can be genetically modified to generate (e.g., induce differentiation into) CD34+ hematopoietic stem cells. The stem cells can be genetically modified to express any one of the heterologous polypeptides (e.g., cytokines, receptors, etc. ) as disclosed herein prior to, subsequent to, or during the induced hematopoietic stem cell differentiation. The stem cells can be genetically modified to reduce expression or activity of any one of the endogenous genes or polypeptides (e.g., cytokines, receptors, etc. ) as disclosed herein prior to, subsequent to, or during the induced hematopoietic stem cell differentiation. In some cases, such genetically modified CD34+hematopoietic stem cell is or is a source of any one of the engineered immune cell of the present disclosure.
In some examples, stem cells as disclosed herein can be cultured in APEL media with ROCKi (Y-27632) (e.g., at about 10 micromolar (μM) ) , SCF (e.g., at about 40 nanograms per milliner (ng/mL) of media) , VEGF (e.g., at about 20 ng/mL of media) , and BMP-4 (e.g., at about 20 ng/mL of media) to differentiate into CD34+ hematopoietic stem cells.
In some cases, the CD34+ hematopoietic stem cells (e.g., genetically modified with one or more features of any one of the engineered immune cell of the present disclosure) can be induced to differentiate in to a committed immune cell, such as T cells or NK cells. As such, in some cases, the induced differentiation process generates any one of the engineered NK cell of the present disclosure.
In some examples, genetically modified CD34+ hematopoietic stem cells are cultured in the presence of IL-3 (e.g., about 5 ng/mL) , IL-7 (e.g., about 20 ng/mL) , IL-15 (e.g., about 10 ng/mL) , SCF (e.g., about 20 ng/mL) , and Flt3L (e.g., about 10 ng/mL) to differentiate into CD45+ NK cells.
In some cases, the CD45+ NK cells can be expanded in culture, e.g., in a media comprising IL-2, mbIL-21 aAPC using Gas Permeable Rapid Expansion (G-Rex) platform.
In some cases, iPSC-derived NK cells as disclosed herein can be cultured with one or more heterologous cytokines comprising Il-2, IL-15, or IL-21. In some cases, iPSC-derived NK cells as disclosed herein can be cultured with (e.g., for cell expansion) one or more heterologous cytokines selected from the group consisting of Il-2, IL-15, and IL-21. In some cases, iPSC-derived NK cells as disclosed herein can be cultured with two or more heterologous cytokines selected from the group consisting of Il-2, IL-15, and IL-21 (e.g., IL-2 and IL-15, IL-2 and IL-21, or IL-15 and IL-21) , either simultaneously or sequentially in any order. In some cases, iPSC-derived NK cells as disclosed herein can be cultured with all of Il-2, IL-15, and IL-21, either simultaneous or sequentially in any order.
F. Gene editing or genetic material delivery
The gene editing moiety as disclosed herein can comprise a CRISPR-associated polypeptide (Cas) , zinc finger nuclease (ZFN) , zinc finger associate gene regulation polypeptides, transcription activator-like effector nuclease (TALEN) , transcription activator-like effector associated gene regulation polypeptides, meganuclease, natural master transcription factors, epigenetic modifying enzymes, recombinase, flippase, transposase, RNA-binding proteins (RBP) , an Argonaute protein, any derivative thereof, any variant thereof, or any fragment thereof. In some embodiments, the actuator moiety comprises a Cas protein, and the system further comprises a guide RNA (gRNA) which complexes with the Cas protein. In some embodiments, the actuator moiety comprises an RBP complexed with a gRNA which is able to form a complex with a Cas protein. In some embodiments, the gRNA comprises a targeting segment which exhibits at least 80%sequence identity to a target polynucleotide. In some embodiments, the Cas protein substantially lacks DNA cleavage activity.
In some cases, a suitable gene editing moiety comprises CRISPR-associated (Cas) proteins or Cas nucleases including type I CRISPR-associated (Cas) polypeptides, type II CRISPR-associated (Cas) polypeptides, type III CRISPR-associated (Cas) polypeptides, type IV CRISPR-associated (Cas) polypeptides, type V CRISPR-associated (Cas) polypeptides, and type VI CRISPR-associated (Cas) polypeptides; zinc finger nucleases (ZFN) ; transcription activator-like effector nucleases (TALEN) ; meganucleases; RNA-binding proteins (RBP) ; CRISPR-associated RNA binding proteins; recombinases; flippases; transposases; Argonaute (Ago) proteins (e.g., prokaryotic Argonaute (pAgo) , archaeal Argonaute (aAgo) , and eukaryotic Argonaute (eAgo) ) ; any derivative thereof, any variant thereof; and any fragment thereof.
Non-limiting examples of Cas proteins include c2c1, C2c2, c2c3, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD) , Cas6, Cas6e, Cas6f, Cas7, Cas8a, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12) , Cas10, Cas10d, Cas1O, Cas1Od, CasF, CasG, CasH, Cpf1, Csy1, Csy2, Csy3, Cse1 (CasA) , Cse2 (CasB) , Cse3 (CasE) , Cse4 (CasC) , Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx1O, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cul966, and homologs or modified versions thereof.
In some cases, the gene editing moiety as disclosed herein can be fused with an additional functional moiety (e.g., to form a fusion moiety) , and non-limiting examples of a function of the additional functional moiety can include methyltransferase activity, demethylase activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, remodelling activity, protease activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, synthase activity, synthetase activity, and demyristoylation activity. For example, a fusion protein can be a fusion in a Cas protein and an effector or repressor functional moiety.
Alternatively or in addition to, gene editing (e.g., knock in) or delivery of heterologous genetic material can be achieved other viral and non-viral based gene transfer methods can be used to introduce nucleic acids in host cells (e.g., stem cells, hematopoietic stem cells, etc. as disclosed herein) . Such methods can be used to administer nucleic acids encoding polypeptide molecules of the present disclosure to cells in culture (or in a host organism) . Viral vector delivery systems can include DNA and RNA viruses, which can have either episomal or integrated genomes after delivery to the cell. Non-viral vector delivery systems can include DNA plasmids, RNA (e.g. a transcript of a vector described herein) , naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
RNA or DNA viral based systems can be used to target specific cells and traffick the viral payload to the nucleus of the cell. Viral vectors can be used to treat cells in vitro, and the modified cells can optionally be administered (ex vivo) . Alternatively, viral vectors can be administered directly (in vivo) to the subject. Viral based systems can include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome can occur with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, which can result in long term expression of the inserted transgene.
Methods of non-viral delivery of nucleic acids can include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides can be used.
Alternatively or in addition to, antisense oligonucleotides can be utilized to suppress or silence a target gene expression. Non-limiting examples of antisense oligonucleotides can include short hairpin RNA (shRNA) , microRNA (miRNA) , and small interfering RNA (siRNA) .
G. Co-therapy
The engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be combined with a co-therapeutic agent to treat a subject in need thereof. In some cases, the engineered immune cell can be administered to the subject prior to, concurrent with, or subsequent to administration of the co-therapeutic agent to the subject.
In one aspect, the present disclosure provides a composition comprising (a) any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein and (b) a co-therapeutic agent (i.e., a separate therapeutic agent) (e.g., an antibody, such as anti-CD20 antibody or anti-PD1 antibody) . In some cases, the engineered immune cell can comprise one or more of: (i) a heterologous cytokine (e.g., a heterologous IL, such as IL-15) as disclosed herein, (ii) a CD16 variant for enhanced CD16 signaling as disclosed herein, and (iii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclose herein. In some examples, the co-therapeutic agent comprises an anti-CD20 antibody.
In some cases, the engineered immune cell can comprise the heterologous cytokine (e.g., IL-15) as disclosed herein and one or both of: (ii) the CD16 variant for enhanced CD16 signaling and (iii) the chimeric polypeptide receptor comprising the antigen binding moiety.
In some cases, the engineered immune cell can comprise the CD16 variant for enhanced CD16 signaling and one or both of: (i) the heterologous cytokine (e.g., IL-15) and (iii) the chimeric polypeptide receptor comprising the antigen binding moiety.
In some cases, the engineered immune cell can comprise the chimeric polypeptide receptor comprising the antigen binding moiety and one or both of: (i) the heterologous cytokine (e.g., IL-15) and (ii) the CD16 variant for enhanced CD16 signaling.
Non-limiting examples of a co-therapeutic agent can include cytotoxic agents, chemotherapeutic agents, growth inhibitory agents, agents used in radiation therapy, anti-angiogenesis agents, apoptotic agents, anti-tubulin agents, and other agents to treat cancer, for example, anti-CD20 antibodies, anti-PD1 antibodies (e.g., Pembrolizumab) platelet derived growth factor inhibitors (e.g., GLEEVEC
TM (imatinib mesylate) ) , a COX-2 inhibitor (e.g., celecoxib) , interferons, cytokines, antagonists (e.g., neutralizing antibodies) that bind to one or more of the following targets PDGFR-β, BlyS, APRIL, BCMA receptor (s) , TRAIL/Apo2, other bioactive and organic chemical agents, and the like.
The term “cytotoxic agent” generally refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. Non-limiting examples of a cytotoxic agent can include radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, and radioactive isotopes of Lu) , chemotherapeutic agents, e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide) , doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin.
Non-limiting examples of a chemotherapeutic agent can include alkylating agents such as thiotepa and
cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone) ; delta-9-tetrahydrocannabinol (dronabinol,
) ; beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan
CPT-11 (irinotecan,
) , acetylcamptothecin, scopolectin, and 9-aminocamptothecin) ; bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues) ; podophyllotoxin; podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8) ; dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1) ; eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics; dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores) , aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine,
doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin) , epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU) ; folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aidophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine;
polysaccharide complex (JHS Natural Products, Eugene, Oreg. ) ; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2′, 2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine) ; urethan; vindesine
dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ( “Ara-C” ) ; thiotepa; taxoids, for example taxanes including
paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N. J. ) , ABRAXANE
TM Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill. ) , and
docetaxel (
Rorer, Antony, France) ; chloranbucil; gemcitabine
6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine
platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine
oxaliplatin; leucovovin; vinorelbine
novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO) ; retinoids such as retinoic acid; capecitabine
pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin (ELOXATIN
TM) combined with 5-FU and leucovorin. Additional chemotherapeutic agents include the cytotoxic agents useful as antibody drug conjugates, such as maytansinoids (DM1, for example) and the auristatins MMAE and MMAF, for example.
Examples of a chemotherapeutic agent can also include “anti-hormonal agents” or “endocrine therapeutics” that act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer, and are often in the form of systemic, or whole-body treatment. They may be hormones themselves. Examples include anti-estrogens and selective estrogen receptor modulators (SERMs) , including, for example, tamoxifen (including
tamoxifen) ,
raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and
toremifene; anti-progesterones; estrogen receptor down-regulators (ERDs) ; agents that function to suppress or shut down the ovaries, for example, leutinizing hormone-releasing hormone (LHRH) agonists such as
and ELIGARD) leuprolide acetate, goserelin acetate, buserelin acetate and tripterelin; other anti-androgens such as flutamide, nilutamide and bicalutamide; and aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4 (5) -imidazoles, aminoglutethimide,
megestrol acetate,
exemestane, formestanie, fadrozole,
vorozole,
letrozole, and
anastrozole. In addition, such definition of chemotherapeutic agents includes bisphosphonates such as clodronate (for example,
or
) ,
etidronate, NE-58095,
zoledronic acid/zoledronate,
alendronate,
pamidronate,
tiludronate, or
risedronate; as well as troxacitabine (a1, 3-dioxolane nucleoside cytosine analog) ; antisense oligonucleotides, particularly those that inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Raf, H-Ras, and epidermal growth factor receptor (EGFR) ; vaccines such as
vaccine and gene therapy vaccines, for example,
vaccine,
vaccine, and
vaccine;
topoisomerase 1 inhibitor;
rmRH; lapatinib ditosylate (an ErbB-2 and EGFR dual tyrosine kinase small-molecule inhibitor also known as GW572016) ; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
Examples of a chemotherapeutic agent can also include antibodies such as alemtuzumab (Campath) , bevacizumab (
Genentech) ; cetuximab (
Imclone) ; panitumumab (
Amgen) , rituximab (
Genentech/Biogen Idec) , pertuzumab (
2C4, Genentech) , trastuzumab (
Genentech) , tositumomab (Bexxar, Corixia) , and the antibody drug conjugate, gemtuzumab ozogamicin (
Wyeth) . Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, feMzumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab, and the anti-interleukin-12 (ABT-874/J695, Wyeth Research and Abbott Laboratories) which is a recombinant exclusively human-sequence, full-length IgG1λ antibody genetically modified to recognize interleukin-12 p40 protein.
Examples of a chemotherapeutic agent can also include “tyrosine kinase inhibitors” such as an EGFR-targeting agent (e.g., small molecule, antibody, etc. ) ; small molecule HER2 tyrosine kinase inhibitor such as TAK165 available from Takeda; CP-724, 714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI) ; dual-HER inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016; available from Glaxo-SmithKline) , an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis) ; pan-HER inhibitors such as canertinib (CI-1033; Pharmacia) ; Raf-1 inhibitors such as antisense agent ISIS-5132 available from ISIS Pharmaceuticals which inhibit Raf-1 signaling; non-HER targeted TK inhibitors such as imatinib mesylate (
available from Glaxo SmithKline) ; multi-targeted tyrosine kinase inhibitors such as sunitinib (
available from Pfizer) ; VEGF receptor tyrosine kinase inhibitors such as vatalanib (PTK787/ZK222584, available from Novartis/Schering AG) ; MAPK extracellular regulated kinase I inhibitor CI-1040 (available from Pharmacia) ; quinazolines, such as PD 153035, 4- (3-chloroanilino) quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines, such as CGP 59326, CGP 60261 and CGP 62706; pyrazolopyrimidines, 4- (phenylamino) -7H-pyrrolo [2, 3-d] pyrimidines; curcumin (diferuloyl methane, 4, 5-bis (4-fluoroanilino) phthalimide) ; tyrphostines containing nitrothiophene moieties; PD-0183805 (Warner-Lamber) ; antisense molecules (e.g., those that bind to HER-encoding nucleic acid) ; quinoxalines (U.S. Pat. No. 5,804,396) ; tryphostins (U.S. Pat. No. 5,804,396) ; ZD6474 (Astra Zeneca) ; PTK-787 (Novartis/Schering AG) ; pan-HER inhibitors such as CI-1033 (Pfizer) ; Affinitac (ISIS 3521; Isis/Lilly) ; imatinib mesylate
PKI 166 (Novartis) ; GW2016 (Glaxo SmithKline) ; CI-1033 (Pfizer) ; EKB-569 (Wyeth) ; Semaxinib (Pfizer) ; ZD6474 (AstraZeneca) ; PTK-787 (Novartis/Schering AG) ; INC-1C11 (Imclone) ; and rapamycin (sirolimus,
) .
Examples of a chemotherapeutic agent can also include dexamethasone, interferons, colchicine, metoprine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG live, bevacuzimab, bexarotene, cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, histrelin acetate, ibritumomab, interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxsalen, nandrolone, nelarabine, nofetumomab, oprelvekin, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed disodium, plicamycin, porfimer sodium, quinacrine, rasburicase, sargramostim, temozolomide, VM-26, 6-TG, toremifene, tretinoin, ATRA, valrubicin, zoledronate, and zoledronic acid, and pharmaceutically acceptable salts thereof.
Examples of a chemotherapeutic agent can also include hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate and fluprednidene acetate: immune selective anti-inflammatory peptides (ImSAIDs) such as phenylalanine-glutamine-glycine (FEG) and its D-isomeric form (feG) (IMULAN BioTherapeutics, LLC) ; anti-rheumatic drugs such as azathioprine, ciclosporin (cyclosporine A) , D-penicillamine, gold salts, hydroxychloroquine, leflunomideminocycline, sulfasalazine, tumor necrosis factor alpha (TNFα) blockers such as etanercept
infliximab
adalimumab
certolizumab pegol
golimumab
Interleukin 1 (IL-1) blockers such as anakinra
T-cell costimulation blockers such as abatacept
Interleukin 6 (IL-6) blockers such as tocilizumab
Interleukin 13 (IL-13) blockers such as lebrikizumab; Interferon alpha (IFN) blockers such as rontalizumab; beta 7 integrin blockers such as rhuMAb Beta7; IgE pathway blockers such as Anti-M1 prime; Secreted homotrimeric LTa3 and membrane bound heterotrimer LTa/β2 blockers such as Anti-lymphotoxin alpha (LTa) ; miscellaneous investigational agents such as thioplatin, PS-341, phenylbutyrate, ET-18-OCH3, or famesyl transferase inhibitors (L-739749, L-744832) ; polyphenols such as quercetin, resveratrol, piceatannol, epigallocatechine gallate, theaflavins, flavanols, procyanidins, betulinic acid and derivatives thereof; autophagy inhibitors such as chloroquine; delta-9-tetrahydrocannabinol (dronabinol,
) ; beta-lapachone; lapachol; colchicines; betulinic acid; acetylcamptothecin, scopolectin, and 9-aminocamptothecin) ; podophyllotoxin; tegafur
bexarotene
bisphosphonates such as clodronate (for example,
or
) , etidronate
NE-58095, zoledronic acid/zoledronate
alendronate
pamidronate
tiludronate
or risedronate
and epidermal growth factor receptor (EGF-R) ; vaccines such as
vaccine; perifosine, COX-2 inhibitor (e.g., celecoxib or etoricoxib) , proteosome inhibitor (e.g., PS341) ; CCI-779; tipifamib (R11577) ; orafenib, ABT510; Bcl-2 inhibitor such as oblimersen sodium
pixantrone; famesyltransferase inhibitors such as lonafamib (SCH 6636, SARASAR
TM) ; and pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above.
The term “growth inhibitory agent” generally refers to a compound or composition which inhibits growth and/or proliferation of a cell (e.g., a cell whose growth is dependent on PD-L1 expression) either in vitro or in vivo. The growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase. Non-limiting examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase) , such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine) , taxanes, and topoisomerase II inhibitors such as the anthracycline antibiotic doxorubicin ( (8S-cis) -10- [ (3-amino-2, 3, 6-trideoxy-α-L-lyxo-hexapyranosyl) oxy] -7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl) -1-methoxy-5, 12-naphthacenedione) , epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. The taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (
Rhone-Poulenc Rorer) , derived from the European yew, is a semisynthetic analogue of paclitaxel (
Bristol-Myers Squibb) . Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.
H. Methods of production and use
In some embodiments, the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be generated from an isolated stem cell (e.g., isolated ESCs, iPSCs, etc. ) . The one or more members of the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) , as disclosed herein, can be introduced during any stage (or cellular state) between (and including) (a) the isolated stem cell and (b) the differentiated immune cell state thereof (e.g., a terminally differentiated immune cell state, such as a terminally differentiated NK cell state) .
In some cases, the engineered NK cell can be derived from iPSCs, and the one or more members of the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) can be introduced to the cell at (A) the iPSC state, (B) the hematopoietic stem cell state, and/or (C) the NK cell state. The one or more members can be introduced to the cell once during one of (A) , (B) , and (C) . Alternatively, the one or more members can be introduced to the cell multiple times during two or all of (A) , (B) , and (C) .
In some cases, the engineered NK cell can be derived from iPSCs, and two or more members of the group consisting of (#1) , (#2) , (#3) , (#4) , (#5) , (#6) , (#7) , (#8) , (#9) , and (#10) can be introduced to the cell at (A) the iPSC state, (B) the hematopoietic stem cell state, and/or (C) the NK cell state. The two or more members can be introduced to the cell at the same state selected from the group comprising (A) , (B) , and/or (C) . Alternatively, the two or more members can be introduced to the cell at different states selected from the group comprising (A) , (B) , and/or (C) . For example, the iPSCs can be (A) engineered to exhibit the heterologous CD16 variant for enhanced CD16 signaling at the iPSC state, (B) subsequently differentiated into hematopoietic stem cells, and (C) engineered to exhibit the enhanced expression and/or activity level of an activating NK receptor during and/or subsequent to being differentiated into NK cells.
The engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be used (e.g., administered) to treat a subject in need thereof. The subject can have or can be suspected of having a condition, such as a disease (e.g., cancer, tumor, tissue degeneration, fibrosis, etc. ) . A cell (e.g., a stem cell or a committed adult cell) can be obtained from the subject, and such cell can be cultured ex vivo and genetically modified to generate any subject engineered immune cell (e.g., any engineered NK cell) as disclosed herein. Subsequently, the engineered immune cell can be administered to the subject for adaptive immunotherapy.
The subject can be treated (e.g., administered with) a population of engineered immune cells (e.g., engineered NK cells) of the present disclosure for at least or up to about 1 dose, at least or up to about 2 doses, at least or up to about 3 doses, at least or up to about 4 doses, at least or up to about 5 doses, at least or up to about 6 doses, at least or up to about 7 doses, at least or up to about 8 doses, at least or up to about 9 doses, or at least or up to about 10 doses.
In one aspect, the present disclosure provides a method comprising (a) obtaining a cell from a subject; and (b) generating, from the cell, any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein. In some cases, the cell obtained from the subject is ESC. In some cases, the cell (e.g., a fibroblast, such as an adult skin fibroblast) obtained from the subject is modified and transformed into an iPSC.
In one aspect, the present disclosure provides a method comprising administering to a subject in need thereof a population of NK cells comprising any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein. In some cases, the method can further comprise administering to the subject a co-therapeutic agent (e.g., a chemotherapeutic agent, anti-CD20 antibody, etc. ) .
In one aspect, the present disclosure provides a method comprising administering to a subject in need thereof any one of the composition disclosed herein. In some cases, the composition can comprise (i) any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein and (ii) a co-therapeutic agent (e.g., a chemotherapeutic agent, anti-CD20 antibody, etc. ) .
Any one of the methods disclosed herein can be utilized to treat a target cell, a target tissue, a target condition, or a target disease of a subject.
A target disease can be a viral, bacterial, and/or parasitic infection; inflammatory and/or autoimmune disease; or neoplasm such as a cancer and/or tumor.
A target cell can be a diseased cell. A diseased cell can have altered metabolic, gene expression, and/or morphologic features. A diseased cell can be a cancer cell, a diabetic cell, and an apoptotic cell. A diseased cell can be a cell from a diseased subject. Exemplary diseases can include blood disorders, cancers, metabolic disorders, eye disorders, organ disorders, musculoskeletal disorders, cardiac disease, and the like.
A variety of target cells can be killed using any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein. A target cell can include a wide variety of cell types. A target cell can be in vitro. A target cell can be in vivo. A target cell can be ex vivo. A target cell can be an isolated cell. A target cell can be a cell inside of an organism. A target cell can be an organism. A target cell can be a cell in a cell culture. A target cell can be one of a collection of cells. A target cell can be a mammalian cell or derived from a mammalian cell. A target cell can be a rodent cell or derived from a rodent cell. A target cell can be a human cell or derived from a human cell. A target cell can be a prokaryotic cell or derived from a prokaryotic cell. A target cell can be a bacterial cell or can be derived from a bacterial cell. A target cell can be an archaeal cell or derived from an archaeal cell. A target cell can be a eukaryotic cell or derived from a eukaryotic cell. A target cell can be a pluripotent stem cell. A target cell can be a plant cell or derived from a plant cell. A target cell can be an animal cell or derived from an animal cell. A target cell can be an invertebrate cell or derived from an invertebrate cell. A target cell can be a vertebrate cell or derived from a vertebrate cell. A target cell can be a microbe cell or derived from a microbe cell. A target cell can be a fungi cell or derived from a fungi cell. A target cell can be from a specific organ or tissue.
A target cell can be a stem cell or progenitor cell. Target cells can include stem cells (e.g., adult stem cells, embryonic stem cells, induced pluripotent stem (iPS) cells) and progenitor cells (e.g., cardiac progenitor cells, neural progenitor cells, etc. ) . Target cells can include mammalian stem cells and progenitor cells, including rodent stem cells, rodent progenitor cells, human stem cells, human progenitor cells, etc. Clonal cells can comprise the progeny of a cell. A target cell can comprise a target nucleic acid. A target cell can be in a living organism. A target cell can be a genetically modified cell. A target cell can be a host cell.
A target cell can be a totipotent stem cell, however, in some embodiments of this disclosure, the term “cell” may be used but may not refer to a totipotent stem cell. A target cell can be a plant cell, but in some embodiments of this disclosure, the term “cell” may be used but may not refer to a plant cell. A target cell can be a pluripotent cell. For example, a target cell can be a pluripotent hematopoietic cell that can differentiate into other cells in the hematopoietic cell lineage but may not be able to differentiate into any other non-hematopoietic cell. A target cell may be able to develop into a whole organism. A target cell may or may not be able to develop into a whole organism. A target cell may be a whole organism.
A target cell can be a primary cell. For example, cultures of primary cells can be passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, 15 times or more. Cells can be unicellular organisms. Cells can be grown in culture.
A target cell can be a diseased cell. A diseased cell can have altered metabolic, gene expression, and/or morphologic features. A diseased cell can be a cancer cell, a diabetic cell, and a apoptotic cell. A diseased cell can be a cell from a diseased subject. Exemplary diseases can include blood disorders, cancers, metabolic disorders, eye disorders, organ disorders, musculoskeletal disorders, cardiac disease, and the like.
If the target cells are primary cells, they may be harvested from an individual by any method. For example, leukocytes may be harvested by apheresis, leukocytapheresis, density gradient separation, etc. Cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc. can be harvested by biopsy. An appropriate solution may be used for dispersion or suspension of the harvested cells. Such solution can generally be a balanced salt solution, (e.g. normal saline, phosphate-buffered saline (PBS) , Hank's balanced salt solution, etc. ) , conveniently supplemented with fetal calf serum or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration. Buffers can include HEPES, phosphate buffers, lactate buffers, etc. Cells may be used immediately, or they may be stored (e.g., by freezing) . Frozen cells can be thawed and can be capable of being reused. Cells can be frozen in a DMSO, serum, medium buffer (e.g., 10%DMSO, 50%serum, 40%buffered medium) , and/or some other such common solution used to preserve cells at freezing temperatures.
Non-limiting examples of cells which can be target cells include, but are not limited to, lymphoid cells, such as B cell, T cell (Cytotoxic T cell, Natural Killer T cell, Regulatory T cell, T helper cell) , Natural killer cell, cytokine induced killer (CIK) cells (see e.g. US20080241194) ; myeloid cells, such as granulocytes (Basophil granulocyte, Eosinophil granulocyte, Neutrophil granulocyte/Hypersegmented neutrophil) , Monocyte/Macrophage, Red blood cell (Reticulocyte) , Mast cell, Thrombocyte/Megakaryocyte, Dendritic cell; cells from the endocrine system, including thyroid (Thyroid epithelial cell, Parafollicular cell) , parathyroid (Parathyroid chief cell, Oxyphil cell) , adrenal (Chromaffin cell) , pineal (Pinealocyte) cells; cells of the nervous system, including glial cells (Astrocyte, Microglia) , Magnocellular neurosecretory cell, Stellate cell, Boettcher cell, and pituitary (Gonadotrope, Corticotrope, Thyrotrope, Somatotrope, Lactotroph) ; cells of the Respiratory system, including Pneumocyte (Type I pneumocyte, Type II pneumocyte) , Clara cell, Goblet cell, Dust cell; cells of the circulatory system, including Myocardiocyte, Pericyte; cells of the digestive system, including stomach (Gastric chief cell, Parietal cell) , Goblet cell, Paneth cell, G cells, D cells, ECL cells, I cells, K cells, S cells; enteroendocrine cells, including enterochromaffm cell, APUD cell, liver (Hepatocyte, Kupffer cell) , Cartilage/bone/muscle; bone cells, including Osteoblast, Osteocyte, Osteoclast, teeth (Cementoblast, Ameloblast) ; cartilage cells, including Chondroblast, Chondrocyte; skin cells, including Trichocyte, Keratinocyte, Melanocyte (Nevus cell) ; muscle cells, including Myocyte; urinary system cells, including Podocyte, Juxtaglomerular cell, Intraglomerular mesangial cell/Extraglomerular mesangial cell, Kidney proximal tubule brush border cell, Macula densa cell; reproductive system cells, including Spermatozoon, Sertoli cell, Leydig cell, Ovum; and other cells, including Adipocyte, Fibroblast, Tendon cell, Epidermal keratinocyte (differentiating epidermal cell) , Epidermal basal cell (stem cell) , Keratinocyte of fingernails and toenails, Nail bed basal cell (stem cell) , Medullary hair shaft cell, Cortical hair shaft cell, Cuticular hair shaft cell, Cuticular hair root sheath cell, Hair root sheath cell of Huxley's layer, Hair root sheath cell of Henle's layer, External hair root sheath cell, Hair matrix cell (stem cell) , Wet stratified barrier epithelial cells, Surface epithelial cell of stratified squamous epithelium of cornea, tongue, oral cavity, esophagus, anal canal, distal urethra and vagina, basal cell (stem cell) of epithelia of cornea, tongue, oral cavity, esophagus, anal canal, distal urethra and vagina, Urinary epithelium cell (lining urinary bladder and urinary ducts) , Exocrine secretory epithelial cells, Salivary gland mucous cell (polysaccharide-rich secretion) , Salivary gland serous cell (glycoprotein enzyme-rich secretion) , Von Ebner's gland cell in tongue (washes taste buds) , Mammary gland cell (milk secretion) , Lacrimal gland cell (tear secretion) , Ceruminous gland cell in ear (wax secretion) , Eccrine sweat gland dark cell (glycoprotein secretion) , Eccrine sweat gland clear cell (small molecule secretion) . Apocrine sweat gland cell (odoriferous secretion, sex-hormone sensitive) , Gland of Moll cell in eyelid (specialized sweat gland) , Sebaceous gland cell (lipid-rich sebum secretion) , Bowman's gland cell in nose (washes olfactory epithelium) , Brunner's gland cell in duodenum (enzymes and alkaline mucus) , Seminal vesicle cell (secretes seminal fluid components, including fructose for swimming sperm) , Prostate gland cell (secretes seminal fluid components) , Bulbourethral gland cell (mucus secretion) , Bartholin's gland cell (vaginal lubricant secretion) , Gland of Littre cell (mucus secretion) , Uterus endometrium cell (carbohydrate secretion) , Isolated goblet cell of respiratory and digestive tracts (mucus secretion) , Stomach lining mucous cell (mucus secretion) , Gastric gland zymogenic cell (pepsinogen secretion) , Gastric gland oxyntic cell (hydrochloric acid secretion) , Pancreatic acinar cell (bicarbonate and digestive enzyme secretion) , Paneth cell of small intestine (lysozyme secretion) , Type II pneumocyte of lung (surfactant secretion) , Clara cell of lung, Hormone secreting cells, Anterior pituitary cells, Somatotropes, Lactotropes, Thyrotropes, Gonadotropes, Corticotropes, Intermediate pituitary cell, Magnocellular neurosecretory cells, Gut and respiratory tract cells, Thyroid gland cells, thyroid epithelial cell, parafollicular cell, Parathyroid gland cells, Parathyroid chief cell, Oxyphil cell, Adrenal gland cells, chromaffin cells, Ley dig cell of testes, Theca interna cell of ovarian follicle, Corpus luteum cell of ruptured ovarian follicle, Granulosa lutein cells, Theca lutein cells, Juxtaglomerular cell (renin secretion) , Macula densa cell of kidney, Metabolism and storage cells, Barrier function cells (Lung, Gut, Exocrine Glands and Urogenital Tract) , Kidney, Type I pneumocyte (lining air space of lung) , Pancreatic duct cell (centroacinar cell) , Nonstriated duct cell (of sweat gland, salivary gland, mammary gland, etc. ) , Duct cell (of seminal vesicle, prostate gland, etc. ) , Epithelial cells lining closed internal body cavities, Ciliated cells with propulsive function, Extracellular matrix secretion cells, Contractile cells; Skeletal muscle cells, stem cell, Heart muscle cells, Blood and immune system cells, Erythrocyte (red blood cell) , Megakaryocyte (platelet precursor) , Monocyte, Connective tissue macrophage (various types) , Epidermal Langerhans cell, Osteoclast (in bone) , Dendritic cell (in lymphoid tissues) , Microglial cell (in central nervous system) , Neutrophil granulocyte, Eosinophil granulocyte, Basophil granulocyte, Mast cell, Helper T cell, Suppressor T cell, Cytotoxic T cell, Natural Killer T cell, B cell, Natural killer cell, Reticulocyte, Stem cells and committed progenitors for the blood and immune system (various types) , Pluripotent stem cells, Totipotent stem cells, Induced pluripotent stem cells, adult stem cells, Sensory transducer cells, Autonomic neuron cells, Sense organ and peripheral neuron supporting cells, Central nervous system neurons and glial cells, Lens cells, Pigment cells, Melanocyte, Retinal pigmented epithelial cell, Germ cells, Oogonium/Oocyte, Spermatid, Spermatocyte, Spermatogonium cell (stem cell for spermatocyte) , Spermatozoon, Nurse cells, Ovarian follicle cell, Sertoli cell (in testis) , Thymus epithelial cell, Interstitial cells, and Interstitial kidney cells.
Of particular interest are cancer cells. In some embodiments, the target cell is a cancer cell. Non-limiting examples of cancer cells include cells of cancers including Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblastic leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic large cell lymphoma, Anaplastic thyroid cancer, Angioimmunoblastic T-cell lymphoma, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Burkitt's lymphoma, Cancer of Unknown Primary Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Chronic Lymphocytic Leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic Myeloproliferative Disorder, Chronic neutrophilic leukemia, Clear-cell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B cell lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymoblastoma, Ependymoma, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Ewing's sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular lymphoma, Follicular thyroid cancer, Gallbladder Cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastric lymphoma, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy Cell Leukemia, Hairy cell leukemia, Head and Neck Cancer, Head and neck cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy, Hepatocellular carcinoma, Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin Lymphoma, Hodgkin's lymphoma, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Islet Cell Tumor, Juvenile myelomonocytic leukemia, Kaposi Sarcoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Laryngeal cancer, Lentigo maligna melanoma, Leukemia, Leukemia, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, MALT lymphoma, Mantle cell lymphoma, Mast cell leukemia, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloblastoma, Medulloepithelioma, Melanoma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Monocytic leukemia, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma, Multiple myeloma, Mycosis Fungoides, Mycosis fungoides, Myelodysplastic Disease, Myelodysplastic Syndromes, Myeloid leukemia, Myeloid sarcoma, Myeloproliferative Disease, Myxoma, Nasal Cavity Cancer, Nasopharyngeal Cancer, Nasopharyngeal carcinoma, Neoplasm, Neurinoma, Neuroblastoma, Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma, Non-Hodgkin Lymphoma, Non-Hodgkin lymphoma, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oral cancer, Oropharyngeal Cancer, Osteosarcoma, Osteosarcoma, Ovarian Cancer, Ovarian cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Pancreatic cancer, Papillary thyroid cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Precursor T-lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma, Secondary neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small cell lymphoma, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Splenic marginal zone lymphoma, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, Teratoma, Terminal lymphatic cancer, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms'tumor, and combinations thereof. In some embodiments, the targeted cancer cell represents a subpopulation within a cancer cell population, such as a cancer stem cell. In some embodiments, the cancer is of a hematopoietic lineage, such as a lymphoma. The antigen can be a tumor associated antigen.
In some cases, the target cell (e.g., B cells) as disclosed herein is associated or is suspected of being associated with an autoimmune disease. The subject being treated with any one of the engineered immune cell (e.g., engineered NK cell) of the present disclosure can have or can be suspected of having an autoimmune disease.
Non-limiting examples of an autoimmune disease can include acute disseminated encephalomyelitis (ADEM) , acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, allergic asthma, allergic rhinitis, alopecia areata, amyloidosis, ankylosing spondylitis, antibody-mediated transplantation rejection, anti-GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS) , autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED) , autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP) , autoimmune thyroid disease, autoimmune urticaria, axonal &neuronal neuropathies, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, celiac disease, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) , chronic recurrent multifocal ostomyelitis (CRMO) , Churg-Strauss syndrome, cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathies, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica) , discoid lupus, Dressler's syndrome, endometriosis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis) , glomerulonephritis, goodpasture's syndrome, granulomatosis with polyangiitis (GPA) , Graves'disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, hypergammaglobulinemia, idiopathic thrombocytopenic purpura (ITP) , IgA nephropathy, IgG4-related sclerosing disease, immunoregulatory lipoproteins, inclusion body myositis, inflammatory bowel disease, insulin-dependent diabetes (type 1) , interstitial cystitis, juvenile arthritis, juvenile diabetes, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD) , lupus (SLE) , lyme disease, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD) , monoclonal gammopathy of undetermined significance (MGUS) , Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's ) , neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus) , paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH) , Parry Romberg syndrome, Parsonnage-Turner syndrome, pars planitis (peripheral uveitis) , pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, type I, II, &III autoimmune polyglandular syndromes, polymyalgia rheumatic, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynauds phenomenon, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren's syndrome, sperm &testicular autoimmunity, stiff person syndrome, subacute bacterial endocarditis (SBE) , Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis/Giant cell arteritis, thrombocytopenic purpura (TTP) , Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease (UCTD) , uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, Waldenstrom's macroglobulinemia (WM) , and Wegener's granulomatosis (Granulomatosis with Polyangiitis (GPA) ) .
In some cases, the autoimmune disease comprises one or more members selected from the group comprising rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus (lupus or SLE) , myasthenia gravis, multiple sclerosis, scleroderma, Addison's Disease, bullous pemphigoid, pemphigus vulgaris, Guillain-Barré syndrome, Sjogren syndrome, dermatomyositis, thrombotic thrombocytopenic purpura, hypergammaglobulinemia, monoclonal gammopathy of undetermined significance (MGUS) , Waldenstrom's macroglobulinemia (WM) , chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) , Hashimoto's Encephalopathy (HE) , Hashimoto's Thyroiditis, Graves'Disease, Wegener's Granulomatosis, and antibody-mediated transplantation rejection (e.g., for tissue transplants such as renal transplant) . In examples, the autoimmune disease can be type 1 diabetes, lupus, or rheumatoid arthritis.
In some cases the target disease is acute myeloid leukemia (AML) . For example, any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein that comprises one or more of: (i) a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to an antigen (e.g., CD33) as disclosed herein, (ii) a heterologous cytokine (e.g., IL-15) as disclosed herein, and (iii) a CD16 variant for enhanced CD16 signaling as disclosed herein can be administered to a subject in need thereof to treat AML.
In some cases, the target disease is non-Hodgkin’s lymphoma (NHL) .
In some cases, the target disease is chronic lymphocytic leukemia (CLL) .
In some cases, the target disease is B-cell leukemia (BCL) . For example, any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein that comprises one or more of: (i) a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to CD19 as disclosed herein, (ii) a heterologous cytokine (e.g., IL-15) as disclosed herein, and (iii) a CD16 variant for enhanced CD16 signaling as disclosed herein can be administered to a subject in need thereof to treat BCL.
In some cases, the target disease is non-small-cell lung carcinoma (NSCLC) .
In some cases, the target cells form a tumor (i.e., a solid tumor) . A tumor treated with the methods herein can result in stabilized tumor growth (e.g., one or more tumors do not increase more than 1%, 5%, 10%, 15%, or 20%in size, and/or do not metastasize) . In some cases, a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks. In some cases, a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months. In some cases, a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years. In some cases, the size of a tumor or the number of tumor cells is reduced by at least about 5%, 10%, 15%, 20%, 25, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%or more. In some cases, the tumor is completely eliminated, or reduced below a level of detection. In some cases, a subject remains tumor free (e.g. in remission) for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks following treatment. In some cases, a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months following treatment. In some cases, a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years after treatment.
EXAMPLES
Example 1: Enhanced expression and/or activity level of an activating NK receptor
For improved cell therapy (e.g., stem cell therapy, adaptive immunotherapy, etc. ) , cells of interest can be engineered with enhanced or introduced expression level of activating NK receptor. The cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) . The cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
For example, iPSCs can be engineered to generate engineered NK cells exhibiting enhanced expression and/or activity level of an activating NK receptor, e.g., NKG2D, NKP30, NKP44, NKP46, DNAM1, NKP80 or a variant thereof (e.g., see TABLE 1) . As illustrated in FIG. 1, FIG. 13, and FIG. 14, a heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200, each heterologous polypeptide encoding at least one activating NK receptor, can be in contact with an iPSC or a differentiated cell derivative thereof, to generate the engineered NK cells. The heterologous polypeptide 110 is a control vector that does not encode any activating NK receptor. Such engineered NK cells can exhibit enhanced cytotoxicity against cancer cells, e.g., for pan-cancer treatment. In some cases, the heterologous polypeptide selected from the group comprising 110, 120, 130, 140, 150, 160, 170, 180, 190, and 200 can further encode a heterologous cytokine and/or a heterologous receptor thereof (e.g., IL15RF) . In some cases, the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can further encode a heterologous CD16 variant for enhanced CD16 signaling.
Table 1
In some examples, any one of the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can come in contact (e.g., via transfection or viral transduction) with the iPSCs prior to inducing differentiation of the iPSCs (e.g., into hematopoietic stem cells) . As shown in FIG. 14, iPSCs can be engineered to express NK receptors.
In some examples, any one of the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can come in contact (e.g., via transfection or viral transduction) with hematopoietic stem cells derived from the iPSCs.
In some examples, any one of the heterologous polypeptide selected from the group comprising 120, 130, 140, 150, 160, 170, 180, 190, and 200 can come in contact (e.g., via transfection or viral transduction) with NK cells derived from the iPSCs.
Example 2: An engineered immune cell with (A) enhanced expression and/or activity level of DAP and (B) enhanced expression and/or activity level of an activating NK receptor.
For improved cell therapy (e.g., stem cell therapy, adaptive immunotherapy, etc. ) , cells of interest can be engineered with enhanced or introduced expression level of a plurality of polypeptides. The plurality of polypeptides can be different polypeptides. The plurality of polypeptides can be complimentary to one another, e.g., in terms of expression level, activity level, etc. The plurality of polypeptides may directly interact (e.g., directly bind) with each other. Alternatively, the plurality of polypeptides may not directly interact with each other. The cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) . The cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
For example, in an engineered immune cell (e.g., an engineered NK cell) as disclosed herein, the presence of (A) enhanced expression and/or activity level of DAP (e.g., DAP10) can facilitate or further amplify (B) enhanced expression and/or activity level of the activating NK receptor (e.g., NKG2D) . Thus, (A) can have a synergistic effect on (B) , or vice versa, in the engineered immune cell.
Referring to FIG. 2A, 293T cells were modified with one of the heterologous polynucleotides 210, 220, and 230. The heterologous polynucleotide 230 encodes a heterologous NKG2D without a heterologous DAP10. The heterologous polynucleotide 220 encodes a heterologous DAP10 without a heterologous NKG2D. The heterologous polynucleotide 210 encodes both the heterologous NKG2D and the heterologous DAP10, to examine the synergy effect of NKG2D and DAP10. Referring to FIGs. 2B and 2C, co-expression of the heterologous NKG2D and the heterologous DAP10 showed enhanced expression of membrane-bound NKG2D, relative to (i) control 293T cells without any heterologous polynucleotide modification, (ii) 293T cells modified with the heterologous NKG2D alone, and (ii) 293T cells modified with the heterologous DAP10 alone. Thus, induced expression of heterologous activating NK receptor (e.g., NKG2D) in cells (e.g., 293T cells, iPSC cells, NK cells) can be dependent on induced expression of an additional heterologous protein, such as DAP (e.g., DAP-10) .
Example 3: Engineered NK cells for acute myeloid leukemia (AML) therapy.
For improved cell therapy (e.g., stem cell therapy, adaptive immunotherapy, etc. ) , cells of interest can be engineered with a plurality of modifications. The cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) . The cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
For example., an engineered NK cell can be prepared to exhibit at least three modifications: (A) a chimeric polypeptide receptor (e.g., a chimeric antigen receptor (CAR) , an engineered T cell receptor (TCR) , etc. ) comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a ligand of the activating NK receptor (e.g., not a ligand of NKG2D; (B) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a ligand of the activating NK receptor (e.g., NKG2D ligand) ; and (C) reduced expression and/or activity (e.g., via genetic knockout) of an endogenous gene, such as CD33, CD70, and/or TIM3. The features (A) , (B) , and (C) can be introduced in any order during the development of the engineered NK cell (e.g., from iPSCs) .
For example, the engineered NK cells can be prepared to express a heterologous CAR encoded by any one of the heterologous polynucleotides 310 (ani-CLL-1 CAR) , 320 (anti-CD33 CAR) , 330 (anti-CD70 CAR) , 340 (anti-CD123 CAR) , and/or 350 (anti-TIM3 CAR) (FIG. 3A) . The engineered NK cells can also be modified to exhibit enhanced CD16 signaling by inserting the CD16 variant 360 (CD16-IL15RF fusion protein) or 365 (CD16-CD64-IL15RF fusion protein) into the cell’s endogenous CD16 gene (FIG. 3B) . The engineered NK cells can also be modified to exhibit knock out of one or more immune regulating proteins, such as 370 (CD33) , 380 (CD70) , and/or 390 (TIM3) (FIG. 3C) . By testing different and various combinations as disclosed herein and the effect thereof on the engineered NK cell’s activity (e.g., persistence or viability, proliferation, survival, cytotoxicity against a target cell such as a cancer cell, etc. ) , different optimal combinations can be identified for different applications, such as AML therapy.
Example 4: Engineered CAR NK cells
For improved cell therapy (e.g., adaptive immunotherapy, etc. ) , cells of interest can be engineered to comprise a heterologous chimeric polypeptide (e.g., a chimeric antigen receptor) comprising an antigen binding moiety against a specific antibody of a target cell (e.g., a cancer or tumor cell) , to exhibit enhanced cytotoxicity against such target cell. The cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. For example, for NK cells derived from stem cells, one or more genetic modifications as disclosed herein can be introduced at (A) the stem cell state (e.g., iPSC state) , (B) the hematopoietic stem cell state, and/or (C) the NK cell state. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
For example, NK cells expressing a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CLL01 was generated. Schematic of anti-CLL-1 CAR structure design is shown in FIG. 4A, wherein TM is short for Transmembrane domain, and SCFV is short for single chain variable fragment. As shown in FIG. 4B, CLL1-CAR NK92 cells demonstrated targeted cytotoxicity against HL60 tumor cells that high express CLL-1, as compared to wild type (WT) NK92 cells that lack the anti-CLL-1 CAR (E/T (Effector/Target) equals 1: 1; 1: 5, or 1: 10) . As shown in FIG. 4C, upon contacting the JL60 tumor cells, NK92 cells comprising anti-CLL-1 CAR exhibited a higher expression level of CD107a, as compared to the NK92 cells lacking the anti-CCL-CAR. NK cells are involved in innate immunity against targets, such as tumors and viral infections. Lysosome-associated membrane protein-1 (LAMP-1 or CD107a, as used interchangeably herein) can be a marker for degranulation of NK cells, and enhanced expression level of CD107a in NK cells can be an indication of cytotoxic activity determination of the NK cell (e.g., the anti-CLL-1 CAR NK cell as disclosed herein) .
Example 5: Engineered NK cells from iPSCs
iPSCs can be engineered to generate engineered NK cells exhibiting enhanced expression and/or activity level of an activating NK receptor, e.g., NKG2D, NKP30, NKP44, NKP46, or a variant thereof. As shown in FIG. 5A, engineered iPSCs were differentiated into engineered NK cells (super NK cells) , where there was no difference in hCD56+ cells versus wildtype (ANB) (e.g., iPSC derived NK cells without genetic modifications) . FACS fluoresces intensity showed that the engineered NK cells overexpressed an activating NK receptor (FIG. 5B) .
Example 6: iPSC derived engineered NK exhibit cytotoxicity in vitro
iPSCs engineered with an activating NK receptor (e.g., NKG2D, NKP30) were differentiated to engineered NK cells (super NK) . Super NK cells were incubated with solid tumor cells (e.g., Calu-3) at various NK to solid tumor cells ratio (e.g., 10: 1, 1: 1) . Super NK cells showed superior cytotoxicity to solid tumor cells, compared to NK cells differentiated from
iPSC cells (FIG. 6A) . Serial cytotoxicity analysis with super NK cells incubated with solid tumor cells (e.g., THP1 or SKOV3) at 1: 1 ratio showed the ability of super NK cells to maintain long-term cytotoxicity to the solid tumor cells (FIG. 6B) . iPSCs was engineered with more than one activating NK receptors (e.g., NKG2D and NKP30) and differentiated to NK cells (super NK v4.0) . As shown in FIG. 6C, super NK v4.0 showed superior killing capability incubated with solid tumor cells (e.g., THP1 or MOLM13) compared to NK cells derived from
iPSCs, while maintaining high expression of the NK receptors (FIG. 6D) .
Example 7: iPSC derived engineered NK exhibit cytotoxicity in vivo
Mice were inoculated with tumor cells labeled with luciferase (e.g., THP1 or SKOV3) only or together with engineered NK cells expressing NK receptors (e.g., NKG2D and NKP30) . Tumor burden, calculated through the luminescence intensity, revealed that engineered NK cells expressing NK receptors (super NK v4.0) exhibited more cytotoxicity compared to NK cells derived from
iPSCs (FIG. 7 and 8D) . The mice with super NK v4.0 had weight change post injection (FIG. 8A) but had higher percent survival compared to mice inoculated with tumor cells only (FIG. 8B) . The mice with high levels of super NK v4.0 also maintained hCD56+ cells, as measured by pharmacokinetics in peripheral blood (FIG. 8C) .
Example 8: Gene knockout to enhance NK function
For improved cell therapy (e.g., adaptive immunotherapy, etc. ) , genes involved in inhibiting NK cell activity can be knocked down to enhance NK function. The cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. For example, for NK cells derived from stem cells, one or more genetic modifications as disclosed herein can be introduced at (A) the stem cell state (e.g., iPSC state) , (B) the hematopoietic stem cell state, and/or (C) the NK cell state. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
TGFb-R2 was knocked out in NK cells (e.g., with sgRNAs targeting TGFb-R2) and were incubated with GFP labeled tumor cells (e.g., THP1 cells) , with different TGF-b dosage (e.g., 10 ng/ml and 50 ng/ml) at various times (e.g., at 24 hours and 72 hours) . As shown in FIG. 9A and 9B, knocking out TGFb-R2 rescued NK function under TGF-b treatment, enhancing NK cytotoxicity function. Knocking out TGFb-R2 (FIG. 10A) in NK cells also rescued NKG2D and NKP30 expression from TGF-b treatment, as analyzed by FACS (FIG. 10B) .
CBNK was incubated with wild type K562 and HLA-E K562 cells at different effector cell to target cell ratios (e.g., E/T ratio at 4: 1, 1: 1, and 0.5: 1) . Cytotoxicity assay showed that HLAE inhibits NK cytotoxicity function (FIG. 11A) . As shown in FIG. 11B, HLA-E K562 cells decreased the percentage of CD107a+ cells, presenting the percentage of activated NK cells. Upon knockout of NKG2A (e.g. with sgRNAs with Cas9 protein) in CBNK (FIG. 11C) , the NKG2A knocked out cells were incubated with wild type K562 and HLA-E K562. As shown in FIG. 11D, NKG2A knock out rescued NK function during targeting of the HLA-E cells, assessed via cytotoxicity assay.
SOCS2 was knocked out in iPSCs. As shown in FIG. 12A, engineered iPSCs were differentiated into engineered NK cells (TD, representing various SOCS2 knock outs) , where there was no difference in hCD56+ cells versus wildtype (ANB) (e.g., iPSC derived NK cells without genetic modifications) , as quantified via FACS fluoresces intensity (FIG. 12B) . When cultured in vitro in presence of allogeneic peripheral blood cells, to mimic in vivo conditions, with IL-2 or IL-15 supplementation, engineered SOCS2 knockout NK cells showed greater persistence compared to unmodified NK cells (FIG. 12C) .
EMBODIMENTS
The following non-limiting embodiments provide illustrative examples of the invention, but do not limit the scope of the invention.
Embodiment 1: An engineered NK cell, comprising:
(1) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell; and/or
(2) one or more members selected from the group consisting of:
(i) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a NKG2D ligand;
(ii) reduced expression and/or activity level of an endogenous CD38 as compared to the control NK cell;
(iii) a reduced expression of one or more genes selected from the group consisting ofBCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, CD70;
(iv) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
(v) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
(vi) a safety switch capable of effecting death of the engineered NK cell.
optionally wherein:
(a) the engineered NK cell comprises (i) the heterologous CD16 variant; and/or
(b) the engineered NK cell comprises (ii) the reduced expression and/or activity level of the endogenous CD38; and/or
(c) the engineered NK cell comprises (iii) the reduced expression of the one or more genes selected from the group consisting of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, CD70; and/or
(d) the engineered NK cell comprises (iv) the reduced expression and/or activity of the immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
(e) the engineered NK cell comprises (v) the reduced expression and/or activity of the hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and/or
(f) the engineered NK cell comprises (vi) the safety switch; and/or
(g) the engineered NK cell comprises two or more members selected from the group consisting of (i) , (ii) , (iii) , (iv) , and (v) ; and/or
(h) wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking (1) the enhanced expression or activity level of the activating NK receptor and/or (2) the one or more members selected from the group consisting of (i) - (iv) ; and/or
(i) wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking (1) the enhanced expression or activity level of the activating NK receptor and/or (2) the one or more members selected from the group consisting of (i) - (iv) ; and/or
(j) further comprising a heterologous interleukin (IL) cytokine and/or receptor for enhanced interleukin signaling as compared to the control NK cell; and/or
(k) further comprising a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
enhanced expression or activity level of an activating NK receptor as compared to a control NK cell,
wherein:
the engineered NK cell exhibits at least about 0.1-fold or at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to the control NK cell; and/or
the enhanced expression or activity level of the activating NK receptor on the engineered NK cell is at least about 0.1-fold or at least about 0.5-fold greater than that in the control NK cell,
optionally wherein:
(a) the activating NK receptor does not comprise a heterologous intracellular signaling domain; and/or
(b) the activating NK receptor does not comprise a heterologous transmembrane domain; and/or
(c) the activating NK receptor does not comprise a heterologous antigen binding domain.
enhanced expression or activity level of an activating NK receptor as compared to a control NK cell, wherein the activating NK receptor is configured to bind an antigen of NKG2D, NKP30, and/or NKP44, NKP46, NKP80, and/or DNAM1 and wherein the activating NK receptor does not comprise a heterologous intracellular signaling domain.
(a) the activating NK receptor is endogenous to the engineered NK cell;
(b) the engineered NK cell comprises a heterologous polynucleotide sequence encoding the activating NK receptor;
(c) the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the enhanced expression or activity level of the activating NK receptor; and/or
(d) the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking the enhanced expression or activity level of the activating NK receptor.
a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is selected from the group consisting of CD70, CLEC12A, and TIM-3, CD9, CD26, TRAIL-R4 (DCR2) , and NKG2D ligand,
wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the chimeric polypeptide receptor,
optionally wherein:
(a) the antigen is selected from the group consisting of CD70, CLEC12A, and TIM-3; and/or
(b) the antigen is CD70 or TIM-3; and/or
(c) the engineered NK cell exhibits at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in the cytotoxicity against the target cell as compared to the control NK cell; and/or
(d) the engineered NK cell exhibits at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in the proliferation as compared to the control NK cell.
(1) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is CD38 and/or BCMA; and
(2) one or more members selected from the group consisting of:
(i) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell;
(ii) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
(iii) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and
(iv) a safety switch capable of effecting death of the engineered NK cell,
wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the one or more members,
optionally wherein:
(a) the engineered NK cell comprises (i) the enhanced expression or activity level of the activating NK receptor; and/or
(b) the engineered NK cell comprises (ii) the reduced expression and/or activity of the immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
(c) the engineered NK cell comprises (iii) the reduced expression and/or activity of rgw hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and/or
(d) the engineered NK cell comprises (iv) the safety switch; and/or
(e) the engineered NK cell comprises two or more members selected from the group consisting of (i) , (ii) , (iii) , and (iv) .
(1) reduced expression or activity level of a suppressor of cytokine (SOCS) protein; and
(2) one or more members selected from the group consisting of:
(i) enhanced expression or activity level of endogenous activating NK receptor as compared to a control NK cell;
(ii) a heterologous interleukin (IL) cytokine and/or receptor for enhanced interleukin signaling as compared to the control NK cell;
(iii) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a NKG2D ligand;
(iv) reduced expression and/or activity level of an endogenous CD38 as compared to the control NK cell;
(v) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;
(vi) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;
(vii) a safety switch capable of effecting death of the engineered NK cell; and
(viii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
(a) the NK cell comprises (i) the enhanced expression or activity level of endogenous activating NK receptor; and/or
(b) the engineered NK cell comprises (ii) the heterologous interleukin (IL) cytokine and/or receptor; and/or
(c) the engineered NK cell comprises (iii) the heterologous CD16 variant; and/or
(d) the engineered NK cell comprises (iv) the reduced expression and/or activity level of the endogenous CD38; and/or
(e) the engineered NK cell comprises (v) the reduced expression and/or activity of the immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
(f) the engineered NK cell comprises (vi) the reduced expression and/or activity of the hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;
(g) the engineered NK cell comprises (vii) the safety switch; and/or
(h) the engineered NK cell comprises (viii) the chimeric polypeptide receptor; and/or
(i) the engineered NK cell comprises two or more members selected from the group consisting of (i) , (ii) , (iii) , (iv) , (v) , (vi) , (vii) , and (viii) ; and/or
(j) the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking reduced expression or activity level of the SOCS protein; and/or
(k) the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking reduced expression or activity level of the SOCS protein; and/or
(l) the SOCS protein is an endogenous protein; and/or
(m) the SOCS protein is selected from the group consisting of CIS, SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, and SOCS-7; and/or
(n) the SOCS protein is SOCS2; and/or
(o) further comprising an enhanced expression or activity level of a dead-associated protein (DAP) , optionally wherein the DAP is DAP-10 or DAP-12; and/or
(p) the activating NK receptor comprises NKG2D, NKP30, NKP44, NKP46, NKP80, DNAM1, a modification thereof, a functional variant thereof, or a combination thereof; and/or
(q) the activating NK receptor comprises NKG2D or a modification thereof; and/or
(r) the activating NK receptor comprises NKP30 or a modification thereof; and/or
(s) the activating NK receptor comprises NKP44 or a modification thereof; and/or
(t) the activating NK receptor comprises NKP46 or a modification thereof; and/or
(u) the activating NK receptor comprises NKP80 or a modification thereof; and/or
(v) the activating NK receptor comprises DNAM1 or a modification thereof; and/or
(w) the activating NK receptor is heterologous to the engineered immune cell; and/or
(x) the activating NK receptor is a chimeric polypeptide receptor comprising at least an extracellular portion of NKG2D, NKP30, NKP44, or NKP46, NKP80, or DNAM1; and/or
(y) the activating NK receptor is endogenous to the engineered immune cell; and/or
(z) the heterologous IL cytokine and/or receptor comprises IL-15, IL-15R, and/or a fragment thereof; and/or
(aa) the antigen is not a NKP30 ligand, a NKP44 ligand, and/or a NKP46 ligand, NKP80 ligand, and/or DNAM1 ligand; and/or
(bb) the antigen comprises BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10; and/or
(cc) the engineered NK cell exhibits enhanced cytotoxic activity against a population of target cells as compared to the control NK cell; and/or
(dd) the enhanced cytotoxic activity against the population of target cells is ascertained by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%decrease in a size of the population of target cells as compared to the control NK cell; and/or
(ee) the engineered NK cell exhibits reduction in tumor size as compared to as compared to the control NK cell; and/or
(ff) the tumor size is reduced by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%as compared to the control NK cell; and/or
(gg) the engineered NK cell induces reduced immune response in a host cell as compared to the control NK cell; and/or
(hh) the engineered NK cell is for use in treating a subject in need thereof; and/or
(ii) the engineered NK cell is allogeneic to the subject; and/or
(jj) the engineered NK cell is autologous to the subject; and/or
(kk) the engineered NK cell is derived from an isolated stem cell or an induced stem cell; and/or
(ll) the engineered NK cell is derived from a cord blood natural killer cell (CBNK) or a peripheral blood natural killer cell (PBNK) ; and/or
(mm) the engineered NK cell is for use in a method for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell; and/or
(nn) the engineered NK cell is for use in a method for treating a subject in need thereof, wherein the subject has or is suspected of having a condition, optionally wherein:
the condition is cancer or tumor; and/or
the engineered NK cell is either autologous or allogeneic to the subject; and/or
(oo) the engineered NK cell is for the manufacture of medicament for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell; and/or
(pp) the engineered NK cell is for the manufacture of medicament for treating a subject in need thereof, wherein the subject has or is suspected of having a condition, optionally wherein the condition is cancer or tumor; and/or
(qq) the engineered NK cell is either autologous or allogeneic to the subject.
optionally wherein the composition further comprises a separate therapeutic agent, further optionally wherein the separate therapeutic agent is a chemotherapeutic agent.
obtaining a cell from a subject; and
generating, from the cell, the engineered NK cell of any one of the Embodiments provided herein.
contacting the target cell with the engineered NK cell of any one of the Embodiments provided herein,
optionally wherein the contacting is sufficient to induce the killing of the target cell.
optionally wherein the method further comprises administering a separate therapeutic agent, further optionally wherein the separate therapeutic agent is a chemotherapeutic agent.
Embodiment 13. A method of converting a stem cell to the engineered NK cell of any one of the Embodiments provided herein, comprising:
contacting in vitro the stem cell with a transgenic nucleic acid encoding the activating NK receptor, wherein the stem cell is an isolated stem cell or an induced stem cell, for conversion of the stem cell to the engineered NK cell,
wherein, upon the contacting, the engineered NK cell exhibits enhanced expression or activity level of the activating NK receptor as compared to a control NK cell.
It shall be understood that different aspects of the invention can be appreciated individually, collectively, or in combination with each other. Various aspects of the invention described herein may be applied to any of the particular applications disclosed herein. The compositions of matter including the engineered immune cells of the present disclosure may be utilized in the method section including methods of use and production disclosed herein, or vice versa.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (84)
- An engineered NK cell, comprising:(1) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell; and(2) one or more members selected from the group consisting of:(i) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a NKG2D ligand;(ii) reduced expression and/or activity level of an endogenous CD38 as compared to the control NK cell;(iii) a reduced expression of one or more genes selected from the group consisting of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, CD70;(iv) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;(v) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and(vi) a safety switch capable of effecting death of the engineered NK cell.
- The engineered NK cell of claim 1, comprising two or more members selected from the group consisting of (i) , (ii) , (iii) , (iv) , and (v) .
- The engineered NK cell of any one of the preceding claims, comprising (i) .
- The engineered NK cell of any one of the preceding claims, comprising (ii) .
- The engineered NK cell of any one of the preceding claims, comprising (iii) .
- The engineered NK cell of any one of the preceding claims, comprising (iv) .
- The engineered NK cell of any one of the preceding claims, comprising (v) .
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking (1) and/or (2) .
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking (1) and/or (2) .
- The engineered NK cell of any one of the preceding claims, further comprising a heterologous interleukin (IL) cytokine and/or receptor for enhanced interleukin signaling as compared to the control NK cell.
- The engineered NK cell of any one of the preceding claims, further comprising a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
- An engineered NK cell, comprising:enhanced expression or activity level of an activating NK receptor as compared to a control NK cell, wherein the activating NK receptor is configured to bind an antigen of NKG2D, NKP30, NKP44, NKP46, NKP80, and/or DNAM1 and wherein the activating NK receptor does not comprise a heterologous intracellular signaling domain.
- The engineered NK cell of claim 12, wherein the activating NK receptor is endogenous to the engineered NK cell.
- The engineered NK cell of claim 12, wherein the engineered NK cell comprises a heterologous polynucleotide sequence encoding the activating NK receptor.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the enhanced expression or activity level of the activating NK receptor.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking the enhanced expression or activity level of the activating NK receptor.
- An engineered NK cell, comprising:a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is selected from the group consisting of CD70, CLEC12A, and TIM-3, CD9, CD26, TRAIL-R4 (DCR2) , and NKG2D ligand,wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the chimeric polypeptide receptor.
- The engineered NK cell of any one of the preceding claims, wherein the antigen is selected from the group consisting of CD70, CLEC12A, and TIM-3.
- The engineered NK cell of any one of the preceding claims, wherein the antigen is CD70 or TIM-3.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in the cytotoxicity against the target cell as compared to the control NK cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in the proliferation as compared to the control NK cell.
- An engineered NK cell, comprising:(1) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is CD38 and/or BCMA; and(2) one or more members selected from the group consisting of:(i) enhanced expression or activity level of an activating NK receptor as compared to a control NK cell;(ii) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;(iii) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and(iv) a safety switch capable of effecting death of the engineered NK cell,wherein the engineered NK cell exhibits at least about 0.5-fold increase in cytotoxicity against a target cell, as compared to a control NK cell lacking the one or more members.
- The engineered NK cell of any one of the preceding claims, comprising two or more members selected from the group consisting of (i) , (ii) , (iii) , and (iv) .
- The engineered NK cell of any one of the preceding claims, comprising (i) .
- The engineered NK cell of any one of the preceding claims, comprising (ii) .
- The engineered NK cell of any one of the preceding claims, comprising (iii) .
- The engineered NK cell of any one of the preceding claims, comprising (iv) .
- An engineered NK cell, comprising:(1) reduced expression or activity level of a suppressor of cytokine (SOCS) protein; and(2) one or more members selected from the group consisting of:(i) enhanced expression or activity level of endogenous activating NK receptor as compared to a control NK cell;(ii) a heterologous interleukin (IL) cytokine and/or receptor for enhanced interleukin signaling as compared to the control NK cell;(iii) a heterologous CD16 variant for enhanced CD16 signaling as compared to the control NK cell, wherein the heterologous CD16 variant does not bind a NKG2D ligand;(iv) reduced expression and/or activity level of an endogenous CD38 as compared to the control NK cell;(v) reduced expression and/or activity of an immune checkpoint inhibitor selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4;(vi) reduced expression and/or activity of a hypo-immunity regulator selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59;(vii) a safety switch capable of effecting death of the engineered NK cell; and(viii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not a NKG2D ligand.
- The engineered NK cell of any one of the preceding claims, comprising two or more members selected from the group consisting of (i) , (ii) , (iii) , (iv) , (v) , (vi) , and (viii) .
- The engineered NK cell of any one of the preceding claims, comprising (i) .
- The engineered NK cell of any one of the preceding claims, comprising (ii) .
- The engineered NK cell of any one of the preceding claims, comprising (iii) .
- The engineered NK cell of any one of the preceding claims, comprising (iv) .
- The engineered NK cell of any one of the preceding claims, comprising (v) .
- The engineered NK cell of any one of the preceding claims, comprising (vi) .
- The engineered NK cell of any one of the preceding claims, comprising (vii) .
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in cytotoxicity against a target cell, as compared to a control NK cell lacking reduced expression or activity level of the SOCS protein.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits at least about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proliferation, as compared to a control NK cell lacking reduced expression or activity level of the SOCS protein.
- The engineered NK cell of any one of the preceding claims, wherein the SOCS protein is an endogenous protein.
- The engineered NK cell of any one of the preceding claims, wherein the SOCS protein is selected from the group consisting of CIS, SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, and SOCS-7.
- The engineered NK cell of any one of the preceding claims, wherein the SOCS protein is SOCS2.
- The engineered NK cell of any one of the preceding claims, further comprising an enhanced expression or activity level of a dead-associated protein (DAP) .
- The engineered NK cell of claim 32, wherein the DAP is DAP-10.
- The engineered NK cell of claim 32, wherein the DAP is DAP-12.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor comprises NKG2D, NKP30, NKP44, NKP46, NKP80, DNAM1, a modification thereof, a functional variant thereof, or a combination thereof.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor comprises NKG2D or a modification thereof.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor comprises NKP30 or a modification thereof.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor comprises NKP44 or a modification thereof.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor comprises NKP46 or a modification thereof.
- The engineered NK cell of any of the preceding claims, wherein the activating NK receptor comprises NKP80 or a modification thereof.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor comprises DNAM1 or a modification thereof.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor is heterologous to the engineered immune cell.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor is a chimeric polypeptide receptor comprising at least an extracellular portion of NKG2D, NKP30, NKP44, or NKP46, NKP80, or DNAM1.
- The engineered NK cell of any one of the preceding claims, wherein the activating NK receptor is endogenous to the engineered immune cell.
- The engineered NK cell of any one of the preceding claims, wherein the heterologous IL cytokine and/or receptor comprises IL-15, IL-15R, and/or a fragment thereof.
- The engineered NK cell of any one of the preceding claims, wherein the antigen is not a NKP30 ligand, a NKP44 ligand, and/or a NKP46 ligand, NKP80 ligand, and/or DNAM1 ligand.
- The engineered NK cell of any one of the preceding claims, wherein the antigen comprises BCMA, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and/or gp10.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits enhanced cytotoxic activity against a population of target cells as compared to the control NK cell.
- The engineered NK cell of claim 58, wherein the enhanced cytotoxic activity against the population of target cells is ascertained by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%decrease in a size of the population of target cells as compared to the control NK cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell exhibits reduction in tumor size as compared to as compared to the control NK cell.
- The engineered NK cell of claim 60, wherein the tumor size is reduced by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%as compared to the control NK cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell induces reduced immune response in a host cell as compared to the control NK cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is for use in treating a subject in need thereof.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is allogeneic to the subject.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is autologous to the subject.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is derived from a cord blood natural killer cell (CBNK) or a peripheral blood natural killer cell (PBNK) .
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is for use in a method for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is for use in a method for treating a subject in need thereof, wherein the subject has or is suspected of having a condition.
- The engineered NK cell of any one of the preceding claims, wherein the condition is cancer or tumor.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is either autologous or allogeneic to the subject.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is for the manufacture of medicament for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell.
- The engineered NK cell of any one of the preceding claims, wherein the engineered NK cell is for the manufacture of medicament for treating a subject in need thereof, wherein the subject has or is suspected of having a condition.
- The engineered NK cell of any one of the preceding claims, wherein the condition is cancer or tumor.
- A composition comprising the engineered NK cell of any one of the preceding claims.
- The composition of claim 75, further comprising a separate therapeutic agent.
- The composition of claim 76, wherein the separate therapeutic agent is a chemotherapeutic agent.
- A method comprising:obtaining a cell from a subject; andgenerating, from the cell, the engineered NK cell of any one of the preceding claims.
- A method of killing a target cell, comprising:contacting the target cell with the engineered NK cell of any one of the preceding claims.
- The method of claim 79, wherein the contacting is sufficient to induce the killing of the target cell.
- A method of treating a subject in need thereof, comprising administering the engineered NK cell of any one of the preceding claims.
- The method of claim 81, further comprising administering a separate therapeutic agent.
- The method of claim 82, wherein the separate therapeutic agent is a chemotherapeutic agent.
- A method of converting a stem cell to an engineered NK cell, comprising:contacting in vitro the stem cell with a transgenic nucleic acid encoding an activating NK receptor, wherein the stem cell is an isolated stem cell or an induced stem cell, for conversion of the stem cell to the engineered NK cell,wherein, upon the contacting, the engineered NK cell exhibits enhanced expression or activity level of the activating NK receptor as compared to a control NK cell.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021128464 | 2021-11-03 | ||
CNPCT/CN2021/128464 | 2021-11-03 | ||
CN2022124454 | 2022-10-10 | ||
CNPCT/CN2022/124454 | 2022-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023078288A1 true WO2023078288A1 (en) | 2023-05-11 |
Family
ID=86240691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/129205 WO2023078288A1 (en) | 2021-11-03 | 2022-11-02 | Systems and methods for enhanced immunotherapies |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202325843A (en) |
WO (1) | WO2023078288A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108295078A (en) * | 2018-04-09 | 2018-07-20 | 徐军 | A kind of application of STAT3 inhibitor in terms of enhancing NK cells against tumor cells lethality |
US20180273903A1 (en) * | 2016-12-30 | 2018-09-27 | Celularity, Inc. | Genetically modified natural killer cells |
CN109306016A (en) * | 2018-08-15 | 2019-02-05 | 华东师范大学 | Co-express the NKG2D-CAR-T cell and application thereof of cell factor IL-7 |
WO2019033023A1 (en) * | 2017-08-11 | 2019-02-14 | Baylor College Of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
WO2020187016A1 (en) * | 2019-03-15 | 2020-09-24 | 阿思科力(苏州)生物科技有限公司 | Robo1 car-nk cell carrying suicide gene, preparation method therefor and application thereof |
-
2022
- 2022-11-02 TW TW111141865A patent/TW202325843A/en unknown
- 2022-11-02 WO PCT/CN2022/129205 patent/WO2023078288A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180273903A1 (en) * | 2016-12-30 | 2018-09-27 | Celularity, Inc. | Genetically modified natural killer cells |
WO2019033023A1 (en) * | 2017-08-11 | 2019-02-14 | Baylor College Of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
CN108295078A (en) * | 2018-04-09 | 2018-07-20 | 徐军 | A kind of application of STAT3 inhibitor in terms of enhancing NK cells against tumor cells lethality |
CN109306016A (en) * | 2018-08-15 | 2019-02-05 | 华东师范大学 | Co-express the NKG2D-CAR-T cell and application thereof of cell factor IL-7 |
WO2020187016A1 (en) * | 2019-03-15 | 2020-09-24 | 阿思科力(苏州)生物科技有限公司 | Robo1 car-nk cell carrying suicide gene, preparation method therefor and application thereof |
Non-Patent Citations (4)
Title |
---|
EL-SHERBINY YASSER M., MEADE JOSEPHINE L., HOLMES TIM D., MCGONAGLE DENNIS, MACKIE SARAH L., MORGAN ANN W., COOK GORDON, FEYLER SY: "The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 67, no. 18, 15 September 2007 (2007-09-15), US, pages 8444 - 8449, XP093064330, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-4230 * |
GURNEY MARK, STIKVOORT ARWEN, NOLAN EMMA, KIRKHAM-MCCARTHY LUCY, KHORUZHENKO STANISLAV, SHIVAKUMAR RAMA, ZWEEGMAN SONJA, VAN DE DO: "CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide", HAEMATOLOGICA, FONDAZIONE FERRATA STORTI, IT, vol. 107, no. 2, IT , pages 437 - 445, XP093005506, ISSN: 0390-6078, DOI: 10.3324/haematol.2020.271908 * |
RUSSICK JULES, JOUBERT PIERRE-EMMANUEL, GILLARD-BOCQUET MÉLANIE, TORSET CARINE, MEYLAN MAXIME, PETITPREZ FLORENT, DRAGON-DUREY MAR: "Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, no. 2, 1 October 2020 (2020-10-01), pages e001054, XP093064332, DOI: 10.1136/jitc-2020-001054 * |
WOAN KARRUNE; BJORDAHL RYAN; CICHOCKI FRANK; GAIDAROVA SVETLANA; PRIDE CAMERON; KAUFMAN DAN S; MALMBERG KARL-JOHAN; COOLEY SARAH; : "CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), US , pages 3224, XP086591802, ISSN: 0006-4971, DOI: 10.1182/blood-2018-99-116459 * |
Also Published As
Publication number | Publication date |
---|---|
TW202325843A (en) | 2023-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11717539B2 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
WO2022095902A1 (en) | Systems and methods for enhanced immunotherapies | |
TWI785009B (en) | Cd70 binding molecules and methods of use thereof | |
ES2778701T3 (en) | Management of toxicity for antitumor activity of CAR | |
TW202042824A (en) | Tn-muc1 chimeric antigen receptor (car) t cell therapy | |
EP4031655A2 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
WO2023078288A1 (en) | Systems and methods for enhanced immunotherapies | |
WO2023093763A1 (en) | Systems and methods for cell-based immunotherapies cross-reference | |
WO2022179563A1 (en) | Systems and compositions for enhanced immunotherapies and methods thereof | |
WO2022179562A1 (en) | Chimeric antigen receptors in immune cells | |
WO2023147777A1 (en) | Systems and methods for enhanced immunotherapies | |
WO2023078287A1 (en) | Systems and methods for enhanced immunotherapies | |
WO2023147776A1 (en) | Systems and methods for enhanced immunotherapies | |
WO2023143475A1 (en) | Methods and compositions for cell-based immunotherapies | |
WO2022099069A1 (en) | Systems and methods for regulating gene expression or activity | |
US20220135642A1 (en) | Cells, compositions and methods for enhancing immune function | |
Valia | Emerging Natural Killer Cell Immunotherapy for Acute Myeloid Leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22889310 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |